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ABSTRACT 
 The human SRC gene encodes pp60c-Src (or c-Src), a 60 kDa, non-receptor tyrosine 
kinase frequently activated in colon and other tumors.  Many studies have demonstrated 
c-Src activation can be accounted for by overexpression of c-Src protein, and that this 
overexpression is important for the fully transformed phenotype of cancer cells.  The 
general goal of this thesis, therefore, was to determine the mechanism of this 
overexpression in human cancer cells. Examination of c-Src expression and activity in 
human colon cancer cell lines showed that c-Src activation was due to transcriptional 
activation of the SRC gene.  SRC transcription is directed by the ubiquitous, Sp1 
regulated SRC1A promoter, and the HNF-1α regulated, tissue restricted SRC1α 
promoter.  To study the mechanism of SRC transcriptional activation in human cancer 
cell lines, a dual SRC promoter reporter construct was generated with both these 
promoters in their natural, physiologically linked context.  Very low activity of the 
SRC1α promoter, relative to SRC1A, was consistently observed from this construct, 
leading to the conclusion that an enhancer element elevates SRC1α promoter activity.  
Interestingly, the HNF binding site in the SRC1α promoter enhanced SRC1A promoter 
activity in the dual promoter construct, but only in a colon cancer cell line with activated 
SRC.  These results therefore suggest SRC transcriptional activation results from 
enhancer action and/or SRC promoter cross-talk in subsets of human cancer cells. 
 This study has also determined that histone deacetylase inhibitors (HDIs), 
compounds with documented anti-neoplastic properties, repress transcription from both 
SRC promoters in various cancer cell lines.  To identify the mechanism of this 
repression, various deletion and mutant SRC promoter constructs were assayed, but HDI 
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response elements were not identified.  However, it was discovered that both promoters 
shared a common requirement for functional TAF1/TAF(II)250, a component of the 
general transcription factor TFIID.  Compromised TAF1 function impaired SRC 
transcription, but also blocked SRC repression by HDIs.  Experiments with SRC:WAF1 
promoter chimeras showed the SRC promoters' TAF1 requirement could be conferred 
on the heterologous, TAF1-independent promoter for the WAF1 gene, which encodes 
the cell cycle inhibitor p21.  These chimeras were also repressed by HDIs, despite 
WAF1 normally being strongly induced by these agents.  These results therefore provide 
a potential functional link between promoter architecture, TAF1 dependence, and HDI 
mediated transcriptional repression. 
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1.  REVIEW OF THE LITERATURE  
1.1.  Introduction 
 SRC encodes pp60c-Src, a signaling protein involved in many important cellular 
processes including proliferation, motility, and apoptosis.  Activation and/or 
overexpression of pp60c-Src have been consistent findings in diverse human cancers, 
including colon cancer.  Therefore, the general goal of this thesis is to investigate the 
mechanisms that regulate SRC transcription, and define their importance in determining 
overall pp60c-Src expression and activity levels in human cancer.  The following review 
of the literature will familiarize the reader with the human SRC gene and gene product, 
as well as summarize current views of the many levels of eukaryotic transcriptional 
regulation.  These themes will subsequently converge, and the present state of 
knowledge regarding SRC transcriptional regulation will be discussed.   
 1 
1.2.  Biology of Src 
1.2.1.  The c-Src Proto-Oncogene and c-Src Gene Product 
1.2.1.1.  v-Src and the Rous Sarcoma Virus 
 One of the first glimpses into the modern field of cancer molecular genetics was 
provided in 1910, when Nobel Laureate Peyton Rous described that a solid tumor could 
be induced in the common hen by a filterable agent extracted from a fibrosarcoma in 
another hen (Rous, 1979).  At the time, this finding was very controversial, because 
cancer had been deemed non-infectious.  Indeed, it took nearly four decades of findings 
similar to these, as well as discovery of viruses, before it became readily accepted that 
certain viruses could induce tumors in appropriate hosts.  Eventually, this filterable 
agent was identified, and now bears the name Rous sarcoma virus (RSV).  Being one of 
the first discovered RNA retroviruses, the findings garnered from early study of RSV 
comprise one of the major cornerstones in the field of molecular virology. 
 Subsequent studies with RSV showed that the virus could alter the morphological 
appearance, or "transform" cultured chick embryo fibroblasts in one of the first 
described focus-forming assays (Temin and Rubin, 1958).  It was concluded that a 
component of the RSV genome was responsible for transformation, and a major 
concentration of efforts went into determining its identity.  The generation of one 
particular temperature sensitive RSV mutant was pivotal in identifying the RSV genetic 
component that caused transformation.  In fibroblasts grown at 30oC, this mutant was 
competent for both replication and transformation.  Conversely, when fibroblasts were 
grown at 39oC, RSV could not elicit transformation, but could still replicate (Martin, 
1970).  Additional RSV mutants were isolated that were replication competent, but 
transformation defective (Golde, 1970; Toyoshima et al., 1970).  Comparison of the 
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genomes of these mutants to wild type RSV led to the conclusion that the genomes of 
transformation defective mutants were smaller.  This allowed for the development of 
markers for the gene hypothesized as responsible for RSV mediated transformation.  
Inevitably, the eventual identification and sequencing of the v-Src gene was reported 
(Czernilofsky et al., 1983; Czernilofsky et al., 1980). 
 At the same time that the v-Src gene was being mapped and cloned, efforts were 
underway to identify the protein product encoded by this proposed transforming gene, or 
oncogene.  Many approaches were tried in vitro to translate the viral RNA, but these 
attempts were to no avail.  Eventually anti-serum was developed to proteins in RSV 
induced, tumor bearing animals, and a 60 kDa phosphoprotein, termed pp60v-Src (or v-
Src) was immunoprecipitated from these tumor lysates (Brugge and Erikson, 1977).  A 
major breakthrough came when immunoprecipitated complexes were incubated with [γ-
32P]-ATP, and it was discovered that v-Src had intrinsic kinase activity (Collett and 
Erikson, 1978; Levinson et al., 1978).  However, it was an unexpected finding that the 
residues phosphorylated by v-Src were tyrosines, because only serine or threonine 
phosphorylation had been described at that time (Hunter and Sefton, 1980).  As such, the 
v-Src gene in the RSV genome represented the very first identified oncogene, which 
encoded the very first protein discovered with tyrosine kinase activity.     
 
1.2.1.2.  The c-Src Proto-Oncogene   
 A stunning finding came in 1976, when Nobel Laureates Michael Bishop and 
Harold Varmus, along with their colleagues, reported that a cDNA probe to v-Src 
hybridized to normal avian DNA (Stehelin et al., 1976).  The ability of this probe to 
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hybridize with normal cellular DNA was conserved in vertebrates as well, suggesting a 
normal cellular counterpart to the v-Src gene.  The transforming viral counterpart, v-Src, 
had previously been coined an oncogene; therefore, to prevent ambiguity, "proto-
oncogene" was the term created to describe the normal cellular counterpart.  Eventually, 
this cellular proto-oncogene, aptly named c-Src (cellular-Src), was cloned and 
sequenced in chickens and humans (Anderson et al., 1985; Shalloway et al., 1981; 
Takeya and Hanafusa, 1983; Tanaka et al., 1987).  This initial landmark discovery led to 
the identification of additional cellular proto-oncogenes that were very closely related to 
their oncogenic viral counterparts.  Therefore, RNA tumor viruses are thought to have 
evolved through capture, or transduction, of proto-oncogenes into their genome followed 
by eventual mutation of these transduced sequences into oncogenes (Bishop, 1983).  A 
revolution in cancer molecular biology soon developed, with the hypothesis that tumors 
could arise through activation of these proto-oncogenes. 
 Characterization and comparison of pp60c-Src and pp60v-Src (or c-Src and v-Src) 
identified that they are highly conserved at the level of amino acid sequence (Fig. 1.1).  
However, the v-Src protein harbors a number of point mutations compared with c-Src as 
well as mutated and substituted C-terminal sequences, resulting in a truncated version of 
the c-Src protein.  Normal cellular proteins with significant homology to c-Src have also 
been identified, and have been grouped together to comprise the Src family.  Currently, 
there are at least nine members of this gene family: Src, Yes, Fyn, Fgr, Yrk, Lyn, Blk, 
Hck, and Lck.  Src, Yes, and Fyn expression appears ubiquitous, while most of the other 
family members differ spatially and temporally in expression patterns (most being 
restricted to cells of the haematopoietic system) (Thomas and Brugge, 1997). 
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Figure 1.1.  Comparison of the c-Src and v-Src proteins.  Modular
domains in the chicken c-Src and v-Src proteins are shown.  M refers to the
SH4, or myristoylation domain, and U refers to the unique region.  Glycine
2, the myristoylated N-terminal residue, is shown.  Important sites of tyrosine
phosphorylation are shown.  Intramolecular interactions that occur in the
closed, inactive conformation of c-Src are illustrated with double-headed
arrows.  X's along the v-Src protein denote mutations compared to the c-Src
protein.  The white box at the C-terminus of the v-Src protein refers to amino
acids that have been deleted and replaced compared to the c-Src protein. 
All c-Src family members share common structural domains (Fig. 1.1).  From N to C 
terminus, they have been defined as the 15 residue region of Src homology 4 (SH4) 
domain, the poorly conserved 40-70 residue unique domain, the 50 residue SH3 domain, 
the 100 residue SH2 domain, and the 250 residue catalytic, tyrosine kinase domain 
(Brown and Cooper, 1996).  Interestingly, the SH2, SH3, and kinase domains of c-Src 
are highly conserved in many proteins involved in signal transduction cascades (Pawson 
and Gish, 1992; Sudol, 1998).  Therefore, c-Src serves as a prototype for many modular 
proteins, especially tyrosine kinases, that function in signaling pathways.  Co-
translational processing of c-Src by an aminopeptidase removes the N-terminal 
methionine residue from the protein, thus exposing glycine 2 within the SH4 domain 
(Buss et al., 1984).  This glycine residue serves as a substrate for the irreversible 
attachment of myristic acid by the enzyme N-myristoyl transferase (NMT) (Buss et al., 
1984).  Other Src family members also serve as substrates for N-terminal lipid 
attachment, but the majority contain palmitic acid rather than myristic acid (Thomas and 
Brugge, 1997).  Lipid modification is essential for Src family activity and localizes the 
protein to the plasma membrane as well as intracellular membranes such as the 
endoplasmic reticulum and endosomes (Brown and Cooper, 1996; Courtneidge et al., 
1980).  The unique domain, located between the SH4 and SH3 domains, is responsible 
for the specificity in the interactions that occur between Src family members and 
upstream activators or downstream effectors.  The SH3 domain binds the core consensus 
PxxP (P = proline, x = any amino acid), which forms a left-handed polyproline helix 
(Ren et al., 1993).  SH3 ligands with the PxxP motif fall into two classes; class I ligands 
bind the SH3 domain in a N to C orientation, while class II ligands bind the SH3 domain 
in a C to N fashion.  For class I SH3 ligands, the amino acids N terminal to the PxxP 
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core dictate specificity, whereas the amino acids C terminal to this core motif are 
responsible for class II ligand specificity (Sudol, 1998).  The final modular element in 
the Src family of proteins is the SH2 domain, which binds phosphotyrosine. This SH2 
domain contains two discrete binding pockets; one binds phosphotyrosine and the other 
binds the amino acid in the +3 position, relative to phosphotyrosine (Sudol, 1998).  
Therefore, the three amino acids immediately C-terminal to the phosphorylated tyrosine 
residue dictate SH2 specificity (Songyang et al., 1995).  The SH2 domains in different 
proteins have been divided into 4 discrete groups based on the amino acid they 
preferentially bind in the +1 position of the phosphotyrosine ligand or the amino acids in 
their binding pockets that interact with the phosphotyrosine ligand (Brown and Cooper, 
1996).  
  
1.2.2.  Regulation of c-Src Activity 
 Negative regulation of pp60c-Src activity occurs primarily through phosphorylation 
of an important tyrosine residue located at the C-terminus of the c-Src protein (Fig. 1.1).  
This tyrosine residue has been identified as tyrosine 527 for the chicken c-Src protein, 
and tyrosine 530 for the human c-Src protein (Bjorge et al., 1996; Brown and Cooper, 
1996; Cooper and Howell, 1993).  Mutation or deletion of Y527/530 constitutively 
activates the c-Src kinase, thus conferring transforming ability on pp60c-Src (Cartwright 
et al., 1987; Courtneidge, 1985).  Phosphorylation of Y527/530 is carried out by cellular 
src kinase (Csk) (Nada et al., 1991).  The importance of this protein in catalyzing 
Y527/530 modification is highlighted by the observation that inactivation of Csk results 
in constitutive c-Src activity (Imamoto and Soriano, 1993).  Interestingly, the primary 
defining feature of v-Src is deletion and replacement of sequences encoding the C-
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terminal negative regulatory regions of its normal cellular counterpart (Parsons and 
Weber, 1989).  The molecular basis for post-translational regulation has been provided 
by the X-ray crystallographic structure of c-Src in its inactive conformation, which has 
demonstrated that Y527/Y530 phosphorylation results in a "closed" conformation of the 
c-Src protein (Xu et al., 1997).  This inactive protein conformation is due to an 
intramolecular association between phosphorylated Y527/530 and the SH2 domain of c-
Src, as well as association between the SH3 domain and a linker region between the SH2 
and kinase domains (Fig. 1.1).  These intramolecular associations prevent the SH2, SH3, 
and kinase domains from interacting with other proteins.  When Y530 is 
dephosphorylated, this allows pp60c-Src to adopt an open conformation and hence interact 
with and phosphorylate other proteins.  The ability to dephosphorylate Y527/530, and 
subsequently activate pp60c-Src, has been demonstrated for the Shp-2, PTPλ, and PTP1B 
protein tyrosine phosphatases (Bjorge et al., 2000; Fang et al., 1994; Walter et al., 1999).  
Once active, pp60c-Src autophosphorylates within its "activation loop" at Y416, resulting 
in fully activated protein. 
 Activation of the c-Src protein is achieved through a combination of SH2 
displacement, Y527/530 dephosphorylation, and Y416 phosphorylation.  However, the 
precise order of these events has not been clearly established.  The classic model of c-
Src activation is through association with growth factor receptors.  Ligand binding 
stimulates the intrinsic tyrosine kinase activity of growth factor receptor proteins by 
inducing their dimerization.  The resulting autophosphorylated tyrosine residues on the 
intracellular domains of these receptors have been proposed as high affinity binding sites 
for the c-Src SH2 domain, which displace the negative intramolecular association with 
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Y527/530 (Schwartzberg, 1998).  Once bound to activated growth factor receptors, 
subsequent Y530/527 dephosphorylation is thought to occur.  This allows generation of 
the "open" conformation of c-Src, which results in Y416 phosphorylation by the 
activated growth factor receptor, or through an autocatalytic mechanism. 
 
1.2.3.  Activation of c-Src Signaling Cascades by Transmembrane Receptors 
 Activation of c-Src is directly achieved by a large number of transmembrane 
proteins, including receptor tyrosine kinases (RTKs), immune recognition/major 
histocompatibility complex receptors, adhesion receptors, G-protein coupled receptors, 
and cytokine receptors (Thomas and Brugge, 1997).  Of these, the best described are 
RTK and adhesion receptor signaling cascades; therefore, they will be discussed in detail 
in subsequent sections.  Although these signaling pathways are usually presented as 
discrete, exclusive, and linear, recent evidence has clearly shown that there is extensive 
cross-talk between them (Uings and Farrow, 2000). 
 
1.2.3.1.  Activation of c-Src Signaling Cascades by Receptor Tyrosine Kinases 
 The majority of studies involving c-Src activation by RTKs have involved mouse 
fibroblast model systems.  While the results garnered from these approaches have 
revealed much about the signaling pathways that c-Src participates in, it is evident that 
there are very specific differences between cell types and species.  Nevertheless, these 
studies have identified that the information flow between RTKs and c-Src is two-way, 
meaning RTKs can bind, phosphorylate, and activate c-Src, and that c-Src can bind, 
phosphorylate and activate RTKs.  One well-studied example is the platelet derived 
growth factor (PDGF) receptor pathway.  The first suggestion that c-Src was involved in 
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PDGF receptor signaling came from the observation that PDGF stimulation of NIH3T3 
mouse fibroblasts resulted in c-Src activation (Ralston and Bishop, 1985).  Mutagenesis 
studies suggested the PDGF receptor/c-Src association is mediated by interactions 
between the c-Src SH2 domain, and phosphorylated Y579 or Y581 PDGF receptor 
residues (Mori et al., 1993; Twamley et al., 1992).  This PDGF receptor mediated 
activation is transient, and results in phosphorylation of c-Src on Y416 (Thomas and 
Brugge, 1997), as well as a novel phosphorylation of c-Src on Y138 (Broome and 
Hunter, 1997).  In turn, the PDGF receptor is phosphorylated directly by c-Src at Y934, 
which enhances PDGF mitogenic signaling (Hansen et al., 1996). 
 Another well-described RTK that activates c-Src is the epidermal growth factor 
(EGF) receptor (EGFR).  c-Src overexpression enhances many EGF receptor mediated 
responses, and EGF treatment increases c-Src catalytic activity 2 to 3 fold  (Thomas and 
Brugge, 1997).  An association between c-Src and human EGF receptor 1 (HER1) has 
been observed in a number of human carcinoma cell lines (Belsches et al., 1997).  This 
association is believed to be EGF dependent, direct, and mediated by c-Src SH2 binding 
to Y992, Y891, or Y920 of the HER1 protein (Belsches et al., 1997).  In addition, c-Src 
has been shown to phosphorylate two of these residues, namely Y891 and Y920 (Stover 
et al., 1995).  Interestingly, there is much evidence implicating EGFR family members 
in human breast tumor progression.  For example, overexpression and/or amplification 
of HER1 or HER2 has been observed in 20 to 30% of breast tumors, and HER2 
overexpression correlates with a poorer prognosis for the disease (Slamon et al., 1987; 
Slamon et al., 1989).  Although HER1 and HER2 can heterodimerize in an EGF 
stimulation dependent manner, HER2 homodimerization is ligand independent, and 
thought to result from overexpression (Tzahar et al., 1996). 
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 1.2.3.2.  Activation of c-Src Signaling Cascades by Adhesion Receptors 
 The integrin adhesion receptors mediate cellular attachment to the extracellular 
matrix (ECM).  The integrin family consists of 15 α subunits and 8 β subunits, which 
can heterodimerize to generate diverse combinations of functional α/β integrin receptors 
with specificities for different ECM ligands (Ruoslahti, 1999).  The model for c-Src 
activation following integrin engagement to fibronectin, an ECM component, begins 
with the recruitment of c-Src and a number of other adhesion signaling proteins to these 
sites of engagement, termed focal adhesions.  This localization has been shown to 
require the SH3 domain of c-Src as well as N-terminal myristoylation (Thomas and 
Brugge, 1997).  Once localized to these focal adhesions, c-Src is transiently 
dephosphorylated at Y527/530, and peak c-Src kinase activity can be observed at 15 min 
(Thomas and Brugge, 1997).  Following this transient enhancement in activity, c-Src 
remains associated with proteins at these sites.  In addition to c-Src, another tyrosine 
kinase, termed focal adhesion kinase (FAK) is recruited to and activated by engaged 
integrin receptors.  Once activated, FAK autophosphorylates on Y397, which serves as a 
docking site for the c-Src SH2 domain (Ruoslahti, 1999).  Interestingly, c-Src and FAK 
have been suggested to play redundant roles in substrate phosphorylation at these sites of 
adhesion.  As a result of this redundancy, the exact kinase responsible for 
phosphorylation of proteins at focal adhesions following integrin engagement remains 
unknown.  Indeed, both FAK and c-Src are able to bind and phosphorylate the majority 
of the structural proteins associated with focal adhesions, including paxillin, p130CAS, 
vinculin, talin, and tensin (Brown and Cooper, 1996).  Ultimately, these proteins 
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generate adhesive contacts with cytoskeletal proteins, thus coupling the ECM to internal 
cellular architecture. 
 The other major complex that mediates cellular adhesion is the adherens junction.  
Like focal adhesions, c-Src and a myriad of other structural proteins localize to these 
subcellular structures (Aberle et al., 1996; Henderson and Rohrschneider, 1987).  
Adherens junctions are sites of cell-cell adhesion regulated by Ca2+ dependent 
homotypic interactions between adjacent transmembrane cadherin proteins (Aberle et 
al., 1996).  Proteins with armadillo-like repeat motifs, such as the catenin family, are 
responsible for transferring cadherin adhesion signals to the cytoskeleton via direct 
interaction with actin filaments (Brown and Cooper, 1996).  In cells transformed with v-
Src, increased tyrosine phosphorylation of cadherin and α-, β-, and γ-catenin proteins is 
observed (Brown and Cooper, 1996).  However, cadherin engagement does not activate 
c-Src kinase activity.  Rather, c-Src is thought to be indirectly recruited to adherens 
junctions by RTKs.  This is supported by the observation that EGFR localizes to 
adherens junctions, and directly interacts with β-catenin (Hoschuetzky et al., 1994). 
         
1.2.4.  Cellular Processes Regulated by Src 
 To summarize the previous section, c-Src is directly activated by various 
transmembrane receptors.  Specific examples of c-Src activation were given for some 
growth factor and adhesion receptors.  Given the diversity in receptors that can activate 
c-Src, it is not surprising that c-Src is found at the hub of a vast array of important 
cellular signaling cascades that influence processes such as proliferation, differentiation, 
motility, architecture, and survival (Fig. 1.2).  The precise substrates that c-Src targets  
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Figure 1.2.  Signaling process mediated by c-Src.  The various
transmembrane receptors that have been implicated in activating c-Src
are shown at the top.  Effector molecules that are directly affected by c-
Src signaling are shown in the middle of the black arrows.  The cellular
processes affected by activation of these c-Src signal transduction
cascades are shown at the bottom.   
once activated are a function of the cell type, subcellular localization, as well as the 
receptor pathway that led to c-Src activation.  A comprehensive list of c-Src substrates 
has been included in a review by Brown and Cooper (Brown and Cooper, 1996). 
 
1.2.4.1.  Cell Cycle Progression 
 c-Src has been shown to influence progression through the cell cycle following 
growth factor receptor activation.  For example, down regulation of c-Src, through 
microinjection of neutralizing anti-Src antibodies or DNA encoding catalytically 
inactive c-Src, blocks DNA synthesis mediated by EGF, PDGF, as well as colony 
stimulating factor-1 (CSF-1) (Roche et al., 1995b; Twamley-Stein et al., 1993).  For 
PDGF, the G1/S arrest caused by blockade of c-Src action is rescued by co-injection of 
c-Myc (Barone and Courtneidge, 1995).  These results therefore implicate c-Src 
activation, following PDGF receptor stimulation, in controlling the activation of c-Myc, 
which in turn drives G1/S progression.  c-Myc activation is at the level of transcription 
and the molecular pathway responsible has been dissected.  This pathway involves direct 
phosphorylation and subsequent activation of the STAT3 transcription factor by c-Src, 
which then binds and activates the MYC promoter (Bowman et al., 2001).  Numerous 
corroborating studies have demonstrated that activation of STAT3 is essential for 
cellular transformation by activated c-Src (Irby and Yeatman, 2000).  Another 
downstream target of c-Src that is important for the G1/S phase of the cell cycle is Shc, 
an adapter protein that activates the Ras/MAPK pathway.  Shc is phosphorylated by c-
Src following engagement of growth factor receptors, immune response receptors, G-
protein coupled receptors, cytokine receptors, and integrins (Thomas and Brugge, 1997).  
In addition, phosphatidylinositol-3-kinase (PI3K) is activated by both the SH2 and SH3 
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domains of c-Src, and is required for PDGF, but not CSF-1, stimulated DNA synthesis 
(Thomas and Brugge, 1997). 
 In addition to the G1/S phase of the cell cycle, increased c-Src kinase activity is 
observed during mitosis, and is believed to result from N-terminal serine 
phosphorylation of c-Src by the cyclin dependent kinase, Cdc2 (Taylor and Shalloway, 
1993).  Indeed, c-Src is required for G2/M progression, as demonstrated by the 
observation that microinjection of inhibitory c-Src antibodies elicits G2/M arrest (Roche 
et al., 1995a).  A mitosis specific substrate, Sam68, has been identified for c-Src.  Sam68 
is a heterogeneous ribonuclear protein that may function in RNA transport, splicing, or 
stability, and is activated by the SH3 and SH2 domains of c-Src (Fumagalli et al., 1994).  
Interestingly, Sam68 is homologous to Caenorhabditis elegans gld-1, which has been 
shown to negatively regulate G2/M (Lin et al., 1997).  In addition to Sam68, c-Src also 
activates the Ras/MAPK pathway during the G2/M phase of the cell cycle (Brown and 
Cooper, 1996). 
 
1.2.4.2.  Differentiation 
 The precise role for c-Src in cellular differentiation remains ambiguous.  For 
example, temperature sensitive RSV infection of avian myoblasts, or chondroblasts has 
shown that v-Src retains these cells in a proliferative state, and prevents their 
differentiation into myotubes or chondrocytes, respectively (Kim et al., 1992; Nie et al., 
1998).  Conversely, however, v-Src induces neurite outgrowth of PC12 rat 
pheochromocytoma cells in a similar fashion to nerve growth factor treatment, 
demonstrating that v-Src can promote differentiation in these cells (Alema et al., 1985).  
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In addition, elevated c-Src activity has been associated with more-well differentiated 
grades of colon tumors (Weber et al., 1992).    
 
1.2.4.3.  Motility, Cellular Architecture, and Adhesion 
 Src-/- mouse fibroblasts display a decreased migration rate.  This alteration can be 
restored upon expression of wild-type c-Src, suggesting c-Src plays an important role in 
motility (Thomas and Brugge, 1997).  This is supported by studies in NBT-11 rat 
carcinoma cells, where EGF treatment causes cells to dissociate from cell clusters and 
display increased motility (Rodier et al., 1995).  A kinase dead c-Src mutant blocks these 
effects, demonstrating a direct role for c-Src kinase activity, under the control of EGF 
signaling, in this process (Rodier et al., 1995).  Lamellipodia, also known as membrane 
ruffles, are essential for this cell motility, as well as the organization of specialized 
membrane domains (Small et al., 2002).  These membrane microstructures rapidly form 
after v-Src activation (Thomas and Brugge, 1997), suggesting the decrease in mobility in 
src-/- fibroblasts is likely due to their impaired formation.  However, the precise 
molecular targets of c-Src signaling that lead to lamellipodia formation and subsequent 
increased motility have yet to be determined.  Some potential effector candidates include 
PI3K, ezrin, vinculin, cortactin, and p190RhoGAP (Brown and Cooper, 1996).  All these 
putative effectors are intimately associated with cytoskeletal proteins, and play a role in 
mediating the architecture of the cell. 
 In addition to diminished migration, src-/- fibroblasts display reduced cellular 
adhesion and spreading, despite being competent for focal adhesion assembly (Thomas 
and Brugge, 1997).  More detailed studies have shown that p130CAS, a c-Src substrate, is 
excluded from focal adhesion complexes in src-/- fibroblasts.  Interestingly, restoration 
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of adhesion and spreading to src-/- fibroblasts can be achieved by expression of a kinase 
dead c-Src mutant, suggesting c-Src may play a role as an adapter protein at focal 
adhesion sites (Nakamoto et al., 1997).  This hypothesis is supported by the observation 
that adhesion/spreading rescue by kinase dead c-Src is accompanied by recruitment of 
p130CAS to focal adhesions (Nakamoto et al., 1997). 
 
1.2.4.4.  Cell Survival 
 The earliest studies implicating the importance of c-Src in cell survival 
demonstrated that v-Src can specifically prevent apoptosis in cells that are deprived of 
growth factors, cytokines, or ECM components (McCubrey et al., 1993).  More recently, 
c-Src has been deemed essential in transducing survival signals from the TNF-related 
activation induced cytokine (TRANCE) receptor in dendritic cells and osteoclasts 
(Wong et al., 1999).  In addition, c-Src prevents detachment induced apoptosis (anoikis) 
in human colon cancer cells (Windham et al., 2002).  The mechanism of c-Src mediated 
cell survival is generally thought to depend upon the ability of c-Src to activate PI3K, 
which in turn is able to activate the PKB/Akt cell survival pathway (Schlessinger, 2000).  
This is supported by the observation that PI3K inhibition sensitizes human colon cancer 
cells with high levels of c-Src activity to anoikis (Windham et al., 2002). 
 
1.2.5.  In vivo Studies of c-Src Function 
 Given the importance of c-Src in such critical cellular signaling processes (Fig. 
1.2), it was an unexpected finding that despite only a bone remodeling defect, 
osteopetrosis, mice with targeted disruption of the src gene develop normally (Soriano et 
al., 1991).  However, src-/- mice do eventually succumb shortly after birth to a wasting 
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syndrome caused by starvation (Soriano et al., 1991).  It was hypothesized that src-/- 
mice appeared to develop normally due to functional redundancy between Src family 
members.  This functional redundancy has historically hampered groups' attempts to 
assign specific in vivo biological functions to c-Src.  Indeed, a more severe form of 
osteopetrosis is seen in hck-/-:src-/- double disruption mutants (Lowell et al., 1996), and 
fyn-/-;src-/- or yes-/-:src-/- mice die perinatally, although the reason for this lethality is 
unknown (Stein et al., 1994). 
 Interestingly, previous to establishment of the src-/- mouse model, no role for c-
Src had been suggested in bone physiology.  Further investigation demonstrated high 
levels of c-Src expression in osteoclasts, cells involved in bone resorption (Horne et al., 
1992).  Recent studies have suggested these high levels of c-Src in the osteoclast are 
likely the result of transcriptional activation during osteoclast differentiation (Higuchi et 
al., 1999).  However it is doubtful c-Src plays a direct role in the differentiation of these 
cells because osteoclasts are present, and even over-represented, in src-/- mice (Hayashi 
et al., 1998).  Rather, these src-/- osteoclasts do not form ruffled borders (lamellipodia), 
structures essential for osteoclast resorption pits, and hence display severe bone 
resorption defects in vivo and in vitro (Boyce et al., 1992; Lowe et al., 1993; Soriano et 
al., 1991).  These observations have been expanded, and src-/- mice maintained on a 
liquid diet to prevent starvation present with progressive osteopetrosis of the whole 
skeleton, leading to odontoma growth which eventually causes complete airway 
obliteration and suffocation (Amling et al., 2000).  The molecular basis for this defect is 
hypothesized to result from impairment of a number of c-Src mediated signaling 
pathways.  The first is regulated by an important receptor for osteoclast attachment to 
the ECM, αvβ3 integrin (osteopontin).  c-Src disruption is thought to abolish 
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osteopontin/ECM interaction and signaling, and perhaps lead to the defective 
lamellipodia formation seen in src-/- osteoclasts (Chellaiah et al., 1996; Hruska et al., 
1995).  The other pathways impaired by c-Src disruption in osteoclasts are RTK 
mediated, and include the CSF-1 and hepatocyte growth factor/scatter factor (HGF/SF) 
growth factor signaling pathways (Grano et al., 1996; Kurihara et al., 1996; Thomas and 
Brugge, 1997).  Interestingly, the osteopetrotic phenotype of src-/- mice can be rescued 
by transgenic expression of a catalytically inactive c-Src, suggesting c-Src signaling 
modules other than the kinase domain are essential for osteoclast function (Schwartzberg 
et al., 1997). 
 
1.2.6.  Src and Human Colon Cancer 
1.2.6.1.  Colon Cancer Progression 
Colon cancer is the fourth most common malignancy affecting the North 
American population, and the second leading cause of deaths due to cancer (Potter, 
1999).  For no other cancer are the genetic events leading to malignancy better 
understood than for this disease.  This knowledge has allowed for the proposal of 
stepwise models of colonic tumorigenesis (Fearon and Vogelstein, 1990; Kinzler and 
Vogelstein, 1996).  For example, a gatekeeper function has been assigned to the 
adenomatous polyposis coli (APC) tumor suppressor gene product, APC, implicating 
this protein in colon tumor initiation (Kinzler and Vogelstein, 1996).  Normally 
functioning APC regulates β-catenin levels by binding cytosolic β-catenin and 
facilitating its phosphorylation by glycogen synthase kinase 3β (GSK-3β), thus targeting 
it for ubiquitin-mediated degradation (Behrens, 1999; Ilyas and Tomlinson, 1997).  Loss 
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of APC function (Kinzler and Vogelstein, 1996; Morin et al., 1997) or mutations in β-
catenin that render it unresponsive to APC regulation (Dashwood et al., 1998; Morin et 
al., 1997; Park et al., 1999) results in accumulation of cytosolic β-catenin.  
Subsequently, β-catenin translocates to the nucleus where it can associate with members 
of the Tcf/Lef family of transcription factors and up-regulate transcription of genes such 
as c-Myc and cyclin D1 (He et al., 1998; Tetsu and McCormick, 1999).  Further tumor 
progression is associated with mutations resulting in the loss of function of additional 
tumor suppressor genes such as p53, DCC, hMLH1, and hMSH2 (Kinzler and 
Vogelstein, 1996).  Another well-characterized event occurring in nearly half of all 
colon cancers is an activating mutation in the KRAS proto-oncogene, which gives it a 
potent transforming ability (Bos et al., 1987; Kinzler and Vogelstein, 1996).  KRAS 
encodes K-Ras, a 21 KDa GTP-binding protein that serves as a molecular switch at the 
centre of a multitude of important and diverse cellular signaling cascades (Khosravi-Far 
et al., 1998).  Mutation locks K-Ras in an active, GTP-bound state, resulting in 
constitutive activation of downstream effectors, driving proliferation, cytoskeletal 
rearrangement, and angiogenesis (Khosravi-Far et al., 1998; Rak et al., 1995; Shirasawa 
et al., 1993). 
   
1.2.6.2.  Src Activation in Colon Cancer 
 In addition to the well-documented mutational events that occur during colon 
cancer progression, increased activity and/or expression of c-Src has been a consistent 
early finding in colon tumors and cell lines derived from them (Biscardi et al., 1999; 
Bolen et al., 1987a; Budde et al., 1994; Cartwright et al., 1994; Cartwright et al., 1990; 
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Han et al., 1996; Iravani et al., 1998; Staley et al., 1997; Talamonti et al., 1993; Zhao et 
al., 1990).  Tyrosine kinase activity of pp60c-Src is significantly increased in nearly 80% 
of colon carcinomas when compared with adjacent normal colon mucosa (Bolen et al., 
1987a; Cartwright et al., 1990).  In addition, examination of colonic polyps and normal 
colon epithelia from ulcerative colitis patients has shown a progressive increase in 
pp60c-Src activity from benign to malignant disease (Cartwright et al., 1994; Cartwright 
et al., 1990).  Increased pp60c-Src activity has also been observed in colorectal carcinoma 
metastasis (hepatic and extrahepatic) compared to normal colonic epithelia and even 
primary colon tumors (Talamonti et al., 1993).  Interestingly, an activating SRC 
mutation has been described in a small (12%) subset of highly advanced colon cancers 
(Irby et al., 1999).  This mutation, converting glutamine 531 to a stop codon, is 
activating, transforming, tumorigenic, and promotes metastasis.  The importance of SRC 
mutation in the majority of colon cancers is suspect, however.  Follow-up studies have 
been unable to detect this mutation in a large number of colon and rectal tumors (Daigo 
et al., 1999; Laghi et al., 2001; Nilbert and Fernebro, 2000).  Indeed, in the majority of 
colon cancer, c-Src is activated through non-mutagenic means, including overexpression 
of c-Src protein (Biscardi et al., 1999).   
 Many groups have designed experiments to support the current view that c-Src 
activation is most often due to increased pp60c-Src levels, and that overexpression of c-
Src is an important oncogenic event in colon tumor progression (Biscardi et al., 1999; 
Iravani et al., 1998; Park and Cartwright, 1995).  For example, immunohistochemical 
studies have demonstrated strong c-Src expression in 95% of adenomatous colon tumors 
compared with very weak expression in normal colonic mucosa; these patterns of 
expression correlated strongly with pp60c-Src kinase activity (Iravani et al., 1998).  
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Further, simple overexpression of murine c-Src is able to elicit transformation of mouse 
fibroblasts, albeit weakly (Lin et al., 1995).  However, when c-Src is transfected into the 
same fibroblasts expressing high levels of EGFR, it can cooperate with this RTK to 
achieve synergistic levels of transformation (Maa et al., 1995).  In addition, specific 
antisense-mediated down-regulation of c-Src in the HT29 human colon adenocarcinoma 
cell line results in diminished growth rate and colony forming ability (Staley et al., 
1997).  When these cells were assayed via nude mouse xenograft, they displayed 
severely diminished tumor forming ability and vascularization compared with parental 
cells.  The reduction in vascularization appears to be the result of reduced vascular 
endothelial growth factor (VEGF) production by these cells (Ellis et al., 1998).  These 
cells are also more susceptible to detachment induced apoptosis, or anoikis, than the 
parental cell line (Windham et al., 2002). 
 
1.2.7.  Src and Other Human Cancers   
 In addition to colon cancer, there are also reports that have suggested c-Src 
overexpression and/or activation could play an important role in other cancers.  For 
example, a c-Src specific antisense strategy has also been employed in the SKOv-3 
ovarian cancer cell line, resulting in diminished anchorage-independent growth and 
tumor forming ability in a xenograft nude mouse model (Wiener et al., 1999).  Similarly, 
antisense-mediated down-regulation of c-Src expression in NIH3T3 cells engineered to 
overexpress the EGFR or an EGFR-HER-2 chimera, a common finding in breast cancer, 
results in reversal of the transformed phenotype of these cells (Karni et al., 1999).  
Observational studies have also reported increased c-Src expression and/or kinase 
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activity in other cancers such as breast, lung, pancreas, and liver (Lutz et al., 1998; 
Masaki et al., 1998; Mazurenko et al., 1992; Verbeek et al., 1996). 
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1.3.  Eukaryotic Transcriptional Control 
 It is essential for the cell to properly execute its gene expression program.  Failure 
to do so can lead to dire consequences, with the extremes being apoptosis or 
transformation.  The DNA sequence of the human genome has been determined (Lander 
et al., 2001; Venter et al., 2001), and various estimates of the number of genes contained 
therein range from 28,000 to 120,000, with the current average consensus being 35,000 
to 45,000 (Das et al., 2001; Saha et al., 2002).  Significantly, any given cell expresses 
roughly 2 to 10% of this gene repertoire, alluding to extensive regulation of processes 
that drive gene expression.  One of the most important, and highly regulated gene 
expression processes is transcription of the DNA template to generate an RNA molecule.  
In eukaryotes, transcription is carried out by three RNA polymerase enzymes, RNA 
Polymerase I, II, and III.  The vast majority of the genes in eukaryotic genomes encode 
functional proteins and contain promoters that recruit RNA Polymerase II (Pol II).  As 
such, the regulation of Pol II transcription has been an area of extensive research.  Pol II 
regulatory mechanisms have been described at the level of promoter sequence and 
architecture, basal transcriptional machinery composition, transcription factor expression 
and modification, covalent DNA modification, histone modification, and chromatin 
structure.  The protein components associated with each of these levels of regulation are 
depicted in Figure 1.3, and will be described in detail in subsequent sections.  These 
control mechanisms are all highly interrelated and are believed to co-operate in a unique 
fashion at each individual promoter in the human genome to allow different cells to 
execute the expression of the appropriate sets of genes in a spatially and temporally 
controlled fashion. 
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Figure 1.3.  Regulation of eukaryotic transcription.  This figure
summarizes the interactions that occur between DNA elements and proteins
that regulate transcription.  Potential modifications of histone proteins, such
as acetylation (Ac), methylation (Me), phosphorylation (P), ADP-
ribosylation (ADP-R), and ubiquitination (Ub), are shown.  Elements and
factors shown here, as well as the abbreviations used to represent them, are
detailed in the text.  
1.3.1.  Core Promoter and Basal Transcription 
1.3.1.1.  RNA Polymerase II Transcriptional Machinery 
 The individual polypeptides that comprise the eukaryotic transcriptional machinery 
were originally identified by extensive biochemical purification.  These polypeptides are 
components of large protein complexes that have been defined as the general 
transcriptional machinery.  The precise functions assigned to these complexes have 
primarily resulted from in vitro transcriptional reconstitution assays using purified 
proteins.  While it is generally accepted that transcriptional regulation is very different in 
intact cells compared to these in vitro assays, the results garnered from these approaches 
have provided the current working models for how this bewildering array of 
polypeptides mediate transcription of a DNA template. 
 The central component of the transcription process is Pol II, a 12-subunit enzyme 
that catalyzes the generation of an RNA transcript from a DNA template.  The crystal 
structure of yeast Pol II comprised of 10 of these subunits has been determined at 2.8 Å 
resolution, as has a 3.3 Å resolution structure of yeast Pol II during the elongation phase 
of transcription (Cramer et al., 2001; Gnatt et al., 2001).  Comparison of these two 
structures has been crucial for the development of models for the mechanism of 
transcription.  The results generated from these yeast Pol II crystallography experiments 
will certainly serve as the benchmark for all eukaryotic Pol II structures, owing to the 
high degree of sequence conservation between Pol II enzymes.  For example, the bulk 
molecular weight of Pol II is accounted for by the Rpb1 and Rpb2 subunits.  These 
subunits make up lower and upper "jaws" of Pol II, with a 25 Å diameter opening 
between them where the enzyme clamps onto the DNA template.  These jaws exist in 
two conformations; an open conformation is hypothesized to allow entry of melted 
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promoter DNA, whereas a closed conformation is hypothesized to separate the newly 
generated DNA/RNA hybrid.  Nascent RNA transcripts then exit Pol II through a 
groove, termed groove 1 (Cramer et al., 2001; Gnatt et al., 2001).  Groove 1 terminates 
just before a 90 residue linker region that separates the Pol II carboxyl terminal domain 
(CTD) from the active centre of the enzyme (Cramer et al., 2001).  The Pol II CTD, 
situated on the Rpb1 subunit, is of considerable regulatory importance because it plays a 
central role in the transition of Pol II from the initiation to elongation phases of 
transcription.  In addition, the CTD is a structural and functional element unique to Pol 
II, as it is not found in RNA Polymerases I or III.  The CTD contains a heptapeptide 
repeat of Tyr-Ser-Pro-Thr-Ser-Pro-Ser, and forms an elongated, unordered structure 
(Cramer et al., 2001). 
 Pol II is unable to initiate transcription at promoters or respond to transcriptional 
regulatory signals on its own.  Promoter dependent transcription is achieved by Pol II in 
the presence the general transcription factors (GTFs) TFIID, A, E, B, H, and F.  The 
general Pol II machinery has therefore been defined as Pol II and GTFs.  TFIIB is the 
only single-polypeptide GTF; the majority of them, rather, are large multi subunit 
complexes (Lee and Young, 2000; Woychik and Hampsey, 2002).  For example, TFIID 
is made up of TATA binding protein (TBP) and 10 to 12 TBP associated factors (TAFs) 
(Albright and Tjian, 2000).  TFIIF is a heterotetramer comprised of two large RAP74 
subunits, and two small RAP30 subunits.  TFIIE is also a heterotetramer made up of two 
large TFIIEα subunits, and two small TFIIEβ subunits.  The largest GTF, TFIIH, is 
comprised of 9 subunits, and has a molecular weight comparable to Pol II.  Two of the 
TFIIH subunits, XPB and XPD, are ATP dependent DNA helicases.  Two additional 
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TFIIH subunits constitute a cyclin/cyclin dependent kinase complex.  As a result, TFIIH 
has been described as two subcomplexes, the TFIIH core, and the cyclin/cyclin 
dependent kinase complex.  The remaining GTF, TFIIA, was originally deemed 
essential for basal transcription in crude extract systems, but more recent investigation 
using highly purified preparations has demonstrated that TFIIA is in fact dispensable for 
basal transcription (Lee and Young, 2000).  
 
1.3.1.2.  Framework for the Mechanism of Transcription 
 Due to the extensive array of individual polypeptides that constitute the general 
transcriptional machinery, a huge effort has been made to understand the precise roles 
these proteins play in transcription.  For example, how do these polypeptides assemble at 
the promoter to direct pre-initiation complex (PIC) formation?  The transcription pre-
initiation complex is defined as the proper assembly of template (promoter) DNA, Pol II 
and the GTFs TFIID, E, B, H, and F.  In vitro transcription reconstitution assays have 
provided a rudimentary framework for understanding the specific mechanistic roles the 
individual GTFs play in assembly of this complex (Orphanides et al., 1996; Roeder, 
1996).  However, these assays have provided only the most basic understanding of 
transcription; therefore, these concepts will be expanded on in subsequent sections.  An 
early observation was that a large number of eukaryotic promoters contain TATA motifs 
in their core region.  As a result, the TATA box was the first identified eukaryotic core 
promoter element (Butler and Kadonaga, 2002).  The core promoter has been defined as 
an approximately 100 bp region that contains motifs essential for GTF function, such as 
the TATA box, as well as the transcription initiation site.  The TATA box, usually 
located 25 or 30 bp upstream from the site of transcription initiation, is the binding 
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recognition site for the TATA binding protein (TBP) component of TFIID (Hoey et al., 
1990).  TBP has been crystallized alone and in complex with the TATA element, and 
resembles a "molecular saddle" that straddles the TATA box and confers a sharp bend in 
the DNA molecule (Kim and Burley, 1994; Kim et al., 1993; Nikolov and Burley, 1994; 
Nikolov et al., 1995).  TBP also provides various interfaces for TAF binding.  Therefore, 
the TATA box plays an important role in directing PIC formation, likely through TFIID 
recruitment.  Following TFIID recruitment, TFIIB enters the PIC and binds a TFIIB 
recognition element (BRE) found immediately upstream of the TATA box in a small 
subset of eukaryotic core promoters (Lagrange et al., 1998).  This binding is the result of 
an interaction between a helix-turn-helix motif in the TFIIB core domain and the major 
groove of the BRE (Bell et al., 1999; Tsai and Sigler, 2000).  Interestingly, TFIIB also 
makes contacts with the minor groove of the DNA helix downstream of the TATA box, 
and this asymmetric binding is proposed to provide directionality for PIC assembly and 
subsequent transcription (Tsai and Sigler, 2000).  TFIIB is also involved in transcription 
start site selection, presumably through direct interaction with Pol II.  Once a stable 
complex has formed between the core promoter, TFIID, and TFIIB, Pol II is escorted to 
the promoter via tight association with TFIIF.  The unphosphorylated form of Pol II 
CTD is required for transcription initiation (Proudfoot et al., 2002).  The RAP30 subunit 
of TFIIF binds on either side of the TATA box, while RAP74 interacts with the core 
promoter downstream of this motif (Woychik and Hampsey, 2002).  TFIIF stabilizes the 
entire PIC, and is an essential pre-requisite for TFIIE and TFIIH entry into the PIC.  As 
a result, TFIIE is recruited to the core promoter after TFIIF and Pol II have bound.  
TFIIE contacts DNA within and immediately downstream of sequences that will be 
melted to generate the transcription bubble (Woychik and Hampsey, 2002).  TFIIE 
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affects the late events in PIC assembly such as TFIIH recruitment and regulating TFIIH 
activity.  The final PIC generates an extensive footprint over the majority of the core 
promoter, suggesting there are multiple weak DNA-protein contacts that combined 
constitute a very stable complex.  This is supported by the observation that no concise 
response elements have been defined for the general transcription factors within 
eukaryotic promoters except for TFIID and perhaps TFIIB.   
 The helicase activities of TFIIH, once part of the PIC, catalyze ATP dependent 
promoter melting, thus generating a 12-15 bp transcription bubble, which is essential for 
transcriptional initiation (Kim et al., 2000).  Following bubble formation, a phenomenon 
called abortive initiation ensues.  This continuous process is characterized by the 
formation of the first few phosphodiester bonds in the transcript, followed by release of 
the resulting short RNA product (Dvir, 2002).  Eventually Pol II is able to exit the 
abortive initiation phase of transcription, and generate progressively longer transcripts, a 
process termed promoter clearance (Gnatt, 2002).  Once Pol II has cleared the promoter, 
it pauses 25 to 30 bp downstream and matures to an elongation-competent complex that 
is able to generate full length RNA transcripts, a transition process called promoter 
escape (Dvir, 2002; Gnatt, 2002).  Although the precise mechanisms that regulate the 
transition through these early stages of transcription are not completely clear, the 
composition of proteins interacting with Pol II, as well as the phosphorylation status of 
the Pol II CTD are tightly associated with each of these individual stages.  For example, 
the Pol II CTD must be unphosphorylated (Pol IIA) in order for transcription initiation 
to proceed.  The cyclin dependent kinase subunit of TFIIH, as well as another 
cyclin/kinase complex, P-TEFb (positive transcription elongation factor b), are two 
proteins capable of phosphorylating serines 2 and 5 in the heptapeptide repeat of the Pol 
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II CTD (Price, 2000) .  This phosphorylation prompts Pol II transition to the elongation-
competent form (Pol IIO).  In early phases of transcription initiation, the Pol II CTD is 
primarily phosphorylated at Ser 5.  Alternatively, serine 2 phosphorylation is associated 
with later stages of transcriptional elongation (Proudfoot et al., 2002).  CTD 
phosphorylation is postulated to cause transcription initiation factors to release, and new 
transcription elongation factors to bind.  This change in binding of factors to Pol II has 
been hypothesized to take place during the pause in transcription that occurs with 
transition from promoter clearance to promoter escape.  Interestingly, the majority of the 
transcription elongation factors are components of the RNA processing machinery, 
demonstrating that transcription and RNA processing are co-regulated, intertwined 
events.  For example, all three enzymatic activities responsible for capping the 5' end of 
the nascent RNA transcript are associated with the phosphorylated CTD of Pol II.  CTD 
phosphorylated at Ser 5 even stimulates the guanyltransferase activity of the capping 
complex (Proudfoot et al., 2002).  In addition, phosphorylated CTD enhances RNA 
splicing events, likely through direct associations with the SR (Ser-Arg) family of 
splicing factors that play a role in recognizing the 3' and 5' splice sites flanking exonic 
DNA (Proudfoot et al., 2002).  Finally, CPSF (cleavage and polyadenylation specificity 
factor) is a component of active TFIID that transfers to Pol IIO immediately after its 
transition from Pol IIA.  Phosphorylated Pol II CTD directs the interaction with CPSF 
and also enhances its activity (Proudfoot et al., 2002).  
 
1.3.1.3.  Core Promoter Heterogeneity 
 The models presented above describing the mechanism of transcription are based 
on a core promoter containing a TATA motif.  Indeed, this motif was the first described 
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core promoter element and therefore serves as the focal point for a basic understanding 
of transcription initiation.  However, the heterogeneity of core promoters has received 
much attention in the past few years, and two additional functional elements have been 
described.  These two functional elements have been termed the initiator (Inr) and 
downstream promoter element (DPE).  In Drosophila, nearly half of core promoters 
contain the combination of TATA and Inr, while the other half contains Inr and DPE.  
However, in mammals, promoters have been catalogued that contain TATA alone, Inr 
alone, both TATA and Inr motifs, both Inr and DPE motifs, or none of these elements at 
all.  The composition of these elements in a eukaryotic core promoter has been proposed 
to play a previously unappreciated role in regulating transcription, likely by offering 
increased combinatorial diversity in promoter structure.   
 The Inr has been defined as the element encompassing the transcription start site 
that binds regulatory factors (Lee and Young, 2000).  The consensus for the Inr element 
is YYA(+1)NTYY (Y = pyrimidine, N = any nucleotide), with transcription usually, but 
not always, arising from the central A residue (Smale et al., 1998).  The Inr, much like 
the TATA box, can direct basic transcription in isolation as assessed by in vitro 
transcription assays (Smale and Baltimore, 1989).  This suggests the Inr has similar GTF 
recruitment properties to the TATA motif.  In addition to supporting basal transcription, 
another similarity to the TATA element is that the Inr can support activated transcription 
when influenced by activators bound to upstream sequences (Chen and Hampsey, 2002).  
Although these findings suggest the Inr and TATA motifs may be functionally 
redundant, many promoters contain both elements.  In this situation, synergistic levels of 
basal transcriptional activity are observed (Lee and Young, 2000).  This synergy is only 
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achieved when the TATA and Inr elements are separated by 25 bp, but not 30, 35, or 40 
bp, suggesting a specific architecture is essential (Smale et al., 1998).   
 Interestingly, for Drosophila promoters with disrupted TATA elements, a 
consensus DPE can functionally compensate for this loss (Burke et al., 1998).  The DPE, 
which was originally identified in Drosophila core promoters, is a distinct 7 bp element 
located 30 bp downstream from the Inr.  The consensus for the DPE in Drosophila has 
been defined as RG(A/T)CGTG (R = purine); however, the DPE consensus in mammals 
has not been determined (Burke et al., 1998).  Nevertheless, evidence exists for similar 
functional elements in mammalian cells, although the exact importance of the DPE in 
regulating mammalian transcription is still largely not described (Burke et al., 1998).   
 A unifying feature of these functional core promoter elements is that they all bind 
distinct TFIID components; therefore, they have been implicated in being able to 
independently nucleate preinitiation complex assembly.  Indeed, the TAF dependence of 
transcriptional activation is not universal, but rather specified by individual core 
promoters (Woychik and Hampsey, 2002).  Therefore, depending on the make-up of the 
individual core promoter, different sets of TAFs will be essential for supporting basal 
transcription.  DNA cross-linking experiments have shown that Drosophila TAF(II)60 
directly interacts with the DPE; therefore, this TAF has been implicated in recognition 
of this site (Burke and Kadonaga, 1996).  In addition, the largest human TAF, 
hTAF(II)250 or TAF1, has been shown to directly bind the Inr motif in concert with 
hTAF(II)150 or TAF2 (Chalkley and Verrijzer, 1999).  Interestingly, TAF2 can bind 
DNA on its own; however, its specificity appears to be for DNA structure rather than 
DNA sequence (Chalkley and Verrijzer, 1999). 
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1.3.1.4.  TATA Binding Protein Associated Factor (TAF)-1 
 In addition to binding the Inr element and thus providing an important TFIID 
recruitment function, TAF1 harbours a multitude of enzymatic activities.  For example, 
TAF1 possesses acetyltransferase (AT) activity; however, this activity is very weak 
towards histone proteins in vitro (Wassarman and Sauer, 2001).  Interestingly, TAF1 has 
been shown to acetylate TFIIEβ and the RAP74 subunit of TFIIF (Imhof et al., 1997).  
The effect acetylation has on the function of these general transcription factors is not 
known.  In addition to its AT domain, TAF1 harbours two distinct N and C terminal 
Ser/Thr kinase domains, termed the NTK and CTK, respectively.  Both the NTK and the 
CTK can phosphorylate the RAP74 subunit of TFIIF (Dikstein et al., 1996).  In addition, 
the NTK can phosphorylate the largest TFIIA subunit, TFIIA-L (Solow et al., 2001).  
Although these NTK and CTK substrates were identified in vitro, they have been 
proposed as likely in vivo candidates for TAF1 kinase activity.  For example, 
dephosphorylated RAP74 has been shown to inhibit its ability to stimulate 
transcriptional elongation in reconstituted in vitro transcription assays (Wassarman and 
Sauer, 2001).  TFIIA phosphorylation stimulates the generation of a complex between 
TFIIA, TBP, and a TATA-containing DNA template in vitro (Wassarman and Sauer, 
2001).  TAF1 also possesses E1 ubiquitin activation and E2 ubiquitin conjugation 
activities.  The only definitive substrate for this activity identified thus far is histone H1, 
as TAF1 has been shown to monoubiqutinate this protein (Pham and Sauer, 2000).  The 
functional consequences of this monoubiquitination have not been described.  Finally, 
TAF1 possesses two tandem bromodomains, which play a role in binding to acetylated 
histones (Wassarman and Sauer, 2001).  The TAF1 bromodomains have been shown to 
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prefer histone H4 doubly acetylated at lysines 5 and 12 (Jacobson et al., 2000).  
Therefore, these domains have been proposed to be responsible for targeting TAF1, and 
hence TFIID, to chromatin packaged promoters (Wassarman and Sauer, 2001). 
 Because of the myriad of important TAF1 activities, it is not surprising that TAF1 
inactivation in Drosophila is lethal (Wassarman et al., 2000).  This supports the current 
view that TAF1 serves a vital TFIID recruitment function at promoters with Inr 
elements, but also contributes essential enzymatic activities at various other classes of 
core promoters.  This theory is strengthened by findings that the transcription of 30% of 
cellular genes in yeast are absolutely dependent on fully functional TAF1 (Holstege et 
al., 1998).  Tools that have been vital for understanding mammalian TAF1 function are 
the tsBN462 and ts13 cell lines, which are both derived from BHK-21 (baby hamster 
kidney) cells and harbor identical G690D mutations in the TAF1 protein (Hayashida et 
al., 1994).  Studies with these cell lines have implicated an essential role for TAF1 in 
cell cycle progression because they grow normally at 33oC, but undergo G1/S arrest 
when shifted to the restrictive temperature of 39oC.  The cell cycle arrest elicited at 39oC 
in ts13 cells is rescued by expression of wild-type TAF1, suggesting disruption of TAF1 
activity is directly responsible for this temperature sensitive phenotype (Wang and Tjian, 
1994).  Early studies suggested this temperature sensitive phenotype could be accounted 
for entirely by abrogation of TAF1 AT activity at the restrictive temperature, because 
AT activity is compromised in vitro at 39oC, but not 33oC (Dunphy et al., 2000).  
However, a recent report has demonstrated the G690D mutation also abolishes the 
ability of a TAF1/TAF2 dimer to bind Inr elements in vitro (Hilton and Wang, 2003).  
Combined, the loss of these two important TAF1 functions alters transcription of 18% of 
cellular genes in these cells (O'Brien and Tjian, 2000).  Perhaps most significantly, 
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temperature shift results in the activation of genes encoding p21 and p27, and reduction 
in the expression of cyclins D1 and A; these transcriptional responses could very likely 
be responsible for the observed G1/S arrest (Rushton et al., 1997; Sekiguchi et al., 1996; 
Suzuki-Yagawa et al., 1997). 
 
1.3.2.  Upstream Activation Sequences and Activated Transcription 
1.3.2.1.  Upstream Activation Sequences 
 Perhaps the best-defined features of eukaryotic promoters are transcriptional 
activating sequences.  These elements are usually divided into two groups, upstream 
activating sequences (UASs) and enhancers, depending on their proximity to the core 
promoter.  The UASs are usually discrete elements bound by activators that directly 
influence the transcription arising from nearby start sites.  The second group, the 
enhancers, are usually clusters of discrete activator binding sites that act in an 
orientation independent manner and can exert their effects on transcription from great 
distances away from the start site.  The commonality of these two different classes of 
elements is that they both contain readily identifiable sequences that recruit sequence 
specific activators, or transcription factors. 
 Most transcriptional activators are comprised of two modular domains:  the DNA 
binding domain, and the transactivation domain.  Based on similarities in DNA binding 
domain and transactivation domain composition, transcription factors have been grouped 
into large superfamilies (Paasinen-Sohns and Holtta, 1997).  The DNA binding domain 
is responsible for the ability of these activators to bind their cognate cis-elements, while 
the transactivation domain has been deemed important for affecting the rate of 
recruitment of the Pol II transcription initiation complex to the core promoter.  Indeed, 
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direct binding of transcription factor transactivation domains to components of the 
general transcriptional machinery has been described (Lee and Young, 2000).  However, 
the precise mechanisms by which activators influence the rate of recruitment of the Pol 
II transcription machinery to the core promoter are still being debated.  In vitro 
reconstitution experiments suggest that transcriptional machinery is recruited to the 
promoter in a factor-by-factor fashion, and that activators directly affect a single rate-
limiting step in this process (Buratowski et al., 1989).  Conversely, large Pol II-
containing complexes have been purified that are competent for directing activated 
transcription, suggesting the GTFs and Pol II can exist as a single complex in vivo that 
can be recruited to the promoter (Greenblatt, 1997).  In this situation, activators have 
been hypothesized to influence the rate of recruitment of this entire complex to the 
promoter.  It is most likely that these two theories represent the extremes of Pol II 
machinery recruitment, and that they both occur to varying degrees at each of the 
individual promoters in the eukaryotic genome.  In addition to influencing its rate of 
recruitment to the promoter, activators have also been described to directly influence the 
activity of the transcriptional machinery.  Examples exist where activators enhance the 
processivity of Pol II, or increase the rate of Pol II elongation, possibly by directly 
affecting processes that regulate promoter clearance and promoter escape (Blau et al., 
1996).  Finally, activators have also been shown to influence the rate of transcriptional 
re-initiation, thus supporting multiple rounds of transcription from a given promoter.  
This has been hypothesized to occur through activators being able to stabilize factors 
that remain promoter bound following promoter escape (Hahn, 1998).   
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1.3.2.2.  The Mediator Complex 
 Early in vitro reconstitution experiments showed that the general transcriptional 
machinery, consisting of Pol II and GTFs, is sufficient for basal, promoter-specific 
transcription in a reconstituted system.  However, a more current definition of the 
general transcriptional machinery includes an additional protein complex, termed 
Mediator.  The Mediator complex was originally defined as an activity in crude 
Saccharomyces cerevisiae cell extracts required to bridge the basal transcriptional 
machinery with upstream activators.  This was the result of observations that purified 
transcription factors could not exert their activation functions on the basic transcriptional 
apparatus in in vitro reconstitution assays without Mediator activity (Flanagan et al., 
1991; Kelleher et al., 1990).  Indeed, although direct interactions have been 
demonstrated between transcription factor activation domains and various TAFs, yeast 
Mediator appears to be the central complex through which transcription factors 
communicate with the basal transcription apparatus (Myers and Kornberg, 2000).  
However, the mechanisms of activator communication with the Mediator complex 
remain obscure.  Interestingly, Mediator is not associated with Pol II during the 
elongation phase of transcription, therefore, the primary role of this complex is likely 
centred around regulating PIC assembly (Gustafsson and Samuelsson, 2001).  Of 
particular importance to this theory, Mediator alone can stimulate basal transcription, 
likely through its ability to regulate TFIIH kinase activity towards the Pol II CTD 
(Woychik and Hampsey, 2002).  Since these early studies in S. cerevisiae, Mediator has 
been identified in Drosophila and mammalian cells, therefore, it has become very 
evident that this complex is essential for regulating all activated eukaryotic transcription 
(Lee and Young, 2000; Myers and Kornberg, 2000; Woychik and Hampsey, 2002).  
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Yeast Mediator has been the most extensively characterized, and is composed of 23 
subunits, with two evident and functionally distinct subcomplexes, termed the Srb4 and 
Rgr1 modules.  SRB genes were originally identified as suppressors of yeast growth 
defects caused by partial RNA Pol II CTD truncations (Nonet and Young, 1989).  Their 
gene products, the Srb proteins, were subsequently isolated in a complex with RNA Pol 
II (Thompson et al., 1993).  These Srb proteins confer Pol II, TBP, and TFIIB binding 
capacity on the Srb4 module (Myers and Kornberg, 2000).  Low-resolution structure 
analysis has shown that Mediator adopts a crescent shaped structure when complexed 
with RNA Pol II.  The Srb4 module represents the head, and the Rgr1 module makes up 
the middle and tail portions of this structure (Dotson et al., 2000).  
 
1.3.3.  Transcription and Chromatin 
1.3.3.1.  Chromatin Structure and Transcriptional Control 
 The diversity in architecture of UASs, enhancers, and core promoters, coupled 
with the abundance of transcriptional activators and components of the general 
transcriptional machinery offer a bewildering number of combinatorial controls to 
regulate the appropriate expression of all genes in the eukaryotic genome.  However, 
even the complicated interactions between all these factors represent a reductionist view 
of transcriptional regulation.  An additional layer of complexity is provided by the 
regulation of the packaging of the DNA template into higher order structures.  In 
eukaryotes, DNA typically exists in vivo as a highly ordered structure based on arrays of 
repeating nucleosomes (Kornberg and Lorch, 1999).  This nucleosomal structure is 
conferred on DNA by histone proteins, and provides the best-defined level of regulation 
of chromatin structure.  A single nucleosome can be defined as a 146 bp segment of 
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DNA wrapped twice around a histone core octamer, which is composed of two of each 
of the histone proteins H2A, H2B, H3, and H4.  Other chromatin associated proteins, 
such as the linker histone H1, the high mobility group (HMG), and silent information 
regulator (SIR) proteins are responsible for mediating the packaging of these simple 
nucleosomes into higher ordered chromatin structures.  The two extremes of these 
higher-order structures are represented by the decondensed, accessible euchromatin 
structure, and the most highly condensed, inaccessible heterochromatin structure (Naar 
et al., 2001).  In general, nucleosomal structure is considered repressive to transcription, 
likely due to its masking of important DNA elements from transcription factors and 
basal transcriptional machinery (Grunstein, 1990).  As a result, an important step in 
transcription initiation is the generation of a nucleosomal organization at promoters that 
is amenable to factor binding and communication.  This regulation is provided by a 
subset of co-activator proteins, which are recruited to promoters during transcriptional 
activation (Naar et al., 2001).  Recently, co-activators have been broadly grouped into 
two categories, but were originally solely defined as proteins that transcriptional 
activators required to elicit activated transcription (Featherstone, 2002).  The first group 
of co-activators includes proteins that are components of, or interact with, the general 
transcriptional machinery.  Examples from this class of co-activators include TAFs and 
various components of the Mediator complex.  The second group of co-activators are 
capable of modifying the structure of chromatin.  This class of co-activators is largely 
comprised of multi-protein complexes that may or may not directly interact with 
transcriptional activators.  Examples of these chromatin modifiers include the ATP-
dependent chromatin-remodeling enzyme SWI/SNF and the p300 histone 
acetyltransferase (HAT) enzyme, respectively. 
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 1.3.3.2.  ATP Dependent Chromatin Remodeling Enzymes 
 ATP dependent chromatin remodeling enzymes are parts of large, multi-subunit 
complexes that utilize ATP hydrolysis to increase the accessibility of nucleosomal DNA.  
Chromatin remodeling is a general term used to describe a collection of documented 
biochemical, ATP-dependent activities that all of these enzymes possess.  The in vitro 
assays developed to demonstrate these activities have been extensively described 
(Narlikar et al., 2002).  These activities include the ability to alter DNaseI cleavage 
patterns, move histone octamers relative to a specific DNA position, and change the 
negative coiling of closed circular arrays catalyzed by topoisomerase enzymes (Narlikar 
et al., 2002).  Chromatin remodeling enzymes have been grouped into three families 
based on the identity of their central ATPase subunit.  It is important to note that this 
central ATPase subunit has remodeling activity in isolation; therefore, the remaining 
subunits in these large complexes are thought to affect substrate specificity as well as the 
efficiency and outcome of remodeling (Narlikar et al., 2002).  These families include the 
SWI2/SNF2 family, the ISWI family, and the Mi-2 family.  Homologues of the yeast 
SWI2/SNF2 central ATPase are the Brahma family of Drosophila and human ATPases, 
BRG1, and hBRM, respectively (Naar et al., 2001).  Examples of the ISWI family of 
chromatin remodelers include yeast ISW1, human RSF, and Drosophila NURF.  The 
human NuRD chromatin-remodeling complex is the prototype for the Mi-2 family.  A 
common generalization is that the chromatin modifications exerted by these enzymes 
always occur before factors bind to promoters.  This arises from the theory that a 
localized chromatin structure appropriate for the binding of transcriptional activators and 
the general transcriptional apparatus must be provided as the initial step in 
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transcriptional activation.  However, the results of experiments with steroid receptor and 
other transcription factors have demonstrated direct activator interaction can occur with 
the SWI/SNF complex, thus suggesting remodeling activity is recruited to specific 
promoters by transcriptional activators (Naar et al., 2001).  These two competing views 
probably represent the extremes, and most likely, the final temporal and spatial outcome 
of chromatin remodeling activity in vivo is a function of the specific signals exerted on 
the individual complex by transcriptional activators, basal transcriptional machinery, and 
local DNA architecture.  Potential for such intricate specificity is highlighted by results 
from large-scale gene expression studies in yeast that have demonstrated the SWI/SNF 
complex only participates in the transcriptional regulation of 6% of cellular genes 
(Sudarsanam et al., 2000)  
 
1.3.3.3.  Enzymes that Covalently Modify Histone Proteins 
 There are numerous enzymes that are able to covalently modify histone proteins.  
Histone modifications described to date are phosphorylation, ubiquitination, acetylation, 
methylation, and ADP-riboslylation.  The majority of these modifications occur within 
each of the histones' basic N-terminal tail regions, which are rich in highly conserved 
lysines, and extend from the globular histone core (Roth et al., 2001).  The strong net 
positive charge associated with the histone tails is thought to mediate strong 
histone/DNA interactions and internucleosomal interactions.  Early interest in histone 
modifications therefore focused on acetylation, because this particular modification was 
postulated to neutralize the overall positive charge on the histone tails.  This 
neutralization is thought to result in disrupted histone/DNA and internucleosomal 
interactions, thus allowing factor access to the DNA template.  This theory is strongly 
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supported by the historical tight correlation between acetylated histones and 
transcriptionally active chromatin (Hebbes et al., 1988).  Further support comes from 
observations that many co-activator complexes recruited to active promoters possess 
histone acetyltransferase (HAT) activity while many co-repressor complexes recruited to 
repressed promoters possess histone deacetylase (HDAC) activity (Pazin and Kadonaga, 
1997).  However, because these associations between HAT activity, histone acetylation, 
and transcriptional activity are not always observed, an alternative to this generalization, 
termed the histone code, has been proposed (Agalioti et al., 2002).  This newly emerging 
hypothesis suggests the combination of modifications on histone tails, in conjunction 
with direct CpG methylation patterns on the DNA template, constitute a code that 
specifies gene expression patterns (Turner, 2002).  The identification of bromodomains 
and chromodomains on nuclear proteins, which are binding motifs specific for 
acetylated and methylated histones, respectively, increases the validity of this theory 
(Turner, 2002).   
 In light of the controversy surrounding these competing theories, and the apparent 
importance of histone acetylation and deacetylation dynamics for transcriptional 
regulation, the HAT and HDAC enzymes that catalyze these reactions have been the 
focus of intense study.  HAT enzymes utilize acetyl-CoA as a substrate to acetylate 
specific lysine residues on histone as well as other proteins.  In situations where histone 
proteins are not the target of acetylation, the generic term acetyltransferase (AT) or 
factor acetyltransferase (FAT) have been employed to describe these enzymes.  Much 
confusion stems from the observations that many HAT enzymes possess more general 
AT, or FAT, activity.  Examples of non-histone nuclear proteins that can be acetylated 
by these AT enzymes include DNA-binding activators such as p53 (Gu and Roeder, 
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1997), Sp3 (Braun et al., 2001), EKLF (Zhang and Bieker, 1998), and GATA-1 (Boyes 
et al., 1998), the general transcription factors TFIIE and TFIIF (Imhof et al., 1997), and 
architectural proteins such as HMG-I and HMG-17 (Lee and Young, 2000)   The HAT 
enzymes have been divided into two types:  type A HATs are nuclear, whereas type B 
HATs are cytoplasmic.  Of the type A HATs, there are the GNAT, MYST, p300/CBP, 
and nuclear receptor coactivator families.  The TAF(II)250 HAT domain is very 
different from the other type A HAT proteins; therefore this TAF is often catalogued as 
"other" with respect to family membership.  These HAT activities are recruited to 
specific genes in part through interactions with sequence specific transcriptional 
activators (Sterner and Berger, 2000).  The best-defined and comprehensively studied set 
of ATs is the GNAT (Gcn5-related N-acetyltransferase) superfamily, which is 
comprised of the Gcn5, PCAF, Hat1, Elp3, and Hpa2 HAT enzymes (Sterner and 
Berger, 2000).  Yeast Gcn5 was the first discovered HAT enzyme; therefore it serves as 
the prototype for this family.  In vitro, recombinant Gcn5 has HAT activity specific for 
lysine 14 on histone H3, and lysines 8 and 16 on histone H4 (Kuo et al., 1996).  
However, in these in vitro assays, Gcn5 is unable to acetylate nucleosomal histone 
proteins, the physiological substrate, unless assayed at high concentration under specific 
reaction conditions (Sterner and Berger, 2000).  Therefore, it is significant that yeast 
Gcn5 exists in a larger HAT complex in vivo, termed the SAGA complex (Spt-Ada-
Gcn5 acetyltransferase).  Similarly, MYST (named after its family members:  MOZ, 
Ybf2, Sas2, Tip60) containing HAT complexes have been identified in yeast.  Yeast 
SAGA has been sized at approximately 1.8 MDa, and 15 of its subunits have been 
identified.  Interestingly, many of these subunits include factors that have previously 
been identified as intimately involved in transcription, including the Sin4 component of 
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the Mediator complex, various TAFs, and the Ada and Spt transcriptional adapter 
proteins (Sterner and Berger, 2000).  This suggests that various subunits are shared 
between TFIID, Mediator, and HAT complexes such as SAGA at promoters in vivo.  It 
is therefore likely that the exact compositions of these mega-complexes offer significant 
degrees of combinatorial control to individual eukaryotic promoters. 
 Balancing the activities of the HAT enzymes are the HDAC enzymes.  Like HAT 
enzymes, there are numerous mammalian HDACs, which have been divided into three 
classes based on their functional homology to yeast HDACs.  The first group of 
mammalian HDAC enzymes, class I HDACs, are homologous to yeast RPD-3, and 
include HDAC1, 2, 3, and 8 (Emiliani et al., 1998; Hu et al., 2000; Laherty et al., 1997; 
Taunton et al., 1996).  Class II mammalian HDACs are homologous to yeast HDA-1, 
and include HDAC4, 5, 6, and 7 (Grozinger et al., 1999).  Class II HDACs are much 
larger proteins than the class I HDACs; however, the catalytic activities of HDACs 
within these two classes are very similar in that they all require a Zn2+ cofactor.  The 
yeast SIR-2-like Class III HDACs are quite different from classes I and II HDACs; there 
are seven enzymes within this family (SIR1-7), and all require nicotinamide adenine 
dinucleotide (NAD) as a co-factor or substrate (Imai et al., 2000).  An additional 
similarity to the HAT enzymes is that HDACs are associated with large, multi-protein 
complexes in vivo.  Two co-repressor complexes, termed Sin3 and NuRD, have been 
characterized to date, and each contains HDAC1 and HDAC2 in their core domain.  
Sin3 was first characterized as a co-repressor for the transcriptionally repressive Mad-
Max heterodimer (Ayer et al., 1995). Interestingly, the HDAC1 and 2 containing NuRD 
complex is actually a Mi-2 family ATP-dependent chromatin remodeler, thus providing 
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an HDAC-chromatin remodeling link and additional complexity to regulation of 
nucleosome dynamics. 
 
1.3.3.4.  Histone Deacetylase Inhibitors                      
 Aberrant HDAC-mediated transcriptional repression has been implicated in the 
development and progression of various human cancers, especially haematological 
malignancies such as acute promyelocytic leukemia (APL) and acute myeloid leukemia 
(AML) (Vigushin and Coombes, 2002).  For example, a subset of APL is characterized 
by the t(15;17) chromosomal translocation, which results in a gene fusion that encodes a 
retinoic acid receptor (RAR)-α:PML transcription factor chimera (Grignani et al., 2000).  
The RAR-α:PML chimera is a strong transcriptional repressor and blocks transcription 
of RAR-regulated genes through recruitment of the HDAC-containing Sin3 co-repressor 
complex (Grignani et al., 1998).   The resulting prevention of myeloid maturation plays 
a direct role in the subsequent development of APL (Grignani et al., 2000).  In light of 
these observations, it is very significant that histone deacetylase (HDAC) inhibitors 
(HDIs) display chemotherapeutic and chemopreventive properties towards transformed 
cells in culture and animal models (Marks et al., 2000).  Interestingly, these agents' anti-
cancer effects have been observed in a large number of haematological malignancies and 
solid tumors; therefore these agents have sparked a great deal of interest as general anti-
neoplastics.   
 The HDIs have been divided into five classes according to the relatedness of their 
chemical structures.  These classes include the hydroxamic acids, cyclic tetrapeptides 
with an epoxyketone moiety, cyclic peptides without an epoxyketone moiety, 
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benzamides, and short chain fatty acids (Vigushin and Coombes, 2002).  The two most 
commonly studied HDI classes are trichostatin A (TSA) and butyrate, which belong to 
the hydroxamic acid and short chain fatty acid classes of HDIs, respectively (Fig. 1.4).  
These agents both effectively and reversibly inhibit HDAC enzymes.  Specifically, both 
butyrate and TSA have been kinetically characterized as non-competitive inhibitors of 
HDAC enzymes (Marks et al., 2000; Yoshida et al., 1990).  However, more recent 
structural studies have shown that TSA is able to directly bind the HDAC active site, 
thus suggesting it would be more likely to act as a competitive inhibitor (Finnin et al., 
1999).  In addition, TSA is much more potent than butyrate, achieving HDAC inhibition 
at nanomolar concentrations (Marks et al., 2000).  In vivo studies have demonstrated 
direct anti-tumor activity of hydroxamic acids in a rat breast cancer model, as well as 
human tumor xenograft experiments with cancer cells derived from melanoma, androgen 
refractive prostate cancer, gastrointestinal tract, lung, and breast (Cohen et al., 1999; 
Komatsu et al., 2001; Marks et al., 2000; Qiu et al., 1999).  Prevention of carcinogen 
induced rat mammary and mouse lung tumors have also been observed for the 
hydroxamic acids (Cohen et al., 1999; Marks et al., 2000).  The general dogma 
surrounding these agents is that they specifically inhibit histone deacetylation, and 
therefore elicit transcriptional induction of cellular genes.  This is illustrated by the most 
well-characterized response to HDI treatment:  the p53-independent transcriptional 
induction of the WAF1 gene, which encodes the cell cycle inhibitor p21WAF1 (Huang et 
al., 2000; Nakano et al., 1997).  Induction of WAF1 has been demonstrated as essential 
for the growth inhibitory effects of these agents (Archer et al., 1998b).  However, the 
common beliefs regarding HDAC action do not take into account the inhibition of 
deacetylation of non-histone proteins.  Indeed, large scale gene expression studies have  
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Figure 1.4.  Chemical structures of HDAC inhibitors.    The 
structures of the hydroxamic acid-based compound, TSA (A), 
and the short chain fatty acid, butyric acid (B), are shown. 
clearly demonstrated that HDIs also elicit direct repression of just as many genes as are 
induced (Mariadason et al., 2000).  Therefore, the anti-cancer effects of HDIs can be 
more accurately attributed to the reprogramming of cellular gene expression, resulting in 
both the induction and repression of a very specific subset of cellular genes (Mariadason 
et al., 2000).  Clearly, repression of growth promoting genes such as cyclin D1 
(Lallemand et al., 1996) and c-Myc (Heruth et al., 1993; Souleimani and Asselin, 1993) 
also offers valid explanation for the anti-cancer effectiveness of HDIs.  Thus, the 
molecular pathways that lead to activation and repression of transcription following HDI 
treatment are currently an area of intense study.       
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1.4.  Regulation of SRC Transcription 
 The human SRC gene is comprised of 15 exons (Anderson et al., 1985; Bonham 
and Fujita, 1993; Bonham et al., 2000; Gibbs et al., 1985; Parker et al., 1985) (Fig 1.5).  
Exons 2-12 encode pp60c-Src as well as the 3' untranslated region of the c-Src mRNA.  
Exons 1B, and 1C are located within the 5' untranslated region of c-Src mRNA.  Two 
distinct promoters, each associated with separate exons, are located at the extreme 5' end 
of the SRC gene.  These promoters have been termed SRC1α and SRC 1A, and their 
associated exons Exon 1α and Exon 1A, respectively (Bonham and Fujita, 1993; 
Bonham et al., 2000; Ritchie et al., 2000).  The SRC promoters are very close 
physically, separated by a distance of roughly 1 kb.  When transcription arises from the 
SRC1α promoter, mature c-Src mRNA transcripts contain Exon 1α spliced to Exon 1B 
(Fig. 1.5).  Conversely, when transcription arises from the SRC1A promoter, c-Src 
mRNA transcripts contain Exon 1A spliced to 1B (Fig. 1.5).  Therefore, differential 
promoter usage results in two different c-Src transcripts that are identical in coding 
capacity, but differ in their 5' non-coding extremity (Fig. 1.5). 
 
1.4.1.  SRC1A Promoter 
 The SRC1A promoter closely resembles a typical housekeeping promoter; it lacks 
TATA or CAAT regulatory sequences, has an extremely high GC content, and 
transcription is initiated from multiple sites (Bonham and Fujita, 1993).  Detailed 
analysis of this promoter has revealed regulation of SRC1A transcription occurs 
primarily through the Sp-family of transcriptional activators (Ritchie et al., 2000).  Sp1, 
or specificity protein-1, is the prototype member for this well-studied transcription factor  
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Figure 1.5.  Organization of the human SRC gene.  The exon/intron boundaries of
the human SRC gene on chromosome 20q12.3 are shown.  Exons 1A, 1α, 1B, and
1C constitute the 5' non-coding region (white boxes), and Exons 2-12 constitute the
open reading frame and 3' non-coding region of c-Src mRNA (dark and light grey
boxes, respectively).  Two separate promoters are associated with Exons 1α and 1A,
and are termed the SRC1α and SRC1A promoters, respectively.  The primary cis-
acting DNA elements in these promoters that have been identified and characterized
are shown, and are discussed in detail in the text.  Alternative promoter use results in
two distinct c-Src mRNA species that are shown at the bottom.  These c-Src
transcripts are identical in their coding capacity, but differ in their extreme 5' ends.    
family, which also includes Sp2, Sp3, and Sp4 (Suske, 1999).  The Sp-family members 
all contain glutamine-rich transactivation domains, and specifically bind GC-rich 
elements through zinc finger motifs in their DNA binding domains (Philipsen and Suske, 
1999).  The Sp-family members, especially Sp1 and Sp3, are ubiquitously expressed, 
versatile in their activities, and obligatory factors at the majority of eukaryotic promoters 
and enhancers (Suske, 1999).  In terms of the SRC1A promoter, both Sp1 and Sp3 are 
capable of binding two Sp-family recognition sites, termed GC1 and GA2 (Fig. 1.5).  
Co-transfection experiments in Drosophila SL2 cells has shown that Sp1 is capable of 
transactivating a SRC1A promoter reporter construct, whereas Sp3 can repress this Sp1-
dependent transactivation, presumably through binding site competition (Ritchie et al., 
2000).  Mutagenesis of the GC1 and GA2 sites reduces SRC1A activity approximately 
90 %, thus demonstrating these sites to be critical for transcription from this promoter.  
In addition to GC1 and GA2, there are also three perfect polypurine:polypyrimidine 
(Pu:Py) tracts within the SRC1A promoter, termed TC1, TC2 and TC3 (Fig. 1.5).  Pu:Py 
sequences such as these have previously been suggested to form non-B-DNA triple-
helical structures, or H-DNA (Mirkin and Frank-Kamenetskii, 1994).  A nuclear factor, 
originally named SPy (Src pyrimidine binding factor), binds these Pu:Py tracts with 
interesting double- and single-stranded affinity.  For example, SPy is capable of binding 
to double stranded CTTCC motifs located within TC1 and TC2.  However, SPy binds 
with a higher affinity to the single-stranded pyrimidine tracts of TC1, TC2, and TC3.  
Recently, a DNA affinity purification approach identified SPy as heterogeneous nuclear 
ribonucleoprotein K (hnRNP K) (Ritchie et al., 2003).  hnRNP K is a well-characterized 
RNA binding protein and component of hnRNP complexes (Bomsztyk et al., 1997).  
However, further versatility for this protein has been highlighted by the observation that 
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hnRNP K is also a transcription factor that binds Pu:Py tracts in the MYC promoter 
(Michelotti et al., 1996).  Indeed, mutations in the SPy binding motifs within TC1 and 
TC2 that abolish SPy double or single stranded binding individually reduce SRC1A 
promoter activity approximately 20 to 50% (Ritchie et al., 2000; Ritchie et al., 2003).  
Interestingly, complete inhibition of SPy single stranded binding to both TC1 and TC2 
reduced SRC1A promoter activity two fold further than complete inhibition of SPy 
double stranded binding to both these tracts (Ritchie et al., 2003).  These results 
therefore signify an important functional role for SPy single stranded binding at the 
SRC1A promoter.  Combinations of mutations in Sp-family and SPy binding sites has 
revealed that the TC1 and GC1 sites act in a cooperative or additive manner, and that the 
individual GC1, GA2, TC1, and TC2 sites all interact in a complex fashion to affect 
transcriptional activity from the SRC1A promoter. 
 
1.4.2.  SRC1α Promoter 
 The SRC1α promoter was discovered following the observation that many c-Src 
mRNAs from human colon cancer cell lines did not contain Exon 1A in their 5' 
extremity (Bonham et al., 2000).  Preliminary experiments showed SRC1α transcripts 
arise from a single major start site in HepG2 liver carcinoma and HT29 colon carcinoma 
cells.  Analysis of promoter use in various human cancer cell lines demonstrated that the 
SRC1A and SRC1α promoters are both utilized in the same cell line, but the ratios of 
promoter use are highly variable.  A single DNA element was identified that resembled a 
binding site for the hepatocyte nuclear factor (HNF)-1 transcription factor, and 
subsequent deletion and mutagenesis experiments verified this site is absolutely essential 
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for SRC1α promoter activity (Fig. 1.5).  The HNF-1 transcription factor is a liver 
enriched transcription factor that was initially found responsible for liver specific 
transcription of β-fibrinogen, albumin, and α1-antitrypsin promoters (Cereghini, 1996).  
Further analysis determined this factor is in fact a homo- or heterodimer comprised of 
distinct HNF-1α and/or HNF-1β subunits (Hayashi et al., 1999).  Each of these HNF-1 
components contain similar dimerization domains, and DNA binding homeodomains, 
but differ significantly in the composition of their transcriptional activation domains.  
The HNF-1α transactivation domain actually contains three distinct regions that have all 
been deemed important for activation of different genes; these include the serine rich 
activation domain I, the proline rich activation domain II, and the glutamine rich 
activation domain III (Cereghini, 1996).  Transient transfection assays have 
demonstrated that both HNF-1α and HNF-1β have transactivation potential, depending 
on the promoter being studied (Hayashi et al., 1999).  Determination of the factors 
bound to the SRC1α promoter in HepG2 cells showed that HNF-1α was the primary 
HNF-1 component interacting with the HNF site.  Co-transfection experiments in HT29 
cells verified that HNF-1α, but not HNF-1β, transactivates the SRC1α promoter 
(Bonham et al., 2000).  Expression analysis of the SRC1α promoter demonstrated that 
SRC1α-derived transcripts are tissue-restricted in their pattern of expression.  While c-
Src expression appears to be ubiquitous (although at different levels) in nearly all 
tissues, c-Src transcripts containing Exon 1α are more restricted to tissues such as 
stomach, kidney, pancreas, and fetal lung.  Lower levels of SRC1α-derived transcripts 
are seen in colon, liver, prostate, fetal kidney, and fetal liver (Bonham et al., 2000).    
Interestingly, these are the same cell types that HNF-1α expression is restricted to.  
 54 
Therefore, these findings support the notion that SRC1α promoter use is regulated in 
normal tissues primarily by HNF-1α expression. 
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2.  SPECIFIC AIMS AND HYPOTHESIS 
 A frequent finding in diverse human cancers, including colon cancer, is activation 
of c-Src.  Often, this activation is accounted for by a concomitant increase in c-Src 
protein levels compared with surrounding normal tissue.  These findings suggest 
overexpression of c-Src protein could play an important role in the development and 
progression of human cancer.  One of key observations that led to the studies detailed in 
this thesis was that c-Src mRNA expression was very high in some cancer cell lines and 
very low in others.  This observation bridged the interests of those studying c-Src 
activation and those of Dr. Bonham's laboratory, which focuses on the regulation of 
SRC transcription in normal and cancerous cells.  SRC transcription is regulated by an 
interesting system of two promoters, which are separated by approximately 1 kb.  
Preliminary analysis of the use of these promoters in normal tissues has demonstrated 
the upstream SRC1α promoter is tissue-restricted in its expression, while the 
downstream SRC1A promoter is ubiquitously expressed.  Combined, these observations 
constitute the basis for the general hypothesis and specific aims of this thesis, which are 
detailed below. 
 
HYPOTHESIS:  The mechanisms regulating SRC transcription are important 
determinants of c-Src expression and activity in human cancer cells. 
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 SPECIFIC AIMS: 
Specific Aim #1:  To determine the contribution of SRC transcriptional activity to the 
overexpression and activation of c-Src in human colon cancer cell lines. 
 
Specific Aim #2:  To study transcriptional regulation of both SRC promoters in their 
natural, physiologically linked context, with emphasis on the mechanism(s) of SRC 
transcriptional activation in human cancer. 
 
Specific Aim #3:  To evaluate the importance of SRC promoter architecture in SRC 
transcriptional repression mediated by histone deacetylase inhibitors.   
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3.  MATERIALS AND METHODS 
3.1.  Reagents and Suppliers 
 The materials and reagents used in this study are listed in Table 3.1.  All were 
molecular biology or reagent grade.  In addition, a number of commercially available 
kits were directly utilized in this study, and are listed in Table 3.2.  Table 3.3 is a list of 
companies that supplied reagents and kits. 
_________________________________________________________ 
Table 3.1.  A List of Reagents and Suppliers 
Reagent Supplier Name 
[γ32P]-ATP (6000 Ci/mmol) NEN Research Products 
[α32P]-dCTP (6000 Ci/mmol) NEN Research Products 
α-MEM Invitrogen Life Technologies 
β-mercaptoethanol BDH 
 λDNA Amersham Biotech 
Actinomycin D Sigma 
agarose EM Science 
alkaline phosphatase Invitrogen Life Technologies 
ampicillin Fisher 
anti-AcH3 (Lys9/14) antibody Upstate Biotechnologies 
anti-HNF1α antibody Santa Cruz 
anti-Sp1 antibody Santa Cruz 
anti-Sp3 antibody Santa Cruz 
anti-Src antibody Oncogene Research Products 
aprotinin Sigma 
APS EM Science 
ATP Amersham Biotech 
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bacto-agar Invitrogen Life Technologies 
bacto-tryptone Difco Laboratories 
bacto-yeast extract Difco Laboratories 
borate BDH 
bovine insulin Eli Lilly 
Bradford protein reagent BioRad 
bromophenol blue BDH 
CaCl2 BDH 
Coomassie protein stain BioRad 
DEPC Sigma 
DMEM Invitrogen Life Technologies 
DMSO Sigma 
dNTP mix Invitrogen Life Technologies 
DTT BioRad 
EDTA BDH 
ethidium bromide Sigma 
ExpressHyb Clontech 
fetal calf serum CanSera 
formaldehyde BDH 
formamide BDH 
G418 Invitrogen Life Technologies 
GeneScreen Plus nylon membrane NEN Research Products 
glycerol BDH 
glycine EM Science 
guanidinium thiocyanite BDH 
HCl EM Science 
HEPES EM Science 
KCl BDH 
Klenow Fragment (DNA Polymerase I) Amersham Biotech 
leupeptin Sigma 
Lowry protein assay kit Sigma 
methanol BDH 
MgCl2 BDH 
MOPS Sigma 
N,N-methylene-bis-acrylamide BioRad 
NaCl BDH 
NaH2PO4 BDH 
NaHPO4 BDH 
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NaOH BDH 
nitrocellulose Sigma 
non-fat dry skim milk powder Carnation 
NP-40 BDH 
ONPG Sigma 
penicillin/streptomycin 100X mix Invitrogen Life Technologies 
Pfu DNA Polymerase Stratagene 
phenol BDH 
PMSF Sigma 
poly(dI-dC) Amersham Biotech 
polyacrylamide EM Science 
prestained molecular weight markers Sigma 
Protease Inhibitor Cocktail Sigma 
proteinase K Qiagen 
RPMI-1640 Invitrogen Life Technologies 
SDS Sigma 
sodium acetate BDH 
sodium azide Sigma 
sodium butyrate Sigma 
sodium carbonate BDH 
sodium citrate BDH 
sodium deoxycholate Sigma 
sodium orthovanadate Sigma 
SRC Optimal Peptide Oncogene Research Products 
Superfect Qiagen 
SuperSignal West chemiluminescent reagent Pierce 
T4 DNA Polymerase Amersham Biotech 
Taq DNA Polymerase Qiagen 
TEMED EM Science 
Trichostatin A Sigma 
Tris Fisher 
Trypan Blue BDH 
trypsin Invitrogen Life Technologies 
Tween-20 Sigma 
Urea BDH 
xylene cyanol FF BDH 
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_________________________________________________________ 
Table 3.2.  Commercially Available Kits 
Commercial Kit Supplier 
5' RACE Kit Invitrogen Life Technologies 
CAT ELISA kit Roche 
Chromatin Immunoprecipitation (ChIP) Kit Upstate Biotechnologies 
EndoFree DNA Plasmid Maxi Kit Qiagen 
Lowry Protein Assay Kit Sigma 
QIAquick Gel Extraction Kit Qiagen 
QIAquick Nucleotide Removal Kit Qiagen 
QIAquick PCR Purification Kit Qiagen 
S1 Nuclease Protection Assay Kit Ambion 
T4 Quick Ligation Kit New England Biolabs 
T7 DNA Sequencing kit Amersham Biotech 
Thermoscript RT System Invitrogen Life Technologies 
 
_________________________________________________________ 
Table 3.3.  Names and Addresses of Suppliers 
Supplier Address 
Ambion, Inc Ambion Inc., Austin, TX, USA 
Amersham Biotech, Inc. Amersham Biotech, Inc., Baie d'Urfe, Quebec, 
BDH BDH Inc., Toronto, Canada 
Beckman-Coulter Beckman-Coulter, Miami, FL, USA 
BioRad BioRad Laboratories, Inc., Mississauga, Canada 
CanSera CanSera International Inc., Rexdale, Canada 
Clontech Clontech, Palo Alto, CA, USA 
Difco Laboratories Difco Laboratories, Detroit, MI, USA 
EM Science EM Science, Gibbstown, NJ, USA 
Fisher Fisher Scientific Ltd., Nepean, Canada 
Invitrogen Life Technologies Invitrogen Technologies, Burlington, Canada 
Millipore Millipore Ltd., Nepean, Canada 
NEN Research Products DuPont NEN Research Products, Boston, MA, USA 
Oncogene Research Products Oncogene Research, San Diego, CA, USA 
Pierce BioLynx, Brockville, Canada 
Promega Promega Corporation, Madison, WI, USA 
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Qiagen Qiagen, Mississauga, Canada 
Roche Diagnostics Roche, Indianapolis, IN, USA 
Santa Cruz Biotechnology Santa Cruz Biotechnology, Santa Cruz, CA, USA 
USB USB Corporation, Cleveland, OH, USA 
 
 
3.2.  Cell Lines and Tissue Culture 
3.2.1.  Cell Lines and Standard Culture Conditions 
 All of the human colon cancer cell lines used in this study were obtained from the 
American Type Culture Collection (ATCC).  All tissue culture media was obtained from 
Invitrogen.  HT29, WiDr, SW480, SW620, LS174-T, and KM12C colon cancer cell 
lines were all grown in DMEM media and 10% fetal calf serum (FCS, CanSera).  Colo 
201, Colo 205, Colo 320, DLD-1, and HCT-15 colon cancer cell lines were grown in 
RPMI-1640 media with 10% FCS.  The HCT-116 colon cancer cell line was grown in 
McCoy's 5A media with 10% FCS.  The Hke-3 and Hkh-2 cell lines were obtained from 
Dr. S. Shirasawa (Kyushu University, Japan) and maintained in HCT-116 growth media 
supplemented with 600 µg/mL G418.  DKO-4 and DKS-8 were also obtained from Dr. 
Shirasawa and grown in DLD-1 growth media containing 600 µg/mL G418.  HeLa 
cervical carcinoma cells were obtained from ATCC and grown in RPMI-1640 with 10% 
FCS.  Molt-4 T-cell leukemia cells were obtained from ATCC and grown in RPMI-1640 
with 10% FCS.  The breast cancer cell lines MDA-MB-231, T47D, and HS578-T were 
obtained from Dr. S. Carlsen (Saskatchewan Cancer Agency) and grown in RPMI-1640 
with 10% FCS.  T47D and HS578-T media was further supplemented with 0.2 IU/mL 
bovine insulin (Eli Lilly).  The SV40 immortalized normal breast cell line, HBL100, was 
also obtained from Dr. Carlsen and grown in α-MEM media with 10% FCS and 0.2 
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IU/mL bovine insulin.  BHK-21 hamster cells and their derivative, tsBN462, were 
obtained from Dr. T. Sekiguchi (Kyushu University, Japan), and grown in DMEM 
media with 10% fetal calf serum.  All cells were maintained at 37oC and 5% CO2, except 
for tsBN462 cells, which were maintained at 33oC and 5% CO2. 
3.2.2.  Actinomycin D Treatments 
  For mRNA half-life studies, Actinomycin D was added to semi-confluent cells to a 
final concentration of 5µg/mL.  Following Actinomycin D addition, cells were harvested 
at various time points. 
3.2.3.  Histone Deacetylase Inhibitor Treatments 
 For HDAC inhibitor studies, exponentially growing cells were trypsinized, seeded 
at 50% confluence, and then allowed to grow for 24 hours.  Cells were then treated with 
5 mM sodium butyrate (NaB, Sigma) or 1 µM trichostatin A (TSA, Sigma) for various 
times prior to harvesting. 
 
3.3.  Bacterial Strains 
 Escherichia coli (E. coli) strain DH5α was used as the host for propagation of all 
plasmid vectors.  Transformed DH5α cells were grown at 37oC in a shaking incubator in 
Lauria-Bertani (LB) broth consisting of 1.0% (w/v) bacto-tryptone, 0.5% (w/v) yeast 
extract, and 1.0% (w/v) NaCl with 100µg/mL ampicillin.  Selective LB-agar plates for 
isolation of transformed DH5α colonies consisted of LB broth with 1.5% (w/v) agar and 
100 µg/mL ampicillin.  Plates were incubated upside-down at 37oC. 
 
 63 
3.4.  General Molecular Techniques 
 The majority of the molecular biology techniques utilized in this study are based 
on those described by Sambrook (Sambrook et al., 1989). 
3.4.1.  Molecular Cloning Techniques 
3.4.1.1.  Polymerase Chain Reaction 
 Polymerase Chain Reaction (PCR) was performed using the buffers supplied with 
heat stable Pfu (Stratagene) or Taq (Qiagen) DNA Polymerases, dNTPs (Invitrogen), 
template DNA, and specifically designed forward and reverse primers.  Components 
were added to achieve the final reaction concentrations recommended by the PCR 
enzyme manufacturer's protocol.  Reaction annealing temperatures were determined 
using MacVector software and input sequences for the template and primers.  Reactions 
were typically performed for between 25 and 35 cycles in a thermocycler (PE 
Biosystems), with a standard melting temperature of 95oC and an extension temperature 
of 68oC (Pfu) or 72oC (Taq).  Extension times were adjusted for the expected product 
size, utilizing an average extension rate of 0.5 kb/min (Pfu) or 2.0 kb/min (Taq).   
3.4.1.2.  Restriction Enzyme Digestion 
 All restriction enzymes used were obtained from New England Biolabs.  
Restriction enzyme digestions were performed on 0.1 µg/µL target DNA using 
restriction enzymes (1 unit per 1 µg DNA) with the buffer supplied by the manufacturer.  
When DNA was digested to completion, reactions were allowed to proceed for 2-3 h at 
37oC.  For partial digestions, reactions were performed for 20 min at room temperature. 
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3.4.1.3.  Generation of Blunt Ends from Recessed or Protruding 3' Termini 
 Recessed 3' termini on double stranded DNA fragments were extended by directly 
adding 1 µL of a 10 mM dNTP mixture, and 5 units of DNA Polymerase I Klenow 
fragment (Amersham) to 20 µL of a restriction enzyme digest reaction.  Reactions 
proceeded for 15 min at room temperature.  To remove protruding 3' termini from 
double stranded DNA fragments, 1 µL of a 10 mM dNTP mixture and 5 units of T4 
DNA Polymerase (Amersham) were added directly to 20 µL of a restriction enzyme 
digest reaction.  Reactions proceeded for 15 min at 12oC, and were terminated by 
heating at 75oC for 10 min.   
3.4.1.4.  Removal of 5' Terminal Phosphate 
 To dephosphorylate the 5' termini of vector DNA prior to ligation reactions, 1 unit 
of calf intestinal alkaline phosphatase (Invitrogen) was added to restriction enzyme 
digests and incubated at room temperature for 30 minutes. 
3.4.1.5.  Agarose Gel Electrophoresis 
 DNA fragments were loaded onto agarose gels in gel loading buffer (0.015% (w/v) 
bromophenol blue, 0.015% (w/v) xylene cyanol FF, 10% (v/v) glycerol, and 10mM 
ethylenediamine tetracetic acid (EDTA)).  Gels consisted of 1-2% agarose (w/v) in TAE 
buffer (40 mM Tris-acetate, 1 mM EDTA, pH. 8.0) or TBE buffer (45 mM Tris-borate, 
1 mM EDTA, pH. 8.0).  Electrophoresis was performed at 100 V for approximately 45 
min using a TAE or TBE running buffer. 
3.4.1.6.  Purification of Linear DNA Fragments 
 Linear DNA fragments generated for ligation reactions were isolated from agarose 
gels and purified using a QIAquick gel purification kit (Qiagen). 
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3.4.1.7.  DNA Ligation 
 DNA ligation reactions consisted of 50 ng of purified, dephosphorylated vector 
DNA, and 200 ng of purified insert DNA in a 20 µL reaction volume with 1 µL of Quick 
T4 DNA ligase (New England Biolabs) in the supplied buffer.  Reactions proceeded for 
15 min at room temperature.  For re-circularization of linear DNA, 100 ng of purified 
vector DNA was used in the ligation reaction. 
3.4.2.  Site Directed Mutagenesis 
 All mutant plasmids were generated using the QuickChange site directed 
mutagenesis protocol (Stratagene) with complementary primers spanning the mutation 
site. 
3.4.3.  DNA Sequencing 
 Manual DNA sequencing was performed using a T7 Polymerase Sequencing kit 
(Amersham).  Sequencing reactions were separated by electrophoresis on denaturing 6% 
polyacrylamide gels (6% acrylamide:N;N-methylene bis-acrylamide (19:1), 8 M urea, 
1X TBE) using a TBE running buffer.  Alternatively, automated DNA sequencing was 
performed by Annette Kerviche at the Saskatchewan Cancer Agency DNA Sequencing 
Facility using an ABI Prism 310 Genetic Analyzer. 
3.4.4.  Preparation and Transformation of Competent Bacterial Cells 
 E. coli DH5α cells were rendered competent for plasmid transformation  according 
the procedure originally described by Hanahan (Hanahan, 1983).  Competent cells were 
transformed as described (Hanahan, 1983), plated onto LB-ampicillin plates, and grown 
for 18 hours at 37oC.  
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3.4.5.  Isolation of Plasmid DNA from Bacterial Cells 
3.4.5.1.  Small Scale Plasmid Purification 
 Isolated, transformed, bacterial colonies were picked from LB-ampicillin plates 
and transferred to LB-ampicillin liquid culture media.  Cultures were grown overnight, 
and then bacteria were pelleted by centrifugation for 1 minute at top speed in a 
microcentrifuge.  Plasmid DNA was subsequently isolated as described (Birnboim and 
Doly, 1979), and re-suspended in TE buffer (10 mM Tris-HCl, pH 7.4, 1mM EDTA) 
containing 20 µg/mL RNase A. 
3.4.5.2.  Large Scale Plasmid Purification 
 Large scale, endotoxin free, plasmid DNA was prepared from 100 mL bacterial 
cultures using an EndoFree DNA Plasmid Maxi Kit (Qiagen) as per the manufacturer's 
protocol. 
3.4.6.  Isolation of RNA from Cultured Eukaryotic Cells 
 RNA was isolated from semi-confluent tissue culture plates according to the 
denaturing guanidinium thiocyanite method described by Chomczynski and Sacci 
(Chomczynski and Sacchi, 1987).  Purified RNA was re-suspended in RNA Storage 
Buffer (0.1 mM EDTA, 0.1 % (v/v) diethyl pyrocarbonate (DEPC)).  RNA 
concentration and purity was determined by A260/A280 followed by verification of 
integrity on ethidium bromide stained agarose gels.  RNA with an A260/A280 ratio above 
1.7 was considered pure. 
3.4.7.  Isolation of Genomic DNA from Cultured Eukaryotic Cells 
 Semi-confluent 150 mm plates were washed with an ice cold phosphate buffered 
saline solution and lysed in 5 mL of proteinase K buffer (10 mM Tris-HCl pH 7.4, 10 
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mM EDTA, 150 mM NaCl, 0.4 % (w/v) sodium dodecyl sulphate (SDS)).  Cell lysates 
were incubated at 37°C with 5 mg of proteinase K followed by several organic 
extractions with equivalent volumes of phenol saturated with Tris-HCl, pH 7.4, and 
chloroform/isoamyl alcohol (49:1, v:v).  Genomic DNA in the aqueous partition was 
precipitated with 2.5 volumes of 95% ethanol, washed, and dissolved in 1 mL TE buffer 
(10 mM Tris-HCl, pH 7.4, 0.1 mM EDTA) with 100µg RNase A, and incubated at 37°C 
for 1 hour.  RNase A was removed by subsequent organic extractions; pure genomic 
DNA in the aqueous fraction was ethanol precipitated, washed, and dissolved in 1 mL of 
TE buffer.  DNA concentration and purity was determined by A260/A280.  DNA with a 
ratio above 1.6 was considered pure.  This protocol was adapted as required to purify 
genomic DNA from a greater or smaller starting cell number. 
3.4.8.  Annealing of Complementary Single Stranded DNA Oligonucleotides 
 Equal molar amounts of complementary single stranded DNA oligonucleotides 
were dissolved in STE buffer (10 mM Tris-HCl, pH 8.0, 50 mM NaCl, 1 mM EDTA) at 
a concentration of approximately 1-2 A260 units/100 µL for each oligonucleotide.  The 
mixture was heated to 95oC, and allowed to gradually cool to room temperature. 
3.4.9.  Generation of DNA Size Markers 
 λ DNA digested with EcoR I or EcoR I/Hind III was used as a DNA size marker 
for fragments ranging from 1 to 20 kb.  For smaller DNA fragments, pBluescript 
digested with Hpa II was used as a size marker. 
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3.4.10.  Generation of Labeled DNA Probes 
3.4.10.1.  Random Prime Method 
 Uniformly [32P]-labeled DNA probes for Northern and Southern hybridization 
procedures were created from double stranded DNA fragments using an oligolabeling kit 
(Amersham) according to the manufacturer's recommendations.  Unincorporated 
radioactivity was removed using a QIAquick nucleotide removal kit (Qiagen). 
3.4.10.2.  In-Fill Method 
 Approximately 1 nmol of double stranded DNA with 5' overhangs was labeled for 
bandshift reactions via an in-fill reaction in one-phor-all buffer (Invitrogen) with 5 units 
of DNA Polymerase I Klenow fragment (Amersham) in the presence of 50 µM each of 
dATP, dGTP, dTTP, and 50 µCi [α32P]-dCTP.  Reactions proceeded for 15 min at room 
temperature.  Labeled DNA was precipitated and re-suspended in TE buffer. 
3.4.10.3.  Linear Amplification Method 
 [32P]-labeled, single-stranded DNA probes for S1 nuclease protection assays were 
generated from 100 ng of double stranded, linear DNA templates using a gene-specific 
primer and Taq DNA Polymerase.  Reactions were set up exactly as for PCR except cold 
dCTP was substituted with 50 µCi [α32P]-dCTP.  Following an initial incubation at 95oC 
for 3 min., reactions proceeded through 25 cycles in a thermocycler (PE Biosystems, 
cycling parameters: melt 95oC, 30 sec; anneal 55oC, 30 sec; extend 72oC, 90 sec.). 
3.4.11.  Determination of Protein Concentration 
3.4.11.1.  Bradford Method 
 The Bradford method of protein quantitation was utilized for analysis of 
transfected cell lysates as well as determination of nuclear extract concentrations.  
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Protein extracts were mixed with 500 µL of Bradford Reagent (BioRad) and incubated 
for 15 min at room temperature.  The intensity of blue colour development was 
measured spectrophotometrically at A595.  Extract volumes were used that gave an A595 
reading in the linear range of the assay (0.2 to 1.0 absorbance units).  Various 
concentrations of bovine serum albumin (BSA) were used as protein standards. 
3.4.11.2.  Lowry Method 
 The Lowry method of protein quantitation was utilized for lysates prepared for 
Western blot analysis or in vitro Src kinase assays.  The Lowry method was employed 
only for these applications because the buffers used were not compatible with the 
Bradford method of protein quantitation.  This technique was performed using a Lowry 
Assay Kit (Sigma). 
 
3.5.  Plasmid Construct Details 
3.5.1.  Expression Vectors and cDNAs 
 c-Src cDNA clones have been described previously (Lin et al., 1995).  HHC189 
containing a 1.1 kb insert of β-Actin and pGD-P-25A containing a 1.5 kb insert of 
glucose-6-phosphate dehydrogenase were obtained from the ATCC.  pMI containing 
exons 2 and 3 of the human c-Myc gene was a gift of Dr. Zheng (Pathology, University 
of Saskatchewan).  pRibo containing a 5.8 kb insert of 18S ribosomal RNA cDNA, as 
well as pCMV-βGAL were a gift of Dr. W. Roesler (Biochemistry, University of 
Saskatchewan).  The GAL4 DNA binding domain/transcription factor fusion constructs 
HNF-1α/GAL4 and HNF-1β/GAL4, as well as their parental GAL4 fusion vector, 
pSG424, were obtained from Dr. R. O'Brien (Vanderbilt University, Tennessee) 
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(Streeper et al., 2000).  GAL4/Sp1 and GAL4/Sp3 fusions, as well as their parental 
GAL4 fusion vector, pM, were obtained from Dr. T. Sakai (Kyoto University, Japan) 
(Nakano et al., 1997).  GAL4/VP16 was obtained from Dr. D. Anderson (Saskatchewan 
Cancer Agency).  pCMV-hTAF(II)250 was a gift of Dr. R. Tjian (Howard Hughes 
Medical Institute and University of California, Berkeley).  pBJ5-HNF-1α and pBJ5-
HNF-1β were obtained from Dr. Gerry Crabtree (Stanford University) (Cereghini, 
1996). 
3.5.2.  CAT Reporter Constructs 
 The 0.38 SRC1A-CAT and 0.54 SRC1A-CAT (CAT = chloramphenicol 
acetyltransferase) promoter constructs with Gem2CAT (Promega) reporter construct 
backbones, as well as the SRC1A promoter:cDNA chimera, pSRC1A-chimera have 
been described (Bonham and Fujita, 1993; Ritchie et al., 2000).  The pCAT3 (Promega) 
based SRC1α constructs, -145 SRC1α-CAT, -777 SRC1α-CAT, and -2852 SRC1α-
CAT, as well as the SRC1α promoter:cDNA chimera, pSRC1α-chimera, were all 
obtained from Mark Boyd (Bonham et al., 2000).   
3.5.3.  SRC Dual Promoter Reporter Study 
3.5.3.1.  SRC Dual Promoter CAT Reporter Construct and Related Plasmids 
 A 2.4 kb EcoR V/BamH I fragment containing the two SRC promoters was 
liberated from pBam4.8 (Bonham and Fujita, 1993) and ligated into a EcoR V/BamH I 
cut pBlue KS+ shuttle vector to form the construct p2.4SRCBlue.  A 1.1 kb DNA 
fragment downstream from the SRC promoter region was isolated from cos11B 
(Bonham and Fujita, 1993) via PCR using Pfu DNA Polymerase and primers FWD:  5'-
GCCTTTTGTTGTGATGCAGCG and REV:  5'-CTTCTAGAATGAATTCGCCAGC.  
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The resulting PCR fragment was digested with BamH I/Xba I, and ligated into BamH 
I/Xba I cut p2.4SRCBlue, to create p3.5SRCBlue, a shuttle vector harbouring a 
contiguous 3.5 kb fragment of the SRC promoters and downstream sequences.  This 3.5 
kb promoter fragment was isolated from p3.5SRCBlue using Sac I/Kpn I, and ligated 
with a Sac I/Kpn I cut version of pCAT3 Basic (Promega) lacking a 223 bp Hind III 
fragment (intronless pCAT3-Basic), thus creating p3.5SRC-CAT.  A 1.3 kb genomic 
DNA fragment containing part of SRC Exon 1B and accompanying upstream sequences 
was generated using PCR with Pfu DNA Polymerase, a cos11B template and the primers 
FWD:  5'-GGGAGAGGAATTCTGCTAATG, and REV:  5'-
AGCTGGGCAAGTTGCTTCACTTC.  This PCR fragment was digested with EcoR I, 
and cloned into p3.5SRC-CAT that had been prepared by Sac I digestion, removal of the 
3' overhang, and subsequent EcoR I digestion.  This construct was termed -
560crypticDPCAT.  The -560 DPCAT construct was created by removing a 1 kb, EcoR 
I/BbvC I fragment between SRC Exons 1A and 1B from -560crypticDPCAT, generation 
of blunt ends, and subsequent re-ligation.  To create -2852 DPCAT, a 2.2 kb EcoR 
V/Kpn I fragment upstream of the SRC1α promoter was isolated from -2852 SRC1α-
CAT (Bonham et al., 2000), and cloned into EcoR V/Kpn I digested -560 DPCAT.  To 
create -145 DPCAT, a complete digest with EcoR V followed by partial digest with Msc 
I was performed on -560 DPCAT, and a 7.3 kb product from this reaction was gel 
purified, blunt ended, and re-ligated.  ∆1α DPCAT was generated by partial Sal I 
digestion of -560 DPCAT, followed by isolation and re-ligation of the 6.0 kb product of 
this reaction.  ∆1A DPCAT was created by removing a Sac II/Sac I fragment from -560 
DPCAT, generation of blunt ends, and subsequent re-ligation.  To create HNFmut 
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DPCAT, p2.4SRCBlue was digested with Hind III/Xho I, blunt-ended, and re-ligated in 
order to remove a small fragment containing an unwanted Hinc II site, thus creating 
p2.4SRCBlue∆Hinc2.  A Pst I/Hinc II fragment from -777 mutSRC1α (Bonham et al., 
2000), containing a mutant Src HNF site in the SRC1α promoter, was cloned into Pst 
I/Hinc II digested p2.4SRCBlue∆Hinc2, creating p1.4HNFmutSRCBlue, a variant of 
p2.4SRCBlue missing a 1 kb Hinc II fragment.  This 1 kb Hinc II fragment from 
p2.4SRCBlue was re-introduced into Hinc II digested p1.4HNFmutSRCBlue, thus 
generating p2.4HNFmutSRCBlue.  A 2.1 kb EcoR V/Rsr II fragment from 
p2.4HNFmutSRCBlue was finally cloned directly into EcoR V/Rsr II digested -560 
DPCAT to generate HNFmut DPCAT.  All constructs were mapped with restriction 
enzymes to verify their integrity, and sequenced to verify the incorporation of correct 
PCR and restriction fragments. 
3.5.3.2.  CAT Constructs Harbouring Proposed Enhancer 
 A 1.65 kb BamH I/EcoR I fragment from cos11B (Bonham and Fujita, 1993) 
containing SRC genomic sequence upstream of Exon 1α was cloned into a BamH 
I/EcoR I digested pBlue shuttle vector, creating p-4496/-2852Blue.  This insert was 
removed via Sac I/EcoR V digestion, and cloned into -2852 SRC1α-CAT that had been 
Kpn I digested, blunt ended, and subsequently Sac I digested, thus generating pBamEco-
2852SRC1α-CAT.  To create -4496 SRC1α-CAT, a 50 bp BamH I fragment was 
removed from pBamEco-2852SRC1α-CAT, and the vector was re-ligated.  To derive -
6882 SRC1α-CAT, a 2.4 kb EcoR I fragment was liberated from cos11B, and cloned 
directly into EcoR I digested -4496 SRC1α-CAT.  A fragment harbouring the HepG2 
DNaseI hypersensitive site, DH3, was prepared from -6882 SRC1α-CAT via Kpn I/ Xho 
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I digest, followed by generation of blunt ends.  This fragment was cloned into Kpn I 
digested, blunt-ended -145 SRC1α-CAT to create -145 SRC1α/DH3-CAT.  This 
fragment was also cloned into Kpn I digested, blunt-ended -560 DPCAT to create -560 
DH3 DPCAT. 
3.5.3.3.  S1 Probe Vectors 
 pSRC1A chimera has been described previously (Bonham and Fujita, 1993).  A 
827 bp PCR product from pSRC1A chimera was generated using Pfu DNA Polymerase 
and the primers FWD:  5'-GGGGTACCAGGGATGTTTTGC, and REV:  5'-
AGCTGGGCAAGTTGCTTCACTTC.  To derive the SRC1A-CAT S1 probe vector, 
pSRC1A-CAT-chimera, this product was digested with Kpn I, and subsequently ligated 
directly into intronless pCAT3-Basic that had been digested with Sac I, blunt-ended, and 
then Kpn I digested.  A 1.4 kb PCR product from pSRC1α chimera (Bonham et al., 
2000) was generated using Pfu DNA Polymerase, a forward primer, FWD:  5'-
GGGGTACCAGGGATGTTTTGC, and the same reverse primer used to isolate the 
pSRC1A chimera fragment.  To create the SRC1α-CAT S1 probe vector, pSRC1α-
CAT-chimera, this fragment was digested with Kpn I, and cloned into intronless 
pCAT3-Basic that had been digested with Sac I and blunt-ended, followed by Kpn I 
digestion.  All constructs were sequenced to verify the integrity of the chimeric 
promoter-cDNA inserts. 
3.5.4.  GAL4 Based SRC1A and SRC1α CAT Constructs 
 A Kpn I site was introduced into 0.38 SRC1A-CAT, downstream of the GC1 Sp-
family binding site, using site directed mutagenesis with mutagenic primers FWD:  5'-
GCTTCTGTGCCCGGTACCCCCACCCCGCCC and REV:  5'-
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GGGCGGGGTGGGGGTACCGGGCACAGAAGC.  This mutant vector was digested 
with Nar I/Kpn I, and a synthetic double stranded DNA cassette created by annealing 
sense (GC1-GAL4 plus, 5'-
CGCCCTGGCGTCGGAGTACTGTCCTCCGATCGGCCCGGTAC, GAL4 DNA 
recognition site underlined), and antisense (GC1-GAL4 minus, 5'-
CGGGCCGATCGGAGGACAGTACTCCGACGCCAGGG) oligonucleotides was 
inserted into this Nar I/Kpn I site.  This resulted in the generation of SRC1A∆GC1-
GAL4-CAT, a 0.38 SRC1A-CAT variant where the GC1 Sp-family binding site had 
been replaced by the core recognition site for the GAL4 yeast transcription factor.  The 
GA2 Sp-family binding site was also replaced with a GAL4 binding site by removing a 
BssH II fragment from SRC1A∆GC1-GAL4-CAT, and inserting a double-stranded 
cassette created by annealing single-stranded sense (GA2-GAL4 plus, 5'-
CGCGCTTCCTCCTTCCTCCTCCTCCCGGCTGCTCGGAGTACTGTCCTCCGATC
GCG, GAL4 recognition sequence underlined), and antisense (GA2-GAL4 minus, 5'-
CGCGCGCGATCGGAGGACAGTACTCCGAGCAGCCGGGAGGAGGAGGAAGG
AGGAAG) oligonucleotides.  The resulting vector was termed SRC1A∆GC1/GA2-
GAL4-CAT.  The entire promoter region from this construct was isolated via Nar I/Sac 
II digestion, and re-introduced into Nar I/Sac II digested wild-type 0.38 SRC1A-CAT to 
ensure the absence of unwanted mutations that could have been generated within the 
plasmid during the mutagenesis protocol.  The Src HNF site was replaced with a GAL4 
binding site in the -145 SRC1α-CAT vector using site directed mutagenesis and the 
primers HNF-GAL4mut sense (5'-
GCTGGGGGCCCGCCCTGAGCCCCTGGGAATCGGAGTACTGTCCTCCGATCGG
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CCTTGCAAACAAGTGCGGCCATTTCAC, GAL4 site underlined), and HNF-
GAL4mut antisense (5'-
GTGAATGGCCGCACTTGTTTGCAAGGCCGATCGGAGGACAGTACTCCGATTC
CCAGGGCTCAGGGCGGGCCCCCAGC), thus creating -145 SRC1α∆HNF-GAL4-
CAT.  The mutant SRC1α promoter region was subcloned back into wild-type -145 
SRC1α-CAT using Kpn I/Pst I, ensuring solely the GAL4 mutation in this plasmid 
construct.  All mutations were verified by DNA sequencing.  
3.5.5.  SRC1A 5' Promoter Deletion CAT Constructs 
 Constructs based on 0.38 SRC1A-CAT, and harbouring various deletions in TC1, 
TC2, and TC3, were described previously (Ritchie and Bonham, 1998; Ritchie et al., 
2000), and obtained from Dr. Shawn Ritchie.  The construct 0.2 SRC1A-CAT was 
created by Nar I/BssH II digestion of 0.38 SRC1A-CAT, generation of blunt ends, and 
subsequent re-ligation of the plasmid vector. 
3.5.6.  SRC1A and SRC1α 3' Promoter Deletion CAT Constructs 
 The SRC1A promoter reporter construct, 0.54 SRC1A-CAT, has been described 
(Bonham and Fujita, 1993).  A Hinc II/Sal I fragment from this construct, containing the 
SRC1A promoter cassette, was blunt-ended and subcloned into EcoR V/Xho I digested, 
blunt ended pCAT3-Basic.  All SRC1A 3' deletion constructs were based on 0.38 
SRC1A-CAT3-Basic, which was generated by deleting a 160 bp Nar I promoter 
fragment from 0.54 SRC1A-CAT3-Basic, as well as a 223 bp Hind III fragment from 
the CAT3 vector backbone.  SRC1A3'∆Sac2-CAT was derived by digesting 0.38 
SRC1A-CAT with Sac II/Hind III, creation of blunt ends, and re-ligation.  The 
remaining SRC1A 3' promoter deletions were isolated as PCR fragments from 0.38 
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SRC1A-CAT using Pfu DNA Polymerase, and a common forward primer 
(SRC1A/1α3'∆FWD, 5'-GGTACCGAGCTCTTACGCGTGC) in conjunction with 
specific reverse primers (SRC1A∆+13REV, 5'-CCGCTCAAGCTTCCAGGCCGG; 
SRC1A∆-26REV, 3'-AGAAAGCTTGAGAGAGAAAGGG; SRC1A∆-60REV, 
AGGAAGCTTCGGCGGCCCGGG).  SRC1α 3' promoter deletion fragments were 
isolated from -145 SRC1α-CAT as PCR fragments using Pfu DNA Polymerase, and a 
common forward primer (SRC1A/1α3'∆FWD), paired with specific reverse primers 
(SRC1α∆+99REV, GGTAAGCTTGTGCTAGATGAATGG; SRC1α∆+41REV, 
GGGAAGCTTGAGGTGCCACAGC; SRC1α∆-20REV, 
GGCCAAGCTTGTTTGCAAGGC).  PCR products were digested with Sac I/Hind III, 
cloned directly into Sac I/Hind III digested pCAT3-Basic, and sequenced to verify their 
integrity. 
3.5.7.  WAF1 Promoter CAT Constructs 
 A p21/WAF1 promoter-luciferase construct, pWWP-Luc, was a gift of Dr. B. 
Vogelstein (el-Deiry et al., 1993).  The 2.3 kb WAF1 promoter fragment was isolated 
from this construct via Hind III digestion, and subcloned into a Hind III digested pBlue 
shuttle vector.  The WAF1 promoter was deleted to -210, relative to the transcription 
start site, via Pst I digestion and re-ligation.  To create -210 WAF1-CAT, the truncated 
WAF1 promoter was removed from pBlue with Sac I/Sal I, and cloned into Sac I/Sal I 
digested pCAT3-Basic.  To allow for further truncation of the WAF1 promoter, site 
directed mutagenesis was employed to introduce a Sac I site at the -101 position using 
the mutagenic primers sense:  5'-
GGGCGGTCCCGGGCGGAGCTCTGGGCCGAGCGAGGGTCCC, and antisense 5'-
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GGGACCCGCGCTCGGCCCAGAGCTCCGCCCGGGACCGCCC.  This WAF1 Sac I 
mutant construct was subsequently digested with Sac I, and re-ligated to create -101 
WAF1-CAT. 
3.5.8.  SRC1A/1α and WAF1 Promoter Chimeras 
3.5.8.1.  SRC1A/1α : WAF1 Core Promoter Chimeras 
 A -145 SRC1α-CAT variant, harbouring a Sac II recognition site at -10, was 
created by site directed mutagenesis and the primers 1αSac FWD (5'-
GCAAACAAGTGCGGCCATTTCCGCGGCCCAGGCTGGCTTCTGC) and 1αSac 
REV (5'-GCAGAAGCCAGCCTGGGCCGCGGAAATGGCCGCACTTGTTTGC).  A 
similar variant of 0.38 SRC1A-CAT3-Basic, with a Sac II recognition site engineered at 
-10, was created using the primers 1ASac FWD (5'-
CGATCTGTCTCTCCCGGCCCGCGGTCCATTCCGGCCTGGGAGC) and 1ASac 
REV (5'-GCTCCCAGGCCGGAATGGACCGCGGGCCGGGAGAGACAGATCG).  
The WAF1 core promoter was amplified from -210 WAF1-CAT, using PCR and 
primers WafSacFWD (5'-GGCGCCGCGGTTGTATATCAGG) and CAT3NcoREV (5'-
TTTCTCCATGGTGGCTTTACC).  The chimeric promoter constructs, 
0.38SRC1A:WAFcore-CAT and -145SRC1α:WAFcore-CAT, were derived by digesting 
the WAF1 PCR product with Sac II/Nco I, and cloning it into the Sac II engineered, Sac 
II/Nco I digested SRC1Α or SRC1α CAT constructs, respectively. 
3.5.8.2.  WAF1 : SRC1A/1α Core Promoter Chimeras 
 A similar strategy was employed to engineer WAF1 and SRC1A or 1α promoter 
chimeras containing WAF1 upstream sequence fused to the SRC1A or 1α core 
promoters.  To this end, EcoR I recognition sites were engineered in the -101 WAF1-
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CAT and -210 WAF1-CAT vectors using site directed mutagenesis with the primers 
EcoWaf FWD (5'-CGGGCGGGGCGGTTGGAATTCAGGGCCGCGCTGAGC) and 
EcoWaf REV (5'-GCTCAGCGCGGCCCTGAATTCCAACCGCCCCGCCCG).  The 
SRC1A and SRC1α core promoters were isolated from 0.38 SRC1A-CAT-Basic and -
145 SRC1α-CAT via PCR using a common reverse primer, CAT3NcoREV, paired with 
the appropriate 1A or 1α specific forward primer (1AEcoFWD, 5'-
CTCCGAATTCTCCCTTTCTCTCTCG; 1αEcoFWD, 5'-
GGTTAGAATTCAAGCCAGCCTTGC).  The SRC1A core promoter PCR product was 
digested with EcoR I/Nco I, and cloned directly into EcoR I/Nco I digested -101 WAF1-
CAT or -210 WAF1-CAT, to create -101WAF1:SRC1Acore-CAT and -
210WAF1:SRC1Acore-CAT, respectively.  The SRC1α core promoter PCR product 
was similarly digested and ligated with -210 WAF1-CAT or -101 WAF1-CAT, thus 
generating -101WAF1:SRC1αcore-CAT and -101WAF1:SRC1αcore-CAT. 
 
3.6.  Transfection of Eukaryotic Cell Lines      
3.6.1.  Standard Transfection Reaction and Conditions 
 All plasmid constructs used in transfection experiments were isolated and purified 
using an EndoFree Plasmid Maxi Kit from Qiagen.  In a typical transfection experiment, 
1.5 µg of a promoter CAT construct, 0.5 µg of pCMVβ-Gal, and 10 µL of Superfect 
reagent (Qiagen) were mixed together in 85 µL of serum free DMEM.  After a 20 
minute incubation at room temperature, the DNA-Superfect mixture was further diluted 
with 600 µL of cell culture media with 10% FCS.  This transfection mix was then added 
directly to plates seeded the previous day at a density of 3X105 cells per 35 mm tissue 
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culture plate.  Transfections were allowed to proceed for 3 hours, followed by the 
addition of 2 mL of the appropriate growth media containing 10% FCS.  Cells were 
grown under standard conditions for an additional 48 h prior to harvesting.   
3.6.2.  Other Transfection Reactions and Conditions 
3.6.2.1.  Co-transfection Studies 
 To assess the effects of HNF-1α or HNF-1β expression on the expression of 
various DPCAT constructs, DNA mixtures consisted of 0.75 µg CAT reporter, 0.5 µg 
pCMV-βGAL, and 0, 21, 125, or 750 ng of pBJ-HNF-1α or -1β.  For SRC1A GAL4-
transcription factor fusion studies, DNA mixtures consisted of 1.0 µg CAT reporter, 0.5 
µg pCMV-βGAL, and 0.25 µg Sp1/Sp3 GAL4 fusion or 1.0 ng VP16/GAL4.  For 
SRC1α GAL4-transcription factor fusion studies, DNA mixtures consisted of 0.5 µg 
CAT reporter, 0.5 µg pCMV-βGAL, and 1.0 µg of HNF-1α/1β GAL4 fusion or 0.5 ng 
VP16/GAL4.  For TAF1 rescue experiments in tsBN462 cells, DNA mixtures consisted 
of 0.75 µg CAT reporter, 0.5 µg pCMV-βGAL, and 0, 47, 94, or 188 ng of pCMV-
hTAF(II)250.  pBlue was always added to transfection mixtures as required to ensure a 
final DNA mass of 2.0 µg.  
3.6.2.2.  HDAC Inhibitor Studies 
  Following incubation with DNA-Superfect complexes, cultured cells were 
supplemented with 2 mL of normal growth media containing 10% FCS, and allowed to 
grow under standard culture conditions.  After 24 hours, the cells were either exposed to 
NaB (5 mM), TSA (1 µM), or left untreated.  Cells were harvested after an additional 24 
hours. 
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3.6.2.3.  tsBN462 and BHK-21 Transfections 
 For tsBN462 and BHK-21 transfection experiments, cells were transfected at 33oC.  
Following transfection, fresh media was added to cells, and they were allowed to grow 
at 33oC for an additional 24 h.  At this time, cells were either maintained at 33oC or 
shifted to 39 oC for 24 h of growth prior to harvesting.  To assess the effects of HDAC 
inhibitors on reporter gene activity, tsBN462 and BHK-21 cells were allowed to grow at 
33 oC for 36 h following transfection.  Cells were then left untreated or exposed to TSA 
(1 mM) or NaB (5 mM) for 18 h at 33 oC or 39 oC before harvesting. 
 
3.7.  Detection of Reporter Gene Activity 
3.7.1.  CAT ELISA 
 Cells transfected on 35 mm plates were washed twice with ice-cold PBS, then 
lysed in 500 µL of 1X Lysis buffer provided with a CAT ELISA kit (Roche).  Levels of 
CAT expression in 200 µL of lysate were subsequently determined by enzyme linked 
immunosorbant assay (ELISA) as per the manufacturer's protocol. 
3.7.2.  β-Galactosidase Assay 
 A colorimetric assay was utilized to measure β-Galactosidase (β-Gal) activity in 
transfection lysates exactly as described (Hall et al., 1983). 
 
3.8.  Northern Blot 
3.8.1.  Northern Procedure 
 RNA samples were prepared for electrophoresis by mixing equal amounts (15 µg) 
of RNA with 15 µL of Northern Gel Loading Buffer (20 mM Morphpropane sulfonic 
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acid (MOPS), 5.6 mM sodium acetate, 1.1 mM EDTA, 50 % (v/v) formamide, 6.7 % 
(v/v) formaldehyde, 5.6 % glycerol) in a final volume of 18 µL, boiling for 2 min, then 
plunging quickly on ice.  Ethidium bromide (5 µg) and gel loading dye (1.5 µL) were 
subsequently added.  Samples were fractionated in 1% denaturing formaldehyde-agarose 
gels.  Gels were photographed, denatured in 50 mM NaOH for 15 min, neutralized in 
100 mM Tris-HCl pH 7.4 for 15 min, and transferred to charged nylon membranes 
(NEN) by capillary elution in 50 mM sodium phosphate pH 7.0.  RNA-bound 
membranes were UV cross-linked using a UV Stratalinker (Stratagene).  Membranes 
were incubated for 30 min at 65°C in ExpressHyb solution (Clontech), prior to addition 
of specific [α32P] dCTP-labeled probes diluted in ExpressHyb.  Hybridizations 
proceeded 2 h at 65°C followed by 20 min washes at 65°C in Wash Buffer 1 ( 0.3 M 
NaCl, 30 mM sodium citrate, 1 % SDS), Wash Buffer 2 (75 mM NaCl, 7.5 mM sodium 
citrate, 1% SDS), and Wash Buffer 3 (30 mM NaCl, 3 mM sodium citrate, 1% SDS).  
Membranes were exposed to Storage Phosphor Screens (Kodak) overnight.  
Phosphorimager analysis was subsequently performed on the screens using a BioRad 
Molecular Imager FX (BioRad).  Alternatively, autoradiography was performed at -
80oC using an intensifier screen (Kodak). 
3.8.2.  Probes Used for Northern Blot Hybridization 
 A 900bp Nco I/Kpn I fragment from c-Src cDNA was utilized to generate Northern 
probe specific for c-Src mRNA expression.  For detection of β-actin mRNA, a 700 bp 
EcoR I fragment from the β-actin cDNA clone, HHC189, was employed.  To detect c-
Myc mRNA expression, a 500 bp Pst I fragment from pMI, a c-myc cDNA clone, was 
used.  All probes were labeled with an oligolabeling kit (Amersham). 
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3.9.  Detection of DNaseI Hypersensitive Sites 
3.9.1.  Nuclei Isolation and DNaseI Treatment 
 Cells were grown to 80-90% confluence, washed, trypsinized, and pelleted.  Cells 
were re-suspended in phosphate buffered saline (PBS, 0.15 M NaCl, 20 mM sodium 
phosphate, pH 7.4), counted, and 14 X 106 cells were pelleted, washed in nuclei isolation 
buffer (NIB, 15 mM NaCl, 60 mM KCl, 5 mM MgCl2, 15 mM Tris-HCl pH 7.4, 0.1 mM 
EDTA, 0.4 mM dithiothreitol, 0.3 M sucrose), pelleted again, and re-suspended in a 
volume of NIB approximately equal to 5 times the pelleted cell volume.  Cells were 
gently lysed on ice by addition of Nonidet-P40 to a final concentration of 0.5% (v/v).  
Cellular lysis was assessed by staining aliquots of the lysis reaction with trypan blue.  
When nuclei were clearly visible, nuclei were pelleted by centrifugation at 500Xg, and 
re-suspended in NIB with 5% glycerol to a final concentration of 2 X 106 cells per 100 
µL.  Aliquots of 100 µL of nuclei were then digested with increasing concentrations of 
DNaseI for 3 min at room temperature.  The optimal range of DNaseI concentrations 
was determined previously by agarose gel analysis, and was typically in the range of 0-
2.0 µg/100 µL nuclei for all cell lines studied.  DNaseI digests were terminated by 
addition of 50 µL of proteinase K buffer.  Genomic DNA was subsequently isolated. 
3.9.2.  Southern Blot 
 Genomic DNA (20 µg) was digested with the appropriate restriction enzymes and 
buffer compositions in 200 µL reactions.  Digest completion was assessed by 
electrophoresis of 5 µL aliquots of in 1 % agarose gels.  Digested genomic DNA was 
ethanol precipitated, washed, and re-suspended in 20 µL of gel loading buffer.  
Restriction fragments were resolved by fractionation through 0.8 % agarose TAE gels.  
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Subsequently, gels were stained, photographed, depurinated for 10 min in 0.2 M HCl, 
denatured for 45 min in 0.5 M NaOH, 1.5 M NaCl, and neutralized for 30 min in 1 M 
Tris-HCl pH 7.4, 1.5 mM NaCl.  Treated gels were transferred to charged nylon 
membranes (DuPont) via capillary elution in 10X SET (1.5 M NaCl, 0.3 M Tris-HCl pH 
8.0, 20 mM EDTA), and cross-linked in a UV Stratalinker (Stratagene).  Membranes 
were incubated for 30 min at 65°C in ExpressHyb solution (Clontech), prior to addition 
of specific [α32P] dCTP-labeled probes diluted in ExpressHyb.  Hybridizations 
proceeded for 2 h at 65°C followed by 20 min washes at 65°C in Wash Buffer 1 (2 X 
SET, 1 % SDS), Wash Buffer 2 (1 X SET, 1% SDS), and Wash Buffer 3 (0.5 X SET, 
1% SDS).  Membranes were exposed to Storage Phosphor Screens (Kodak) overnight.  
Phosphorimager analysis was subsequently performed on the screens using a BioRad 
Molecular Imager FX (BioRad). 
3.9.3.  Probes used for Southern Blot Hybridization 
 For all Southern Blot experiments, probes were designed that would hybridize to 
the extreme 5' or 3' ends of genomic DNA restriction fragments.  For detection of the 
13.9 kb EcoR V restriction fragment immediately upstream of the SRC promoters, a 259 
bp PCR fragment was generated using Taq DNA Polymerase and PCR primers 
Eco13.9FWD (5'-TAGCAAAAGCCCAGAGGGGTAG) and Eco13.9REV (5'-
TGAAATGAGGTGATGCCCGC).  This PCR product was purified and labeled using 
an oligolabeling kit (Amersham). 
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3.10.  S1 Nuclease Protection Assays 
3.10.1.  Determination of SRC DPCAT Promoter Use 
 [32P]-labeled SRC1A-CAT and SRC1α-CAT specific single stranded DNA probes 
were generated by primer extension using a CAT-specific reverse primer (5'-
AAGGCCGGATAAAACTTGTGC) with a Stu I-digested pSRC1A-CAT-chimera 
template or a Nar I-digested pSRC1α-CAT-chimera template.  Full-length primer 
extension products were obtained by purifying labeled species of the desired lengths 
from denaturing 4% polyacrylamide sequencing gels.  RNA isolated from transfected or 
untransfected cells was thoroughly digested with DNaseI prior to S1 nuclease protection 
assays.  Hybridization of labeled complementary probes to target RNA species and S1 
nuclease digestions were performed using an S1 Assay kit (Ambion).  Probe:target 
hybridizations were carried out overnight at 46oC for the 1α-CAT specific probe, and 
56oC for the 1A-CAT specific probe.  Protected species were separated using denaturing 
6% polyacrylamide sequencing gels, and exposed to a Storage Phosphor Screen 
(Kodak).  Screens were scanned using a Molecular Imager FX (BioRad).  Alternatively, 
autoradiography was performed at -80oC using an intensifier screen (Kodak).    
3.10.2.  Determination of Endogenous SRC Promoter Use 
 S1 nuclease protection assays were performed essentially as described for 
determining SRC DPCAT promoter usage with the following modification.  A [32P]-
labeled SRC1α specific S1 primer was generated from a Stu I digested pSRC1α-chimera 
vector by primer extension reaction with an exon 1C-specific reverse primer (5'-
GAGTCAGGGGTCTCGAAATAGAG).    
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3.10.3.  Mapping of SRC1A Transcription Start Sites 
 SRC1A promoter transcription start sites were mapped using a S1 nuclease 
protection approach in HepG2, HT29, and SW480 cells exactly as described previously 
(Bonham and Fujita, 1993). 
 
3.11.  Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) 
 Total RNA was isolated from HepG2 cells transfected with -560 DPCAT, and 
thoroughly digested with DNaseI.  RNA was reverse transcribed using the Thermoscript 
RT System (Invitrogen), and a CAT specific reverse primer (5'-
TCACCGTAACACGCCACATC).  Subsequently, 2 µL of the reverse transcription 
reaction was amplified by PCR using forward primers specific for SRC1α (5'-
CCTCTAGCCTCAGTTTATCACCGC) or SRC1A (CTCCCGTGCGTCCGTCTGCC), 
paired with a nested, CAT-specific reverse primer (5'-
CGGAAATCGTCGTGGTATTCACTC).  PCR products were analyzed via agarose gel 
electrophoresis. 
   
3.12.  5' Rapid Amplification of cDNA Ends (RACE) 
 HepG2 RNA was isolated, DNaseI digested, and reverse transcribed exactly as 
described for RT-PCR.  cDNAs generated by reverse transcription were subsequently 
purified using QIAquick columns (Qiagen).  Purified cDNAs were tailed using a 5' 
RACE kit (Invitrogen).  First round PCR was performed for 30 cycles on tailed cDNA 
using the forward Abridged Anchor Primer supplied with the 5' RACE kit, paired with a 
CAT specific reverse primer (5'-CGGAAATCGTCGTGGTATTCACTC).  PCR 
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products were diluted 1 in 1000, and 1 µL of this dilution was used as a template for a 
second round, 30 cycle, PCR reaction using a forward nested AUAP primer supplied 
with the 5' RACE kit and a nested CAT reverse primer (5'-
AAGGCCGGATAAAACTTGTGC).  Second round PCR products were analyzed by 
agarose gel electrophoresis.  PCR bands were gel-purified, digested with Sal I/Hind III, 
cloned into Sal I/Hind III digested pBlue, and sequenced. 
   
3.13.  Chromatin Immunoprecipitation-PCR 
 Semi-confluent HT29 and SW480 cells were treated with 1 µM TSA for various 
times.  Formaldehyde was then added directly to the growth media to a final 
concentration of 1%, and cells were incubated at 37oC for 10 min.  Cells were washed 
twice in ice cold PBS containing freshly added protease inhibitor cocktail (Sigma), 0.1 
mM phenylmethylsulfonyl fluoride (PMSF), and 1mM dithiothreitol (DTT).  Cells were 
then scraped off the plate, pelleted, and lysed in 350 mL of a lysis buffer supplied with a 
chromatin immunoprecipitation (ChIP) kit (Upstate Biotech), supplemented with freshly 
added protease inhibitors, PMSF, and DTT.  Genomic DNA in the lysates was sheared 
to lengths between 200 and 500 bp by sonication (Branson Sonifier 450, output control 
set to 3, 60% duty cycle).  Sheared lysates were cleared by centrifugation, and 50 µL 
was set aside as an input fraction.  The remaining lysate was split; one half was 
immunoprecipitated with 5 µg of anti -acetyl histone H3 (9/14) antibody (Upstate 
Biotech), and the other half was immunoprecipitated with pre-immune rabbit IgG using 
reagents and protocols supplied with the ChIP kit.  Following the ChIP protocol, cross-
links were reversed and genomic DNA was isolated from the immunoprecipitated 
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samples as well as the input fraction.  These samples were then subjected to PCR using 
primers specific for the SRC1α promoter (FWD, 5'-CACTGGGTAAATGTCCCTGCC; 
REV, 5'-CAACAGCAGAAGCCAGCCTG) or the SRC1A promoter (FWD, 5'-
GTGCCCAGCCCCAAAAGG; REV, ATTCCGGGCCGGGAGAGAC).  PCR products 
were analyzed via agarose gel electrophoresis. 
                 
3.14.  Nuclear Run-On Assay 
 This experiment was performed in collaboration with Dr. Keith Bonham at the 
Saskatchewan Cancer Agency.  Nuclear run-ons were performed essentially as described 
(Fei and Drake, 1993) with minor modifications (Dehm et al., 2001).  
 
3.15.  Electrophoretic Mobility Shift Assay 
 HepG2 cells were harvested at various time points following treatment with 1µM 
TSA, and nuclear extracts were prepared by the method of Andrews (Andrews and 
Faller, 1991).  A [32P]-dCTP labeled probe encompassing the -145 to +19 region of the 
SRC1α promoter was prepared via an in-fill reaction of a Cla I/Hinc II promoter 
restriction fragment derived from a SRC1α promoter construct (Bonham et al., 2000).  
The SRC1A EMSA probes A and B were prepared simultaneously by digestion of 0.38 
SRC1A-CAT with Nar I and BssH II, followed by a Klenow in-fill reaction with [α32P]-
dCTP, and subsequent agarose gel purification.  Electrophoretic mobility shift assay 
(EMSA) reactions were carried out by initially incubating 5 µg of nuclear extract in 
Binding Buffer (25 mM N-2-Hydroxyethylpiperazine-N'-2-ethanesulfonic acid 
(HEPES), pH 7.0, 4 mM Tris-HCl (pH 8.0), 5 mM MgCl2, 1 mM CaCl2, and 1 mM 
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DTT), 3 µg of poly(dI-dC), and 10 µg of bovine serum albumin for 15 minutes on ice.  
Following this incubation period, 4 X 105 cpm of the appropriate probe was added, thus 
making the final EMSA reaction volume 20 µL, and incubated at 25oC for 30 min.   
Bound and unbound probe were resolved in 4% polyacrylamide gels with an 
electrophoresis buffer containing 50 mM Tris, 380 mM glycine, and 2 mM EDTA at 
150 V for 3 h at 4 °C.  Gels were dried and exposed to Storage Phosphor Screens 
(Kodak) overnight.  Phosphorimager analysis was subsequently performed on the 
screens using a BioRad Molecular Imager FX (BioRad). 
 
3.16.  TAF1-TAF2 Binding Assays 
 These assays were performed in collaboration with Dr. Edith Wang at the 
University of Washington in Seattle, Washington, USA.  Recombinant baculovirus 
vectors were used to express HA-tagged wild-type or G690D mutant TAF1 and FLAG-
tagged TAF2 in Sf9 cells.  HA-TAF1 and FLAG-TAF2 were immunoaffinity purified 
and assembled into heterodimers in vitro as described (Chen and Tjian, 1996).  Double 
stranded, [32P]-labeled probes encompassing the SRC1A (5'-
CCGCTCCGGCTCCCAGGCCGGAATGGATTCCGGGCCGGGAGAGACAGAT), or 
SRC1α (5'-
ACAAGTGCGGCCATTTCACCAGCCCAGGCTGGCTTCTGCTGTTGACTGG), 
core promoters were generated.  For EMSA reactions, 5 µg of TAF1/2 heterodimer was 
incubated in a binding buffer (Hilton and Wang, 2003) with 1 µg poly dG-dC and 300 
µg/mL BSA at 25oC or 37oC for 20 min.  Labeled, double stranded probes were 
subsequently added, and the reaction proceeded at the same temperature for an 
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additional 20 min.  For competition experiments, double stranded competitors 
representing wild-type SRC1A or SRC1α core promoters, or SRC core promoters 
harbouring mutations in the Inr elements (mutant SRC1A, 5'-
ATCTGTCTCTCCCGGCCCGGCCTCCGGGCCGGCCTGGGAGCCGGAGCGG; 
mutant SRC1α, 5'-
ACAAGTGCGGCCATTTCACCAGCCCGGGCTGGCTTCTGCTGTTGACTGG) 
were added to the initial pre-incubation reaction with the TAF1/2 heterodimer prior to 
the addition of [32P]-labeled probe.  Bound and unbound core promoter probes were 
fractionated on agarose gels as described (Hilton and Wang, 2003), and visualized via 
autoradiography. 
 
3.17.  Western Blot 
 Cells were lysed directly in a loading buffer containing 65 mM Tris-HCl (pH 7.0), 
2% (w/v) SDS, 5% β-mercaptoethanol, 10% (v/v) glycerol, and 0.5% (w/v) 
bromophenol blue.  Equal amounts (typically 30 µg per lane) of protein were resolved 
on a 10% SDS-polyacrylamide gel, followed by transfer to nitrocellulose.  Membranes 
were washed in a TBST buffer (10 mM Tris, 15 mM NaCl, 0.5% (v/v) Tween-20), and 
blocked at room temperature in a blocking buffer consisting of 5% (w/v) fat-free skim 
milk powder (Carnation) in TBST.  Membranes were incubated with anti-Src (Oncogene 
Research) at 1 µg/mL, anti-Sp1 (Santa Cruz) at 2ug/mL, anti-Sp3 (Santa Cruz) at 
2ug/mL, or anti -HNF-1α (Santa Cruz) at 2ug/mL, for 2 h at room temperature.  All 
antibodies were diluted in blocking buffer.  Following primary antibody incubation, 
membranes were washed in TBST, and incubated with the appropriate secondary anti-
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host -horseradish peroxidase conjugate (Santa Cruz) diluted 1:2000 in blocking buffer 
for 1 hr at room temperature.  Membranes were washed in TBST, immersed in 
chemiluminescence reagents (Pierce) and exposed to Kodak X-Omat Blue XB-1 film for 
signal detection. 
 
3.18.  Src Kinase Assay 
 Cells were lysed in ice-cold, modified RIPA buffer (25 mM Tris-HCl, pH 7.2, 
0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate, 150 mM NaCl, 1mM EDTA) 
with protease inhibitors (aprotinin, leupeptin, and pepstatin A, each at 1 µg/mL) and 100 
µg/mL PMSF freshly added.  Immunoprecipitation and in vitro c-Src kinase assays were 
subsequently performed as described (Bjorge et al., 1995).  Briefly, lysate containing 
500 µg of total cellular protein was incubated with excess anti -Src antibody (Oncogene 
Research) for 1h at 4°C, and centrifugation at 10,000 g for 1 min at 4°C.  
Immunoprecipitate pellets were re-suspended in 40 µL of a kinase reaction buffer 
containing 0.25 M N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES), pH 
7.8, 25 mM MgCl2, 0.75 M NaCl, 1µCi [γ-32P]ATP, 10 µM ATP, 300 µM Src optimal 
peptide (AEEEIYGEFEAKKKK) (Zhou et al., 1995), 200 µM sodium orthovanadate, 
and 4 mg/mL p-nitrophenol phosphate for 15 min at 30ºC.  Reactions were terminated 
by the addition of 25 µL of 50% (v/v) acetic acid.  Aliquots from each reaction were 
spotted onto p81 phosphocellulose squares, which were subsequently washed three times 
in 0.5% (v/v) acetic acid, dried and counted in a scintillation counter. 
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4.  RESULTS AND DISCUSSION 
4.1.  SRC TRANSCRIPTIONAL ACTIVATION IN HUMAN COLON CANCER CELL LINES 
4.1.1.  c-Src mRNA Expression in Human Cancer Cells 
 To better understand the mechanism(s) of c-Src activation in human cancer, the 
expression of c-Src mRNA was examined in various human cancer cell lines by 
Northern blot (Fig. 4.1).  To control for RNA loading, the expression of β-actin was also 
examined on the same membrane.  The HeLa cervical carcinoma and Molt-4 T-cell 
leukemia cell lines displayed very low levels of c-Src mRNA expression.  Similar low 
levels of c-Src were also noted in colon cancer cell lines such as SW480, SW620, 
KM12C, as well as the HS578T breast cancer cell line.  However, much higher levels of 
c-Src mRNA expression were observed in the HT29, LS174T, LS180, WiDr, Colo 201, 
Colo 205, and Colo 320 colon cancer cell lines, HepG2 hepatoma cell line, and T47D, 
MDA-MB-231, and HBL100 breast cancer cell lines.  Previous studies have shown that 
the activation of c-Src in a subset of human colon cancer cell lines (HCCLs) can be 
accounted for by increased expression of c-Src protein (Park et al., 1993).  Therefore, 
these findings led to the hypothesis that overexpression of c-Src mRNA could play a 
role in pp60c-Src activation in human cancer cells. 
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Figure 4.1.  c-Src mRNA expression in human cancer cell lines.  Total
cellular RNA was isolated from (L to R) HT29, HT29, LS174T, LS180,
SW480, SW620, WiDr, KM12C, Colo 201, Colo 205, and Colo 320 colon
cancer cells, HeLa cervical carcinoma cells, HepG2 hepatoma cells, T47D,
HS578T, MDA-MB-231, and HBL100 breast cancer cells, and Molt-4 T-
cell leukemia cells and subjected to Northern blot analysis using probes
specific for c-Src and β-Actin. 
4.1.2.  c-Src Expression and Activity in HCCLs 
 To examine whether increased c-Src mRNA levels could explain c-Src protein 
overexpression in HCCLs, Western and Northern blots were generated (Figs. 4.2 A and 
B).  Cell lines that were found to constitutively overexpress pp60c-Src (HT29, Colo 201, 
Colo 205, WiDr, and LS174-T) also expressed high levels of c-Src mRNA.  Conversely, 
cell lines displaying lower pp60c-Src levels (HCT-15, DLD-1, KM12C, SW620, SW480, 
and HCT-116) also displayed lower c-Src mRNA expression.  Therefore, a strong 
positive correlation existed for c-Src mRNA and protein expression.  The only cell line 
that did not follow this tight correlation was the Colo 320 cell line.  These cells 
displayed intermediate steady-state c-Src mRNA levels and low protein levels.  
Interestingly, this particular cell line also displayed unusually high levels of c-Myc 
mRNA due to a massive amplification of the MYC gene in the form of double minute 
chromosomes (Bianchi et al., 1991). 
 To expand this correlation between c-Src mRNA and protein levels, in vitro c-Src 
kinase assays were performed (Fig. 4.2 C).  Low pp60c-Src activity was observed in 
HCT-15, DLD-1, Colo 320, KM12C, SW620, SW480, and HCT-116 cell lines.  These 
were the same cell lines that displayed low c-Src protein levels.  High pp60c-Src was 
demonstrated in the same cell lines that displayed high c-Src mRNA and protein levels 
(HT29, Colo 201, WiDr Colo 205, LS-174T.  These data confirmed that elevated 
pp60c-Src activity in HCCLs could be explained by overexpression of c-Src mRNA. 
 
4.1.3.  c-Src Transcriptional Activity in HCCLs 
 To address whether the observed increase in c-Src mRNA levels resulted from 
increased transcription of the SRC gene, nuclear run-on analysis was performed by Dr.  
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Figure 4.2.  c-Src mRNA, protein, and kinase activity levels in HCCLs.
(A) Northern blot of total RNA from semi-confluent cells sequentially
probed for c-Src, c-Myc, and β-Actin.  The figure shown is representative
of several repeated experiments.  (B) Western blot of total cellular proteins
from the same cell lines harvested at the same time as in (A), using a
specific anti-pp60c-Src monoclonal antibody.  (C) Evaluation of c-Src kinase
activity in anti-pp60c-Src immunoprecipitates using a synthetic peptide
(AEEEIYGEFEAKKK) substrate.  Kinase activity is expressed as pmol of
radioactive phosphate incorporated per minute per mg of total cellular
protein.  The bar graph represents the mean +/- the standard deviation from
three replicate experiments.  
Keith Bonham (Saskatchewan Cancer Agency).  A higher signal for c-Src transcription 
was detected in cell lines that displayed elevated c-Src mRNA levels (HT29, Colo 205) 
when compared to cell lines with lower levels of c-Src mRNA expression (Fig. 4.3).  
These results suggested that the SRC gene was transcribed at relatively higher rates in 
the c-Src overexpressing cell lines compared to the low expressing cell lines. 
 
4.1.4.  Determination of c-Src mRNA Stability in HCCLs 
 The level of SRC transcription measured in HT29 and Colo 205 cells by the 
nuclear run-on approach was at the lower level of the detection limit of the assay.  
Because of this, and the possibility that steady state levels of mRNA detected in the 
Northern blots could also be influenced by differential mRNA stability, a study of c-Src 
mRNA half-life in these HCCLs was necessary.  Cellular transcription in HT29, Colo 
201, Colo 205, SW480 and SW620 cells was inhibited by treatment with Actinomycin 
D, and isolated RNA was analyzed by Northern blot (Fig. 4.4).  A consistent observation 
was the rapid degradation of c-Myc transcripts, confirming Actinomycin D was exerting 
a similar level of transcriptional inhibition in the HCCLs studied.  Conversely, β-Actin 
mRNA levels were steady throughout the course of the experiment.  In cells that express 
low levels of c-Src (SW480, SW620), the c-Src transcripts were stable over the time 
course of the study.  However, in high c-Src expressing cell lines, the c-Src transcripts 
were rapidly degraded, with an estimated half-life of less than 2 hours.  Decreased c-Src 
mRNA stability in cell lines with elevated c-Src mRNA levels suggests an even higher 
level of SRC transcription necessary to account for steady-state c-Src mRNA levels than 
previously anticipated.  Taken together, the data from mRNA stability studies and  
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Figure 4.3.  SRC transcriptional activity in HCCLs.  Nuclei were
prepared from HT29, Colo 205, and SW620 cell lines and run-ons
performed.  [32P]-labeled RNA from these nuclei was then hybridized to
nylon membranes containing 10 µg slot-blots of denatured c-Src, pBS
(pBluescript), β-Actin, c-Myc, pGD (glucose-6-phosphate dehydrogenase),
and pRibo (18S ribosomal RNA cDNA) cDNAs as indicated. 
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Figure 4.4.  c-Src mRNA half-life determination in HCCLs.  Total RNA
was isolated from five colon cancer cell lines at various times following
exposure to 5 µg/mL Actinomycin D.  Total RNA was blotted to charged
nylon membranes and hybridized sequentially with probes specific for c-
Src, c-Myc and β-Actin.  Lane numbering refers to hours after initial
Actinomycin D exposure that cells were harvested.  The Northern blots
shown are representative of several repeated experiments.  Much longer
exposures to film were necessary to obtain signals for c-Src mRNA
expression in SW480 and SW620 (4 to 5 days) compared with HT29, Colo
201, and Colo 205 (overnight). 
nuclear run-on experiments strongly implicate that the mechanism of c-Src 
overexpression in this subset of HCCLs is at the level of transcription. 
 
4.1.5.  c-Src Expression Levels vs. KRAS Gene Status 
 Activating mutations in the KRAS gene have been well documented as a frequent 
and important event in colon cancer (Bos et al., 1987; Burmer and Loeb, 1989; Kinzler 
and Vogelstein, 1996).  Interestingly, SRC transcription was activated only in HCCLs 
containing two normal KRAS alleles (Table 4.1).  Conversely, those cell lines that 
expressed low levels of c-Src harboured a mutant KRAS allele encoding an activated K-
Ras protein (Nagasu et al., 1995).  The only exception to this pattern was the Colo 320 
cell line, which expresses unusually high levels of c-Myc from the amplified MYC locus 
(Bianchi et al., 1991).  This interesting correlation therefore leads to the proposal that 
mutational activation of the KRAS gene or transcriptional activation of SRC may 
represent two parallel and mutually exclusive pathways that ultimately contribute to 
colon cancer progression. 
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__________________________________________________________ 
Table 4.1.  Relative c-Src Expression Levels and KRAS Gene Status 
in Human Colon Cancer Cell Lines 
 
 
Cell Line 
c-Src Expression  
(Northern, Western) 
 
KRAS Status 
HT29 +++++a wild-type 
Colo 201 +++++ wild-type 
Colo 205 +++++ wild-type 
WiDr +++++ wild-type 
LS-174T +++++ not determined 
Colo 320 ++ wild-type 
SW480 + K12V 
SW620 + K12V 
HCT-15 + K13D 
HCT-116 + K13D 
DLD-1 + K13D 
KM12C + not determined 
a (+++++) represents high and (+) represents low levels of c-
Src expression as visually determined by Northern and Western 
blot analysis. 
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4.1.6.  c-Src Expression and Activity in Mutant KRAS Knock-Out Cell Lines 
 In order to initially address the apparent reciprocal relationship between SRC 
transcriptional activation and activating KRAS mutations, c-Src expression and activity 
were assessed in HCCLs with the mutant K13D KRAS allele disrupted by homologous 
recombination.  Hke-3 and Hkh-2 are two such HCT-116 derivatives, and DKO-4 and 
DKS-8 are two such DLD-1 variants (Okada et al., 1998; Shirasawa et al., 1993).  As 
shown in Fig. 4.5 C, c-Src kinase activity was elevated 2 to 5 fold in Hke-3 and Hkh-2 
cell lines relative to HCT-116.  A similar level of increased c-Src kinase activity was 
observed in DKO-4 and DKS-8 cell lines relative to DLD-1.  The increase in c-Src 
kinase activity was matched by a slight increase in c-Src protein levels in knock-out vs. 
parental HCCLs (Fig. 4.5 B).  However, when c-Src mRNA levels were measured by 
Northern blot, only the Hke-3 cell line displayed an increase relative to the parental cell 
line (Fig. 4.5 A).  These data suggest that the elevation in c-Src kinase activity in knock-
out cell lines is compensatory and necessary for the cells to overcome the growth 
inhibition caused by targeted disruption of the mutant K13D allele. 
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Figure 4.5.  c-Src expression and activity in HCCLs with targeted
disruption of mutant KRAS.  (A) Northern blot of total RNA from semi-
confluent cells sequentially probed for c-Src and β-Actin.  (B) Western blot
of total cellular proteins from the same cell lines harvested at the same time
as in (A), using a specific anti-pp60c-Src monoclonal antibody.  (C)
Evaluation of c-Src kinase activity in anti-pp60c-Src immunoprecipitates
using a synthetic peptide (AEEEIYGEFEAKKK) substrate.  Bar graphs
represent the mean +/- the standard deviation from three replicate
experiments.  
 
4.1.7.  DISCUSSION 
4.1.7.1.  SRC Transcriptional Activation in Human Cancer Cell Lines 
 Activation and/or overexpression of the tyrosine kinase pp60c-Src has been 
frequently reported in both human colon cancer cell lines and tumors (Bolen et al., 
1987a; Cartwright et al., 1990; Talamonti et al., 1993),  However, the precise 
mechanism of this activation has remained elusive.  An activating SRC mutation has 
been described in a small (12%) subset of highly advanced colon cancers (Irby et al., 
1999).  This mutation converts glutamine 531 to a stop codon, resulting in a truncated 
version of c-Src.  The truncation at the C-terminal tail prevents phosphorylation of 
Y530, and hence prevents pp60c-Src inactivation.  Transfection studies have shown this 
mutation is activating, transforming, tumorigenic, and promotes metastasis.  However, 
the importance of this SRC mutation in the majority of colon cancers is suspect.  
Numerous follow-up studies have analyzed hundreds of advanced colon cancer 
specimens, and not one has been able to reproduce the results from the initial report 
(Daigo et al., 1999; Laghi et al., 2001; Nilbert and Fernebro, 2000).  Therefore, SRC 
mutation is considered a very rare event, and in the vast majority of colon cancers, c-Src 
is activated through non-mutagenic means. 
 A subset of the reports describing c-Src tyrosine kinase activation in colon cancer 
has demonstrated an increase in the specific activity of pp60c-Src.  (Bolen et al., 1987a; 
Bolen et al., 1987b; Cartwright et al., 1989).  Early studies attempting to explain this 
observation focused on the kinase capable of phosphorylating the Y530 residue of pp60c-
Src, Csk (Nada et al., 1991).  However, no correlation has been observed between Csk 
expression and/or activity and c-Src activity.  In fact, high levels of Csk activity and 
expression have been observed in colorectal tumors and cell lines with high levels of c-
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Src kinase activity (Li et al., 1996).  In addition, several proteins capable of enhancing c-
Src kinase activity by de-phosphorylating the Y530 residue have been identified, but 
none have been shown to have elevated expression or activity in colon cancer (Bjorge et 
al., 2000; Fang et al., 1994; Walter et al., 1999).  Therefore, the post-translational 
mechanisms leading to c-Src kinase activation in colon cancer remain undefined. 
 One of the more consistent findings in various human tumors and tumor derived 
cell lines is that increased c-Src activity can be explained by an increase in c-Src protein 
levels (Biscardi et al., 1999; Iravani et al., 1998; Irby et al., 1997).  In this study, these 
observations have been verified and expanded, and increased c-Src protein levels and 
resulting kinase activity have been shown to be due to elevated c-Src mRNA expression.  
Furthermore, transcriptional activation of the SRC gene was demonstrated, which was 
responsible for the overexpression of c-Src mRNA observed in a subset of HCCLs.  
Therefore, although controls such as covalent modification exist to finely modulate c-
Src kinase activity, coarse controls such as SRC transcriptional activation are an 
important determinant of overall c-Src expression and activity in HCCLs. 
 An interesting and unexpected finding from this line of investigation was 
decreased stability of c-Src mRNA in cell lines that displayed SRC transcriptional 
activation.  These results suggest a negative feedback loop exists that leads to reduced 
stability of c-Src mRNA when SRC transcription is increased.  The mechanism of c-Src 
mRNA destabilization is currently unknown; however, this observation parallels 
findings that pp60c-Src with higher kinase activity is degraded more rapidly by a 
ubiquitin-dependent mechanism than pp60c-Src with lower levels of kinase activity 
(Hakak and Martin, 1999; Harris et al., 1999). 
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 There have also been many reports that have suggested c-Src overexpression 
and/or activation could play an important role in non-colon cancers.  For example, a c-
Src specific antisense strategy employed in the SKOv-3 ovarian cancer cell line resulted 
in diminished anchorage-independent growth and tumor forming ability in a xenograft 
nude mouse model (Wiener et al., 1999).  Similarly, antisense-mediated down-regulation 
of c-Src expression in NIH3T3 cells engineered to mimic breast cancer by 
overexpressing the EGFR or an EGFR-HER-2 chimera resulted in reversal of the 
transformed phenotype of these cells (Karni et al., 1999).  Observational studies have 
also reported increased c-Src expression and/or kinase activity in cancers such as breast, 
lung, pancreas, and liver (Lutz et al., 1998; Masaki et al., 1998; Mazurenko et al., 1992; 
Verbeek et al., 1996).  Therefore, it is important to note that the c-Src mRNA expression 
analysis employed in this study detected elevated c-Src mRNA levels in cell lines 
derived from cancers of the liver and breast.  Additional studies will be necessary to 
determine if SRC transcriptional activation plays a role in determining overall pp60c-Src 
activity in these and other cancers. 
 
4.1.7.2.  SRC Transcription and Colon Cancer Progression 
 Colon cancer is the best understood cancer both in terms of staging and 
documentation of specific genetic lesions.  This has allowed for the proposal of stepwise 
models of colonic tumorigenesis (Fearon and Vogelstein, 1990; Kinzler and Vogelstein, 
1996).  For example, loss of APC function (Kinzler and Vogelstein, 1996; Morin et al., 
1997) or mutations in β-catenin that render it unresponsive to APC regulation 
(Dashwood et al., 1998; Morin et al., 1997; Park et al., 1999) have been identified as 
 105 
crucial initiating events for colon tumorigenesis.  Colon tumor progression is associated 
with further genetic lesions resulting in the loss of function of additional tumor 
suppressor genes such as p53, DCC, hMLH1, and hMSH2, and activation of oncogenes 
such as KRAS (Kinzler and Vogelstein, 1996).  KRAS mutations are reported to occur 
early in colon cancer development, during progression from early adenoma to late 
adenoma, at a rate of about 50% (Bos et al., 1987; Burmer and Loeb, 1989; Fearon and 
Vogelstein, 1990; Kinzler and Vogelstein, 1996).  These mutations have significant 
impact on proliferation, transformation, and tumorigenicity (Fearon and Vogelstein, 
1990; Kinzler and Vogelstein, 1996).  Similarly, c-Src overexpression or activation is a 
frequent early event in colon cancer (Biscardi et al., 1999; Bolen et al., 1987a; Budde et 
al., 1994; Cartwright et al., 1994; Cartwright et al., 1990; Han et al., 1996; Iravani et al., 
1998; Staley et al., 1997; Talamonti et al., 1993; Zhao et al., 1990), and simple 
overexpression of normal c-Src in mouse fibroblasts is transforming (Lin et al., 1995).  
Therefore, the observation of a strong inverse correlation between SRC transcriptional 
activation and the presence of activating KRAS mutations in the HCCLs examined in 
this study is of potential clinical importance.  The possibility is raised that increased 
SRC transcription and KRAS mutation represent two mutually exclusive and parallel 
oncogenic pathways activated early in colon tumorigenesis.    
 The hypothesis of SRC and KRAS mutual exclusion is further supported by the 
similarities between c-Src and K-Ras activated signaling pathways.  For example, 
inactivation of c-Src or mutant KRAS alleles in HCCLs by antisense technology (HT29) 
or homologous recombination (HCT-116, DLD-1) results in cells with decreased 
proliferative rates, focus forming ability, and tumorigenicity (Shirasawa et al., 1993; 
Staley et al., 1997).  These same cells with down-regulated c-Src or disrupted KRAS 
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also exhibit diminished levels of VEGF, a growth factor closely associated with 
angiogenesis and tumor growth (Ellis et al., 1998; Shirasawa et al., 1993).  Also, c-Src 
has often been placed upstream of Ras in signal transduction pathways because several 
studies have shown that v-Src transformation of NIH 3T3 mouse fibroblast cells is 
dependent on Ras (Rak et al., 1995).  However more recent work in rat intestinal 
epithelial cells and rat fibroblasts has clearly shown that Src and Ras can induce 
transformation via independent and quite distinct mechanisms (Oldham et al., 1998; Rak 
et al., 1995).  Thus, a de-regulated c-Src or K-Ras can ultimately act on similar or even 
identical downstream targets and contribute independently to transformation and tumor 
progression.  This theory is supported by the findings from this study that c-Src kinase 
activity was elevated in HCT-116 and DLD-1 cells that have had the mutant KRAS 
allele disrupted by homologous recombination.  This potentially compensatory increase 
in c-Src kinase activity did not appear to result directly from SRC transcriptional 
activation, demonstrating alternative mechanisms can also be activated in HCCLs that 
result in increased c-Src kinase activity. 
 
4.1.7.3.  Scope and Significance 
 This line of investigation has demonstrated SRC transcriptional activation as a 
mechanism leading to elevated pp60c-Src expression and activity in HCCLs.  SRC 
transcriptional activation was only observed in HCCLs with wild type KRAS, 
suggesting an inverse relationship between c-Src or K-Ras activation.  If the 
observations reported here can be translated into studies with colon and other tumor 
samples, then this would hold important ramifications for both diagnosis and future 
targeted therapy of various human cancers. 
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4.2.  MECHANISMS OF SRC TRANSCRIPTIONAL ACTIVATION IN HUMAN CANCER CELL 
LINES 
4.2.1.  Differential SRC Promoter Use in Cancer Cell Lines 
 Studies outlined in the previous chapter showed SRC transcriptional activation is 
an important determinant of overall c-Src expression and kinase activity levels in a 
subset of HCCLs.  Therefore, an important issue became the mechanisms regulating this 
transcriptional activation.  At the same time the experimentation outlined in the 
preceding chapter was being carried out, Dr. Keith Bonham and other members of his 
laboratory had identified and were characterizing the SRC1α promoter (Bonham et al., 
2000).   The discovery of another SRC promoter, SRC1A, had been reported by Dr. 
Bonham seven years earlier (Bonham and Fujita, 1993).  Interestingly, SRC1α, unlike 
the Sp-regulated, ubiquitously expressed SRC1A promoter, is regulated by a liver 
enriched transcription factor, HNF-1α.  HNF-1α mediated regulation of SRC1α 
provides a solid rationale for the tissue-restricted expression of this promoter.  For 
example, SRC1α promoter use is mainly restricted to the same tissues that HNF-1α is 
expressed in, such as liver, lung, pancreas, kidney, and intestine (Bonham et al., 2000).  
Interestingly, elevated c-Src activity has been documented in liver cancer (Masaki et al., 
1998), and results from Northern blotting demonstrated that c-Src mRNA is 
overexpressed in the HepG2 hepatocellular carcinoma cell line (Fig. 4.1.).  Because of 
these observations, HepG2 cells were incorporated into the majority of the experiments 
performed in this thesis.  S1 nuclease protection assays, designed to examine relative 
SRC promoter use in HepG2 cells, have shown that 80-90% of the c-Src transcripts arise 
from the SRC1α promoter (Bonham et al., 2000).  These S1 protections have been 
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repeated, and verify that c-Src mRNA in HepG2 cells contain a much higher abundance 
of transcripts with Exon 1α at the extreme 5' terminus than Exon 1A (Fig. 4.6 A).  This 
is in contrast to S1 experiments with HT29 cells, which have shown that c-Src mRNA 
overexpression in this cell line results from near equal utilization of both SRC promoters 
(Bonham et al., 2000).  Both SRC promoters are also used in SW480 cells, however at 
much lower levels than HT29 cells, resulting in very weak signals for the two different 
c-Src mRNA transcripts when assayed via S1 nuclease protections (Bonham et al., 
2000).  This experiment has been repeated, and confirms both SRC promoters are 
utilized at very low levels in SW480 cells (Fig. 4.6 B).  These findings led to the 
hypothesis that understanding the mechanisms governing differential promoter usage 
could lead to an understanding of the mechanisms leading to SRC transcriptional 
activation in these cell lines. 
 
4.2.2.  Transcription Factor Expression Analysis in Cancer Cell Lines 
 To initially address the differential usage of the two SRC promoters, Western blot 
analysis was performed to determine the relative expression levels of the HNF-1α, Sp1 
and Sp3 transcription factors in various cancer cell lines (Fig. 4.7).  At the time these 
experiments were performed, SPy had not yet been identified as hnRNP K; therefore, 
expression data for this factor was not obtained.  As expected, Sp1 and Sp3 expression 
was fairly ubiquitous, although expression levels did vary somewhat among cell lines.  
However, significant differences in HNF-1α expression were observed in these cell 
lines.  HNF-1α expression was highest in the HepG2 hepatocellular carcinoma cell line, 
intermediate in the SW480, COLO201, WiDr, HT29, COLO205, and SW620 colon  
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Figure 4.6.  Differential Usage of the SRC1α and SRC1A promoters.  Total 
RNA was isolated from HepG2 (A) and SW480 (B) cells, and hybridized with an 
S1 probe specific for endogenous 1α transcripts.  RNA from yeast was utilized to 
ensure the specificity of the S1 probe for c-Src mRNA transcripts (A and B, Lane 
2).  A schematic of the expected protection pattern is shown below.  pBH2 refers 
to fragments from a Hpa II pBluescript digest [32P]-labeled via an in-fill reaction 
with Klenow fragment.   
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Figure 4.7.  HNF-1α, Sp1, and Sp3 expression levels in human
cancer cell lines.  Western blots were performed using equal amounts
of protein from various whole cell lysates of human cancer cell lines.
Blots were probed, stripped, and re-probed sequentially using
antibodies specific for HNF-1α, Sp1, and Sp3. 
carcinoma cell lines, and absent in HCT-116 and DLD-1 colon carcinoma cells as well 
as the HTB10 neuroblastoma cell line.  These results suggested HNF-1α could be an 
important regulator of SRC promoter usage and expression levels in colon and other 
cancer cell lines.  This possibility led to the development of various models that could 
explain differential SRC promoter usage.  For example, HepG2 cells, which display 
preferential SRC1α promoter usage, were found to contain high levels of HNF-1α and 
intermediate levels of Sp1 and Sp3.  In this situation, the SRC1α promoter could be 
strongly transactivated due to high levels of HNF-1α, thus preventing preinitiation 
complex formation at the SRC1A promoter.  This phenomenon, where strong upstream 
promoter usage inhibits downstream promoter usage, has been termed promoter 
occlusion (Corbin and Maniatis, 1989; Cullen et al., 1984; Ju and Cullen, 1985; 
Proudfoot, 1986).  Alternatively, in HT29 cells, intermediate levels of HNF-1α, Sp1 and 
Sp3 expression were observed.  Previous S1 analysis has shown the SRC1α and SRC1A 
promoters are utilized at similar levels in these cells (Bonham et al., 2000).  Both 
promoters could be utilized in this circumstance because less SRC1α promoter usage, 
due to intermediate HNF-1α levels, would allow for preinitiation complex formation at 
the SRC1A promoter. 
 
4.2.3  A Strategy for Studying the SRC Promoters in their Natural Linked Context 
4.2.3.1.  Dual SRC Promoter CAT Reporter Construct 
 A key observation made early in the course of these studies was that the SRC1A 
promoter was always stronger in isolation than the SRC1α promoter.  As will be 
demonstrated in subsequent sections, this consistent finding arose from transfection 
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experiments with SRC1A-CAT and SRC1α-CAT reporter constructs in HepG2, HT29, 
HCT-116, and SW480 cells.  This was a very intriguing observation, because previous 
S1 analysis had determined that the high levels of c-Src mRNA in HepG2 cells arose 
from preferential use of the SRC1α promoter, while the high levels of c-Src mRNA in 
HT29 cells arose from near equal use of both the SRC1α and SRC1A promoters 
(Bonham et al., 2000).  This discrepancy between endogenous SRC promoter use and 
the strength of SRC promoter CAT constructs in cancer cell lines prompted the design of 
a CAT-based plasmid construct that would allow the study of both SRC promoters in 
their natural, physiologically linked context.  It was hypothesized that studying the 
promoters in such a way would circumvent this problematic observation of SRC1A-
CAT constructs always being more active than SRC1α-CAT constructs in transfection 
experiments.  The desire was to create a construct that would allow the measurement of 
overall combined activity of the two SRC promoters as well as quantitative comparison 
of their relative usage.  Such a construct would be a very valuable tool to test models of 
differential SRC promoter use observed in human cancer cell lines, especially the 
promoter occlusion model proposed for HepG2 cells.  To this end, a series of CAT 
reporter vectors were generated that contained both SRC promoters and associated exons 
in their normal genomic architecture, separated by a small intron from Exon 1B, a 
common non-coding splicing exon for both Exon 1A and Exon 1α (Fig. 4.8 A and B).  
These SRC Dual Promoter CAT Constructs (SRC DPCATs) differed only in the amount 
of DNA sequence they harboured upstream from Exon 1α.  In addition to being able to 
drive transcription of the CAT gene, the SRC DPCAT constructs theoretically contained 
intronic DNA splicing recognition sequences upstream from Exon 1B and downstream  
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Figure 4.8.  Schematic of the SRC DPCAT Strategy.  (A,B) The -560 SRC
DPCAT construct was generated by inserting a genomic SRC promoter
cassette upstream of a genomic DNA fragment containing Exon 1B and
upstream sequences.  (B) Variants of the -560 DPCAT construct, -2852 SRC
DPCAT and -145 SRC DPCAT were created by adding or removing
genomic fragments upstream from Exon 1α.  The extreme 5' boundaries of
the -2852, -560, and -145 SRC DPCAT constructs are defined by Kpn I,
EcoR V, and Msc I restriction sites, respectively.  (C) Following transfection
into cells, the 1α-CAT transcript would be predicted to arise from usage of
the SRC1α promoter, and the 1A-CAT transcript would be predicted to arise
from usage of the SRC1A promoter. 
from Exons 1α and 1A to allow for selective splicing of Exon 1α or Exon 1A to 1B 
following transfection into cells (Fig. 4.8 C) (Breathnach et al., 1978; Chu and Sharp, 
1981; Lerner et al., 1980; Mount, 1982; Rogers and Wall, 1980; Seif et al., 1979; 
Treisman et al., 1982; Wieringa et al., 1983). 
 
4.2.3.2.  SRC DPCAT Splicing Following Transient Transfection 
 In order to verify the validity of this approach, a number of preliminary 
transfection experiments were performed with the SRC DPCAT reporters in HepG2 
cells (Fig. 4.9).  The HepG2 cell line was chosen for these initial experiments due to the 
observation that these cells can be transfected at a very high efficiency.  The CAT levels 
arising from a 0.54 SRC1A-CAT reporter were higher than for a -145 SRC1α-CAT 
reporter (Fig. 4.9 A), demonstrating the SRC1A promoter has higher activity in isolation 
than the SRC1α promoter in HepG2 cells.  When CAT expression levels arising from 
the -145, -560, and -2852 SRC DPCAT reporters were compared, very similar activities 
were observed.  These results demonstrated the amount of genomic sequence contained 
upstream from Exon 1α had little effect on the overall activity of these constructs.  
Activity of these SRC DPCAT reporters was very similar to the activity of the SRC1α 
promoter in isolation (Fig. 4.9 A).  These results showed the SRC DPCAT constructs 
were able to efficiently drive CAT expression in transient transfection experiments. 
 A combination of RT-PCR and 5' RACE approaches were then utilized to verify 
correct exon splicing and the generation of predicted transcripts following transfection.  
First, total RNA was isolated from -560 DPCAT transfected HepG2 cells and subjected 
to RT-PCR analysis to assess whether Exons 1α and 1A were effectively spliced to  
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Figure 4.9.  Activity and splicing patterns of SRC DPCAT constructs 
in HepG2 cells.  (A) HepG2 cells were transfected with various SRC 
DPCAT reporters as well as 0.54 SRC1A-CAT and -145 SRC1α-CAT 
reporters.  CAT levels in cell lysates were subsequently determined. 
Activity of the 0.54 SRC1A-CAT reporter was arbitrarily chosen to 
represent 100%.  Bar graphs represent the mean +/- the standard 
deviation from two separate experiments, each performed in duplicate. 
(B) Total RNA was isolated from HepG2 cells that were transfected with 
-560 SRC DPCAT.  Reverse transcription was performed using a CAT 
specific primer.  Subsequent PCR was performed using a nested CAT 
specific reverse primer coupled with Exon 1α or 1A specific forward 
primers.  PCR products were separated on agarose gels. (C) Reverse 
transcription products from (B) were subjected to 5' RACE, and products 
were separated on agarose gels.  Bands were subsequently cloned and 
sequenced.   
Exon 1B.  A CAT-anchored primer was utilized for reverse transcription, and 
subsequent PCR reactions were performed on these reverse transcription products using 
a nested CAT reverse primer coupled with specific forward primers recognizing Exon 
1α or Exon 1A (Fig. 4.9 B).  Following electrophoretic separation on agarose gels, 
bands of the predicted size (508 bp for Exon 1A splicing to Exon 1B, and 585 bp for 
Exon 1α splicing to Exon 1B) were observed, suggesting that the predicted spliced 
transcripts were generated following transfections with the SRC DPCAT reporter.  To 
confirm this, these fragments were isolated from the agarose gels and sequenced.  
Second, to verify that transcripts arising from the SRC DPCAT reporter originated 
exclusively from the SRC1α or SRC1A promoters, 5' RACE was performed using the 
reverse transcription reaction generated for RT-PCR experiments.  When 5' RACE 
products were separated on agarose gels, two discrete bands were observed that were 
exactly the size predicted for transcripts containing Exon 1α or Exon 1A at the extreme 
5' terminus (Fig. 4.9 C).  To verify this, the two bands were excised from the gel and 
cloned into pBluescript.  Results from DNA sequencing analysis of 5' RACE clones 
confirmed these two bands represented Exon 1α or Exon 1A properly spliced to Exon 
1B-CAT.  Taken together, these experiments demonstrated the two SRC promoters were 
active within the SRC DPCAT construct, and generated pre-mRNA products that 
properly spliced to form mature mRNAs of a predicted composition following transient 
transfection. 
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4.2.3.3.  Quantitation of SRC DPCAT Promoter Usage 
 Due to the demonstration that the predicted mRNA species arose from the SRC 
DPCAT construct, a S1 nuclease protection strategy was developed to specifically and 
quantitatively measure their relative abundance following transient transfections.  
Vectors were engineered that perfectly matched the sequences of 1α-CAT or 1A-CAT 
transcripts (Fig. 4.10).  These vectors were subsequently used in linear amplification 
reactions to generate [32P]-labeled S1 probes perfectly complementary to these two 
mRNA species.  When the 1α-CAT specific S1 probe was hybridized with RNA from 
cells that had been transfected with -145 or -560 SRC DPCAT and subjected to 
digestion with S1 nuclease, three distinct protected species were observed (Fig. 4.10 A, 
Lanes 4 and 5).  The largest, 472 bp band represented the 1α-CAT transcript, the 
intermediate, 299 bp band represented the 1A-CAT transcript, and the smallest, 217 bp 
band represented the endogenous c-Src mRNA transcript arising from usage of the 
SRC1α promoter.  The origin of these species was confirmed by the observation that the 
1α-CAT S1 probe only protected a 217 bp species in RNA from untransfected HepG2 
cells (Fig 4.10 A, Lane 3).  Specificity of the 1α-CAT S1 probe was further confirmed 
by the absence of protected species from yeast RNA (Fig 4.10 A, Lane 2).  A higher 
abundance of 1α-CAT transcripts were generated in HepG2 cells transfected with -145 
SRC DPCAT, compared with -560 SRC DPCAT (Fig. 4.10 A, compare Lanes 4 and 5).  
These findings agree with previous studies that have demonstrated negative regulatory 
elements present in SRC1α promoter constructs larger than -145 SRC1α-CAT (Bonham 
et al., 2000). These results also demonstrated a much higher abundance of 1A-CAT 
transcripts relative to 1α-CAT transcripts arising from the -145 and -560 SRC DPCAT  
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Figure 4.10.  Determination of relative promoter usage from the SRC
DPCAT reporter following transient transfections.  (A) Total RNA was
isolated from transfected as well as untransfected HepG2 cells.  RNA was
hybridized with a 1α-CAT specific S1 probe and then digested with S1
nuclease.  Protected fragments were separated on standard DNA sequencing
gels.  A schematic of the expected protection pattern is shown below.  (B)
Experiments were performed exactly as in (A), using a 1A-CAT specific S1
probe.  A schematic of the expected protection is shown below.  pBH2 refers
to fragments from a Hpa II pBluescript digest [32P]-labeled via an in-fill
reaction with Klenow fragment   
 
reporters (Fig. 4.10, Lanes 4 and 5).  When the reciprocal experiment was 
performed,and a 1Α-CAT specific S1 probe was hybridized with RNA from cells that 
had been transfected with -145 or -560 SRC DPCAT and subjected to digestion with S1 
nuclease, a similar pattern of protected species was observed (Fig. 4.10 B, Lanes 4 and 
5).  The 397 bp and 299 bp bands represented 1A-CAT and 1α-CAT transcripts, 
respectively.  Bands spanning 147 bp to 180 bp represented endogenous c-Src transcripts 
arising from multiple transcription start sites within the SRC1A promoter.  
Quantification of the relative abundance of 1A-CAT and 1α-CAT transcripts determined 
using the 1A-CAT specific S1 probe correlated very closely with the relative abundance 
determined using the 1α-CAT specific S1 probe.  Taken together, these results 
demonstrated S1 nuclease protection assays specifically designed to target 1α-CAT and 
1A-CAT transcripts represented an excellent approach to measuring relative SRC 
promoter use following transient transfections with SRC DPCAT constructs. 
 
4.2.4.  Search for Enhancer Elements in the SRC Locus 
4.2.4.1.  Evidence for a SRC Enhancer in Human Cancer Cells 
 Preliminary SRC DPCAT transfection experiments in HepG2 cells suggested 
preferential SRC1A promoter use from this construct.  Subsequent S1 nuclease 
protection assays of transfected HepG2 cells have confirmed this initial observation, 
which is in stark contrast to the preferential SRC1α promoter use seen endogenously in 
these cells (Fig. 4.11).  An S1 probe perfectly complementary to endogenous SRC1α 
derived transcripts was hybridized with HepG2 RNA, followed by S1 nuclease 
digestion.  The largest, 345 bp protected band representing the endogenous 1α transcript  
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Figure 4.11.  Endogenous vs. SRC DPCAT promoter usage in HepG2
cells.  (A) Total RNA was isolated from HepG2 cells and hybridized with
an S1 probe specific for endogenous 1α transcripts.  A schematic of the
expected protection pattern is shown below.  (B) Total RNA was isolated
from untransfected or transfected HepG2 cells and hybridized with an S1
probe specific for 1α-CAT transcripts.  A schematic of the expected
protection pattern is shown below.  pBH2 refers to fragments from a Hpa
II pBluescript digest [32P]-labeled via an in-fill reaction with Klenow
fragment.   
was observed at a much higher abundance than the smaller, 170 bp protected band 
representing the endogenous 1A transcript (Fig. 4.11 A).  Conversely, 1α-CAT 
transcripts were in very low abundance compared with 1A-CAT transcripts in HepG2 
cells that had been transfected with -560 SRC DPCAT (Figs. 4.10 and 4.11 B).  This 
demonstrated the SRC1A promoter was utilized at a much higher rate than the SRC1α 
promoter in the SRC DPCAT construct.  Therefore, this finding excludes the promoter 
occlusion model that was developed to explain the preferential SRC1α use in HepG2 
cells in vitro.  In addition, these observations parallel previous transient transfection 
experiments, which have demonstrated that the SRC1A promoter in isolation is stronger 
than the SRC1α promoter (Fig. 4.9 A).   
 To determine if these results extended to HCCLs as well, the same experiments 
were performed in HT29, SW480, and HCT-116 cells.  Indeed, the activity of a SRC1A 
construct was consistently much higher in isolation than activity of a SRC1α construct 
in these HCCLs (Fig. 4.12).  This difference in activity was even more pronounced than 
in HepG2 cells (Fig. 4.9 A).  In SW480 and HCT-116 cells, the activities of the -145 and 
-560 DPCAT constructs were comparable to the activity of the SRC1A promoter in 
isolation (Fig. 4.12 B,C).  S1 analysis of SW480 and HCT-116 showed that both of these 
cell lines display weak endogenous use of both SRC promoters, resulting in the low 
levels of c-Src mRNA expressed in these cells (Fig. 4.13 A).  When S1 assays were 
utilized to determine promoter use from the -560 DPCAT construct in these cells, near 
exclusive SRC1A usage was observed (Fig. 4.13 B).  Similarly, preferential strong 
SRC1A usage was observed from the -145 and -560 SRC DPCAT reporters in HT29 
cells (Fig. 4.13 C).  This contrasts previous studies, which have determined that the  
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Figure 4.12.  Activities of SRC DPCAT constructs relative to isolated
SRC promoter-CAT constructs in HCCLs.  The indicated reporter
constructs were transiently transfected in HT29 (A), SW480 (B), or HCT-
116 (C) cell lines.  SRC1α refers to the -145 SRC1α-CAT construct.
Activity of the 0.54 SRC1A-CAT reporter was arbitrarily chosen to
represent 100%.  Bar graphs represent the mean +/- the standard deviation
from three separate experiments, each performed in duplicate.   
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Figure 4.13.  Determination of SRC DPCAT promoter use in
HCCLs.  (A) S1 analysis, using an S1 probe complementary to 1α c-
Src transcripts, was employed to assess endogenous SRC promoter use
in HCT-116 and SW480 cells.  An S1 probe complementary to 1α-
CAT transcripts was also used in S1 protection assays to determine
promoter usage from the SRC DPCAT construct following transient
transfections in HCT-116 and SW480 (B) and HT29 (C) cells.  
overexpression of c-Src in these cells results from near equal usage of both SRC 
promoters.  Interestingly, in HT29 cells, the activity of these SRC DPCAT constructs 
was much higher than the activity of either promoter in isolation, suggesting differential 
regulation of this construct in HT29 cells than SW480 or HCT-116 (Fig. 4.12 A).  Taken 
together, this investigation has shown the SRC1α promoter displays very weak activity 
compared with the SRC1A promoter when assayed in isolation.  Even in the context of 
the SRC DPCAT reporter, the SRC1A promoter was observed to be much stronger than 
the SRC1α promoter, in all cell lines studied.  Therefore, there was consistent 
discrepancy between SRC promoter use in SRC DPCAT constructs, and promoter use 
seen endogenously in any given cell line.  As a result of these observations, the 
conclusion was made that some element, not present in the SRC DPCAT constructs, was 
responsible for increasing SRC1α activity in HepG2 cells as well as HCCLs.  Strong 
evidence was therefore provided for the hypothesis that an enhancer element existed and 
was responsible for elevating SRC1α promoter use relative to SRC1A in human cancer 
cells.  Identification of this putative enhancer element became of immediate interest, 
because its activity could explain the SRC transcriptional activation observed in human 
cancer cells.  
 
4.2.4.2.  Search for Nuclease Hypersensitive Sites in the SRC Locus 
 There are many examples of genes that require liver- or intestine-specific enhancer 
elements to achieve specific and full activation in these tissues (Bisaha et al., 1995; 
Shachter et al., 1993; Shelley and Baralle, 1987; Vergnes et al., 1997).  Such elements, 
therefore, could also exist within the SRC locus.  As shown in Fig. 4.14 A, the SRC  
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Figure 4.14.  SRC enhancer search in human cancer cells.  (A) Schematic of the
human SRC gene on chromosome 20q12.  The neighboring MANBAL gene,
predicted by gene search algorithms (NCBI) to exist upstream of Exon 1α, is shown.
(B) Nuclei from HT29, SW480, or HepG2 cell lines were digested with increasing
concentrations of DNase I.  Genomic DNA was subsequently purified and subjected
to digestion with EcoR V.  Southern blot analysis was employed, and DH sites were
detected with a labeled DNA probe specifically targeted to the 3' end of an EcoR V
fragment immediately upstream from the SRC promoters.  (C) Nuclei were prepared
and genomic DNA was digested as in (B), and DH sites were detected with a labeled
probe specifically targeted to the 5' end of an EcoR V fragment encompassing Exon
1B.  DH sites are identified by black arrows.  Maps of the relative locations of the
EcoR V fragments detected in this experiment are shown at the bottom of each
figure.    
locus is quite large, with 20 kb introns separating the 5' non-coding exons (Bonham and 
Fujita, 1993).  In addition, 20 kb of non-coding genomic DNA is contained upstream of 
Exon 1α and downstream of the hypothetical MANBAL gene (Lander et al., 2001 and 
references therein).  As a result of these observations, the enhancer proposed to elevate 
SRC1α activity in human cancer cells was hypothesized to exist within this 60 kb region 
of genomic DNA, which spanned 20 kb upstream of Exon 1α to Exon 1C (Fig. 4.14 A).  
Although the putative SRC enhancer could also exist outside this relatively small search 
area, this 60 kb region at the 5' end of the SRC gene was selected as the primary focus.  
A strategy of searching for DNaseI hypersensitive (DH) sites was therefore developed to 
identify putative enhancer elements within this search area.  DH sites often represent 
functional regions of genomic DNA, and identification of these regions has allowed for 
the isolation of enhancer elements within other genes (Bisaha et al., 1995; Grandien et 
al., 1993; Pullner et al., 1996; Shachter et al., 1993; Vaulont et al., 1989).  Combinations 
of overlapping restriction fragments encompassing the entire 60 kb region were assessed 
for their DH site composition in HepG2, HT29, SW480, and HepG2 cells.  The typical 
DH patterns observed within these restriction fragments are illustrated in Fig 4.14.  For 
example, a 3.4 kb EcoR V restriction fragment upstream of the SRC promoter region did 
not display any obvious DH sites in any of the cell lines examined when detected with a 
probe targeted to its 3' terminus (Fig. 4.14 B).  Conversely, when a larger 20 kb 
fragment located downstream of the SRC promoters was assessed, many weak DH sites 
were observed in HT29 and SW480 cells (Fig. 4.14 C).  This approach, which resulted 
in the generation of dozens of Southern blots, did not reveal any obvious, strong DH 
sites in HT29, SW480, or HCT-116 cells that might represent candidate enhancer 
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elements.   However, a single intense DNaseI hypersensitive site, specific to HepG2 
cells was discovered using this approach, and was denoted DH3 (Fig. 4.15).  This site 
was contained within an EcoR V fragment, immediately upstream of Exon 1α, and 
mapped to a multitude of potential transcription factor binding motifs as determined by 
the TFSearch transcription factor binding site search algorithm.  Two common DH sites, 
termed DH1 and DH2, were also observed within this restriction fragment.  Additional 
restriction enzyme combinations were employed to more precisely map this interesting 
DH3 site, and confirmed its location between -4400 and -4000, relative to the 
transcription start site in the SRC1α promoter. 
 
4.2.4.3.  Cloning and Characterization of a Putative HepG2 Specific SRC Enhancer 
 Due to the marked discrepancy between endogenous SRC promoter use and 
promoter use observed from SRC DPCAT constructs in HepG2 cells, an immediate 
priority was to clone and characterize the genomic DNA fragment representing the DH3 
site.  It was hypothesized that this element could be an enhancer that was responsible for 
the preferential, strong SRC1α promoter usage seen in HepG2 cells.  The region 
encompassing this putative HepG2 specific enhancer element was contained within 
existing SRC genomic cosmid clones (Bonham and Fujita, 1993), allowing this element 
to be readily isolated.  Therefore, various reporter constructs harboring this putative 
enhancer were generated.  When analyzed in transient transfection experiments, this 
element displayed a very modest ability to increase the activity of the SRC1α promoter 
(Fig. 4.16 A).  For example, the presence of the fragment representing the HepG2 DH3 
site (-6882 SRC1α-CAT) increased the activity of a -2852 SRC1α-CAT reporter  
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Figure 4.15.  A HepG2 specific DH site.  Nuclei from HepG2, SW480,
HT29, or HCT-116 cell lines were digested with increasing
concentrations of DNaseI.  Genomic DNA was subsequently purified and
subjected to digestion with EcoR V.  Southern blot analysis was
employed, and DH sites were detected with a labeled DNA probe
specifically targeted to the 3' end of an EcoR V fragment immediately
upstream from the SRC promoters.  A map of the relative locations of the
DH sites in this experiment is shown at the bottom of the figure. 
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Figure 4.16.  Characterization of the putative HepG2 specific SRC enhancer.  (A)
The genomic fragment representing the HepG2 DH3 site was cloned upstream of the
promoter(s) in various SRC reporter constructs  shown at left.  Activities of these
constructs were subsequently determined in transient HepG2 transfections.  CAT
levels are shown relative to a viral promoter driven pCAT3 control vector.  Bar graphs
represent the mean +/- the standard deviation from three separate experiments, each
performed in duplicate. (B) RNA from HepG2 cells transfected with -560 SRC
DPCAT or -560 SRC DPCAT containing the putative enhancer was hybridized with
an S1 probe specifically targeted to 1α-CAT transcripts; probe:target duplexes were
subsequently digested with S1 nuclease and separated on sequencing gels. 
construct approximately 80 to 90%.  This fragment mediated a similar level of increased 
activity in a -145 SRC1α-CAT reporter.  When analyzed in the context of the -560 SRC 
DPCAT construct, a slight decrease in CAT levels was observed.  In order to 
specifically assess the effect of this genomic DNA fragment on SRC1α promoter 
activity in the -560 SRC DPCAT reporter, S1 protection analysis was employed.  In the 
construct harboring the HepG2 DH3 site, a slightly higher signal for SRC1α promoter 
use was observed relative to SRC1A promoter use compared with -560 SRC DPCAT 
alone (Fig. 4.16 B, compare lanes 4 and 5).  However, SRC1A was still the predominant 
promoter used to drive CAT expression from this construct.  In conclusion, these 
observations suggested the HepG2 DH3 site contained detectable, yet very weak 
activating potential towards the SRC1α promoter in HepG2 cells. 
 
4.2.5.  Differential Activity of the SRC DPCAT Reporter in HT29 Cells 
4.2.5.1.  SRC DPCAT Activity and Promoter Use in HCCLs 
 An interesting observation noted during SRC DPCAT transfection experiments in 
various human cancer cell lines was that the SRC DPCAT constructs displayed a much 
higher activity than either SRC promoter in isolation in HT29 cells (Fig. 4.12 A).  This 
finding contrasted the observation that the activity of SRC DPCAT constructs was 
comparable to the isolated SRC promoters in all other cell lines examined (Figs. 4.9 A, 
4.12 B and C).  Therefore, the combined activities of the individual SRC promoters 
could not account for the activity observed from the SRC DPCAT constructs in HT29 
cells.  Previous S1 protection assays demonstrated that SRC1A is the predominant 
promoter used from the SRC DPCAT constructs in these cell lines (Fig. 4.13 C).  These 
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findings suggested the SRC1A promoter in these reporter constructs was somehow 
activated, exclusively in HT29 cells.  
 
4.2.5.2.  The SRC1α HNF Site Activates the SRC1A Promoter in HT29 Cells 
 To address the mechanism of SRC1A promoter activation in the SRC DPCAT 
construct in HT29 cells, various deletion and mutant DPCAT constructs were generated 
(Fig. 4.17 A) and their activities assessed following transient transfections in SW480, 
HCT-116, and HT29 cells (Fig. 4.17 B-D).  Deletion of the SRC1A promoter from the -
560 DPCAT reporter severely impaired CAT expression in all three cell lines.  These 
findings corroborated the results from S1 protection assays (Fig. 4.13), which 
demonstrated the SRC1A promoter was primarily responsible for generating the CAT 
levels observed from the SRC DPCAT in HCCLs.  The remaining activity in this ∆1A 
DPCAT construct was very similar to -145 SRC1α-CAT, confirming weak residual 
activity of the SRC1α promoter was responsible for the low CAT expression levels 
detected.  Surprisingly, deletion of the SRC1α promoter from the -560 SRC DPCAT 
construct also severely impaired SRC DPCAT activity in HT29 cells (Fig. 4.17 D).  This 
deletion reduced SRC DPCAT activity to identical levels observed from the 0.54 
SRC1A-CAT construct.  This same deletion, however, did not have any detectable effect 
on CAT expression levels in SW480 or HCT-116 cells (Fig. 4.17 B,C).  In these cell 
lines, rather, this ∆1α DPCAT construct displayed an activity very similar to 0.54 
SRC1A-CAT, verifying S1 protection findings that the SRC1α promoter contributed 
little to the overall CAT levels generated from SRC DPCAT constructs in these cell 
lines.  Most significantly, however, these findings implicated that an element within the  
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Figure 4.17.  Activity of deletion and point mutant SRC DPCAT
constructs.  (A) Schematics of the constructs utilized in this study.  Various
DPCAT reporters and mutants derived from -560 DPCAT were transiently
transfected in SW480 (B), HCT-116 (C), and HT29 (D) cells.  Activities of the
0.54 SRC1A-CAT and -145 SRC1α-CAT constructs are included; all CAT
levels are shown relative to 0.54 SRC1A-CAT, which was arbitrarily chosen as
100%.  Bar graphs represent the mean +/- the standard deviation from two to
three separate experiments, each performed in duplicate.   
deleted SRC1α fragment was activating the SRC1A promoter in the SRC DPCAT 
constructs, specifically in HT29 cells.   A hypothesis was subsequently developed that 
the SrcHNF binding site in the SRC1α promoter could be responsible for the observed 
SRC1A specific activation in HT29 cells.  Therefore, a -560 DPCAT variant harboring 
point mutations in the SRC1α HNF binding site was generated, and its activity 
determined in HT29 and SW480 cells (Fig 4.17 B, D).  Previous studies have 
demonstrated such a mutation has a drastic effect  
on SRC1α promoter activity as well as HNF-1α binding in HepG2 cells (Bonham et al., 
2000).  In this study, mutation of the SrcHNF site in the -560 DPCAT construct had a 
nearly identical effect as deletion of the entire SRC1α promoter in HT29 cells, reducing 
activity approximately 5-fold.  In SW480 cells, conversely, the SrcHNF mutation 
reduced -560 DPCAT activity by only 25%.  These results clearly demonstrate the 
SrcHNF site in the SRC DPCAT construct increases the activity of the SRC1A 
promoter, only in HT29 cells. 
 
4.2.5.3.  HNF-1 Represses SRC DPCAT Activity in HCCLs 
 The results from these studies strongly suggested that HNF-1α, through binding 
the SrcHNF site in the SRC1α promoter, was activating the SRC1A promoter in HT29 
cells.  It was therefore investigated whether co-expression of HNF-1α could further 
elevate SRC1A activity in the -560 SRC DPCAT reporter in these cell lines (Fig. 4.18).  
Surprisingly, however, exactly the opposite result was observed; HNF-1α or HNF-1β 
co-expression effectively inhibited activity of the -560 SRC DPCAT construct in HT29 
cells (Fig. 4.18 A).  A -560 SRC DPCAT construct harboring mutations in the SrcHNF  
 134 
 135 
Figure 4.18.  Effect of HNF-1α expression on activities of SRC
promoter constructs in HT29 cells.  (A) The -560 DPCAT reporter
was co-transfected with increasing amounts of HNF-1α or HNF-1β
expression vector. (B) The HNFmut DPCAT reporter was transfected
as in (A).  (C) The ∆1α DPCAT or 0.54 SRC1A-CAT reporters were
co-transfected with the highest amount of HNF-1α from (A).  (D) The -
145 SRC1α-CAT reporter was co-transfected with the highest amount
of HNF-1α from (A).  Bar graphs represent the mean +/- the standard
deviation from three separate experiments, each performed in duplicate. 
 
binding site was also significantly repressed by both HNF-1α and HNF-1β co-
expression (Fig. 4.18 B).  Interestingly, this effect appeared to be due to direct inhibition 
of SRC1A, because this promoter in isolation was also significantly repressed by HNF-
1α expression (Fig. 4.18 C).  Most significantly, however, and contrary to previous 
observations (Bonham et al., 2000), HNF-1α was not able to transactivate the SRC1α 
promoter in HT29 cells (Fig. 4.18 D).  To corroborate these observations, transfection 
experiments were repeated in SW480 cells (Fig. 4.19).  A very similar effect of HNF-1α 
or HNF-1β co-expression on SRC DPCAT (Fig. 4.19 A), HNFmut DPCAT (Fig. 4.19 
B), or SRC1A-CAT (Fig. 4.19 C) was observed in these cells compared with HT29.  
However, as has previously been reported (Bonham et al., 2000), and in contrast to 
HT29 cells in this thesis study, HNF-1α co-expression was able to effectively activate 
the SRC1α promoter approximately 6-fold in SW480 cells (Fig. 4.19 D).  Therefore, 
HNF-1α appeared to be the factor responsible for SRC1α activity in SW480 cells.  
However, these results also suggested a factor other than HNF-1α was responsible for 
activating SRC1α transcription and increasing SRC1A activity in HT29 cells. 
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Figure 4.19.  Effect of HNF-1α expression on activities of SRC
promoter constructs in SW480 cells.  (A) The -560 DPCAT
reporter was co-transfected with increasing amounts of HNF-1α
or HNF-1β expression vector. (B) The HNFmut DPCAT reporter
was co-transfected with the highest amount of HNF-1α from (A).
(C) The ∆1α DPCAT or 0.54 SRC1A-CAT reporters were co-
transfected with the highest amount of HNF-1α from (A).  (D)
The -145 SRC1α-CAT reporter was co-transfected with the
highest amount of HNF-1α from (A).  Bar graphs represent the
mean +/- the standard deviation from two separate experiments,
each performed in duplicate. 
4.2.6.  DISCUSSION 
4.2.6.1.  Evidence for a SRC Enhancer in Human Cancer Cells 
 This study detailed the construction of a SRC dual promoter reporter vector that 
was intended to alleviate the problematic finding that the relative strengths of the SRC 
promoters in isolation did not match the relative usage of these promoters seen 
endogenously.  Specifically, the SRC1α promoter was consistently much weaker in 
isolation than the SRC1A promoter as assessed by transient HepG2, HT29, SW480, and 
HCT-116 transfections.  However, when SRC DPCAT transfections were performed in 
these same cell lines, it was determined that promoter use was still consistently biased 
for SRC1A activity, despite the SRC promoters being assayed in their natural, 
physiologically linked context.  These findings strongly suggested an enhancer was 
responsible for SRC1α specific up-regulation in various cancer cell lines.  Because of 
these observations, a strategy of searching for DH sites in the SRC locus was developed, 
and led to the identification of a strong, HepG2 specific DH site situated approximately 
4 kb upstream of Exon 1α.  This approach, however, was unsuccessful in identifying 
any DH sites specific to HT29 or other colon cancer cells.  Numerous weak, apparently 
ubiquitous, DH sites were observed in all the cell lines studied, but none presented with 
the strength and restricted nature of the HepG2 DH3 site. 
 When the HepG2 DH3 element was cloned, it displayed a very weak ability to 
activate the SRC1α promoter, both in isolation, and in the context of the SRC DPCAT 
reporter.  These results suggested that this element at -4000 to -4400 was not responsible 
for the full SRC transcriptional activation from the SRC1α promoter in HepG2 cells.  
However, the activity of this putative enhancer element was assessed in transient HepG2 
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transfection experiments, where the reporter plasmid remained episomal.  Therefore, any 
significant activity of this element that relies upon eliciting changes in chromatin 
structure would not be observed using this approach.  The best example of this type of 
enhancer action is the locus control region (LCR), which was first described for the 
human β-globin gene cluster (Grosveld et al., 1987).  Other genes have also been 
identified that contain LCRs, but the β-globin LCR has been the best characterized, 
primarily due to its compact, linked nature.  LCRs are defined as elements that often 
map to DH sites, and enhance the expression of linked genes to physiological levels in a 
tissue specific and copy number dependent manner following integration into chromatin 
(Li et al., 2002).  Numerous arrays of binding sites for ubiquitous and tissue restricted 
transcription factors are located within these LCRs.  The fact that levels of reporter gene 
expression are copy number dependent when linked to LCR elements in stable 
transfection experiments supports the view that LCR activity creates open chromatin 
(Forrester et al., 1990).  Additional investigation of the properties of the SRC DH3 site 
in the context of stably integrated reporter constructs is therefore necessary to fully 
exclude this DH site as a functional enhancer, and potential LCR in HepG2 cells. 
 In addition to the DH3 site mapped 4 kb upstream of Exon 1α, numerous 
ubiquitous, weak DH sites were observed throughout the SRC locus in HepG2 cells.  It 
is very likely that one or many of these sites could be required, perhaps in conjunction 
with DH3, for strong SRC1α activity in transient or stable HepG2 transfection 
experiments.  This possibility is supported by studies of the human apoA-
I/apoCIII/apoA-IV gene cluster, which have identified a myriad of discrete, highly 
dispersed elements within the locus that play a combined role in directing the tissue 
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specificity and overall levels of expression of the apolipoprotein family members 
(Zannis et al., 2001).  However, it is also quite likely that the putative element(s) 
responsible for elevating SRC1α activity in HepG2 cells, as well as HCCLs, reside 
outside of the narrow search area focused on in this study.  For example, DH site 
composition was not assessed within or downstream from the SRC coding region in this 
study.  Therefore, it will be important for future studies to expand the search for putative 
enhancer elements by assessing DH site composition outside of the 60 kb search area 
encompassing the SRC promoter region. 
 
4.2.6.2.  Binding of Factors to the SrcHNF site in the SRC1α Promoter 
 An interesting, but very unexpected finding arising from DPCAT transfection 
experiments in HCCLs was that the SrcHNF site activates the SRC1A promoter, 
exclusively in HT29 cells.  Even more striking was the observation that HNF-1α binding 
to this site did not appear responsible for this phenomenon.  Rather, HNF-1 co-
expression inhibited the activity of the SRC DPCAT reporter.  This repression appeared 
to be due to a non-specific squelching phenomenon, because a -560 DPCAT construct 
with a mutant SrcHNF site, and the SRC1A promoter in isolation, were also 
significantly inhibited by HNF-1 expression.  Squelching is a term used to describe the 
paradoxical repression of an episomal reporter gene by a strong transactivator (Natesan 
et al., 1997).  It is believed to result from titration of limiting, essential general 
transcription factors or co-activators away from the template being analyzed.  Therefore, 
it is likely the repression observed in these experiments was the result of HNF-1 
sequestering factors essential for full SRC1A activity. 
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 A previous report has determined that the SrcHNF site is absolutely essential for 
SRC1α promoter activity in HepG2 cells.  For example, mutation of this site nearly 
abolishes all SRC1α activity in this cell line (Bonham et al., 2000).  Further analysis 
with HepG2 nuclear extracts demonstrated the primary factor that interacts with this site 
is HNF-1α (Bonham et al., 2000).  Also, co-transfection experiments in HT29 cells 
showed that HNF-1α, but not HNF-1β, is able to transactivate the SRC1α promoter 
(Bonham et al., 2000).  Consistent with these observations, experiments described in this 
thesis showed that HNF-1α was able to transactivate an isolated SRC1α promoter 
construct in SW480 transfections.  However, in contrast to previous observations, 
studies in this thesis demonstrated that HNF-1α was not capable of SRC1α 
transactivation in HT29 cells.  The best explanation for this lack of HNF-1α mediated 
SRC1α transactivation in HT29 cells is that another factor binds to and activates the 
SrcHNF site.  This possibility led to a re-evaluation of data in Dr. Bonham's laboratory, 
which do indeed hint at this possibility that another factor exists, and can compete with 
HNF-1α for binding to the SrcHNF site.  For example, in EMSA experiments with 
HepG2 nuclear extracts and a [32P]-labeled probe representing the SrcHNF site, the 
major complex observed contained HNF-1α (Bonham et al., 2000).  Significantly, 
however, competition experiments employing an unlabeled competitor representing a 
consensus HNF binding site disrupted this HNF-1α binding, but also enriched for 
binding of a smaller, unknown factor to the SrcHNF probe (Bonham et al., 2000).  This 
observation is even more evident in a similar HepG2 EMSA experiment previously 
performed by Dr. Bonham, which utilized even higher levels of competitor 
oligonucleotides (Fig. 4.20).  In this experiment, competitors representing the SrcHNF  
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Figure 4.20.  An unknown factor binds the SrcHNF site.  (A) Origin
of the probe used for these EMSA experiments.  (B) Competitor
oligonucleotides.  (C) HepG2 nuclear extracts were incubated with a
labeled SRC1α promoter restriction fragment.  When present,
competitor oligonucleotides were added at a 5 or 50 fold molar excess.
The major complex, previously identified as containing HNF-1α, is
shown.  A unknown factor that binds the probe is denoted by a question
mark. 
or a consensus HNF site, but not a mutant HNF site, were able to effectively block the 
binding of HNF-1α to a labeled SRC1α promoter restriction fragment.  However, with a 
50 M excess of consensus HNF competitor oligonucleotide present, enrichment for 
binding of a smaller, unknown factor to the labeled SRC1α probe was very evident (Fig. 
4.20, Lane 6).  These results therefore suggest that the major factor binding the SrcHNF 
site in HepG2 cells is HNF-1α, but another factor also exists in these cells that is able to 
compete with HNF-1α for SrcHNF binding.  This factor likely binds the SrcHNF site in 
HCCLs also, because HCT-116 cells don't express detectable levels of HNF-1α (Fig. 
4.7), yet still display SRC1α activity endogenously (Fig. 4.13) as well as following 
transient transfections (Figs. 4.12 and 4.17).  If a similar factor that competes for 
SrcHNF binding exists in HT29 cells, and is the main factor that interacts with this 
binding site, then this would strongly implicate it in SRC1α transactivation.  
Unfortunately, the findings shown here represent the very last sets of experiments 
performed for this thesis study.  Therefore, adequate experimental pursuit of this very 
interesting factor could not be carried out.  However, the current hypothesis is that 
preferential binding of this factor to the SrcHNF site is responsible for SRC1α activity 
in isolation, as well as the high SRC1A activity seen in HT29 cells following SRC 
DPCAT transfection experiments.  Therefore, identification and characterization of this 
factor will be very important in order to understand the mechanism of communication 
between the SrcHNF site in the SRC1α promoter and the SRC1A promoter. 
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4.2.6.3.  Significance of SrcHNF mediated SRC1A Activation 
 Initial experiments with the SRC DPCAT constructs in various cancer cell lines led 
to the conclusion that one or more enhancer elements were needed to elevate SRC1α 
activity in the context of these reporters.  It was also hypothesized that this element(s) 
could be responsible for the SRC transcriptional activation observed in HT29 and 
HepG2 cells.  Therefore, it could be argued that the observation of SrcHNF mediated 
SRC1A activation within the SRC DPCAT reporters in HT29 cells is irrelevant, because 
the putative element(s) necessary for full SRC1α activity was absent from these 
constructs.  However, S1 nuclease protection assays previously performed with T47D 
breast cancer cells showed this cell line to express high levels of c-Src mRNA, nearly 
exclusively from the SRC1A promoter (Bonham et al., 2000).  Therefore, the possibility 
can be raised that the SrcHNF site could play a role in the elevated SRC1A activity seen 
in these breast cancer cells.  This theory could be addressed by repeating the 
experiments detailed in this study in the T47D breast cancer cell line. 
 Perhaps the best illustration of the potential relevance of SrcHNF mediated 
SRC1A activation comes from comparison of the SRC promoter regions in humans and 
mice.  The SRC1A promoter, and its associated exon, Exon 1A, are highly conserved 
between these two species, with an interesting finding being that the TC tracts are 
shorter in mouse than human (Fig. 4.21). Similarly, the regions surrounding human 
Exon 1α are highly conserved between human and mouse, with a near identical match 
for the SrcHNF site.  However, sequences representing Exon 1α are not apparent in the 
mouse SRC locus.  In addition, no potential splice recognition junctions downstream 
from the SrcHNF are identifiable.  These findings therefore suggest a fundamental  
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Figure 4.21.  Sequence comparison of the human and mouse SRC promoter loci.
Functional elements in the human SRC1α and SRC1A promoters are highlighted in
grey and labeled.  Stars below the aligned sequences denote perfect homology.
Numbering at right refers to mouse genomic sequence.  Alignments were generated
using the ClustalW DNA sequence alignment algorithm. 
 
difference between mouse and human SRC transcriptional regulation is that the human 
genome harbors Exon 1α while the mouse genome does not.  These conclusions are 
supported by observations that 5' RACE experiments with mouse tissues have identified 
c-Src mRNA transcripts that contain Exon 1A equivalents, but no Exon 1α equivalents 
(K. Bonham, personal communication).  Interestingly, however, not only is the SrcHNF 
site highly conserved between mouse and human, its location relative to the SRC1A 
promoter is also very similar.  The possibility arises then that this putative murine 
SrcHNF site acts as an activator element for the SRC1A promoter, very much like what 
was observed with SRC DPCAT transfections in HT29 cells.  Various experiments are 
necessary to determine whether this site binds HNF-1α and/or other factor(s) in mice, 
and what functional role this binding could play in mouse SRC1A transcription. 
 
4.2.6.4.  Models of Differential Promoter Use and Transcriptional Activation 
 The studies outlined in this chapter were unsuccessful in identifying enhancer 
elements responsible for elevating SRC1α activity, and potentially activating SRC 
transcription in HepG2 and HT29 cells.  In all cell lines studied, CAT expression from 
the SRC DPCAT reporter originated from the SRC1A promoter.  However, S1 analysis 
determined that HepG2 cells display strong, preferential SRC1α usage, and HT29 cells 
display strong SRC1α and SRC1A usage endogenously (Bonham et al., 2000).  The 
signals for c-Src mRNA transcripts containing Exon 1α and Exon 1A were very weak in 
SW480 cells, but previous experiments agree with the findings from this thesis study 
that both promoters are utilized very weakly, but nearly equally, in these cells (Bonham 
et al., 2000).  Therefore, it is important that testable models of enhancer action be 
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designed that can account for all of these observations.   Indeed, models for activity of 
these putative enhancer elements can be derived from the findings presented in this 
chapter.  For example, it is possible that separate HepG2 and HCCL enhancers exist, due 
to the observation of very different patterns of SRC promoter use seen between these 
different cell lines.  Precedent has been made for this possibility by studies of tissue 
restricted expression patterns of the apolipoprotein gene cluster.  For example, in the 
case of the apoA-I gene, transgenic approaches led to the identification of two enhancers 
responsible for liver or intestine specific expression.  The region for liver restricted 
expression was located directly upstream of the transcription start site (Shachter et al., 
1993), whereas the region for intestine restricted expression was localized to 9 kb 
upstream of the apoA-I transcription start site, within the apoC-III gene promoter 
(Bisaha et al., 1995). 
 Based on the studies presented, a HepG2 specific enhancer element would be 
hypothesized to exclusively and strongly activate the SRC1α promoter.  As discussed in 
previous sections, the DH3 element identified in HepG2 cells could account in part or in 
whole for this enhancer activity.  The model proposed for HepG2 specific SRC enhancer 
activity involves multiple ubiquitous and liver specific trans-acting factors binding to 
their cognate cis-acting elements, which in turn are able to communicate directly or 
indirectly with HNF-1α and/or the transcriptional apparatus at the SRC1α promoter 
(Fig. 4.22 A).  HNF-1α has previously been characterized as a transcription factor with 
very weak transactivation potential; rather, this factor serves as a nucleation point for 
recruitment of various co-activator molecules that synergistically enhance 
transactivation (Soutoglou et al., 2000).  Therefore, this model predicts a multi-protein  
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Figure 4.22.  Models for differential SRC promoter use and transcriptional
activity in human cancer cells.  (A)  DNA elements that bind tissue specific and
ubiquitous transcription factors synergize with HNF-1α and co-activator molecules
to elicit very strong SRC1α promoter use in HepG2 cells.  (B) DNA elements that
bind tissue specific and ubiquitous transcription factors cooperate with HNF-1α and
co-activator molecules to elicit increased SRC1α promoter use in SW480 cells.  (C)
When a factor other than HNF-1 is bound to the SrcHNF site in HT29 cells, the
HCCL specific enhancer complex is much stronger, and mediates very strong
activation of both the SRC1α and SRC1A promoters.  These models depict DNA
elements as existing upstream of the SRC promoters, but they could exist anywhere
within the SRC locus.  Thickness of the bent arrows represents relative levels of
transcriptional activity arising from either SRC promoter.        
complex, consisting of DNA-protein and protein-protein interactions, would exist 
between the SRC1α promoter and the putative enhancer element(s) that would allow for 
very strong transcriptional activity from the SRC1α promoter.  SRC1A promoter 
activity would be expected to remain at the same levels observed in SRC1A-CAT 
constructs or in the context of the SRC DPCAT reporters.  The end result of enhancer 
presence in the SRC DPCAT reporter would be the elevation of SRC1α activity to the 
same level seen endogenously, relative to the SRC1A promoter. 
 The interplay between factors that bind the SrcHNF site and a putative HCCL 
specific enhancer form the basis of models explaining differential SRC transcriptional 
activity and equal use of both promoters in HCCLs.  In all HCCLs, regardless of their 
relative SRC transcription levels, activity of this putative enhancer would elevate the 
activity of the SRC1α promoter.  For example, in SW480 cells, this HCCL specific 
enhancer element could bind various tissue specific and ubiquitous transcription factors.  
Because HNF-1α is the major factor interacting with the SRC1α promoter HNF site in 
these cells, factors binding the HCCL specific enhancer would interact with HNF-1α.  
This would result in the generation of a weak, SRC1α specific enhancer complex that 
boosts SRC1α activity to the same levels seen from the SRC1A promoter in isolation or 
in the context of SRC DPCAT reporters in SW480 cells (Fig. 4.22 B).  Conversely, this 
study has raised the possibility that a novel factor can also bind to the SrcHNF site.  This 
factor, therefore, is hypothesized to be responsible in part for the activation of the 
SRC1A promoter seen in SRC DPCAT reporter constructs in HT29 cells.  This model 
suggests that communication between the SrcHNF site and the SRC1A promoter takes 
place through GC1 and/or GA2, the two Sp-family binding sites in the SRC1A 
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promoter.  However, the mechanism of this communication requires experimental 
investigation.  Interaction between factors that bind to the putative HCCL specific 
enhancer and a novel SrcHNF-bound factor would result in the generation of a very 
strong enhancer complex (Fig. 4.22 C).  Therefore, these models suggest the strength of 
the HCCL specific enhancer is mediated by whether HNF-1α or other factors are bound 
to the SrcHNF site.  Because the SrcHNF site is "wired" to the SRC1A promoter in 
HT29 cells, the strong activity of this enhancer would be distributed over both the 
SRC1α and SRC1A promoters, resulting in the high SRC transcriptional activity 
observed endogenously.  Identification of the proposed HepG2 and/or HCCL specific 
enhancers will be a key step in testing these models and understanding the mechanisms 
of SRC transcriptional activation in these human cancer cell lines.   
 
4.2.6.5.  Significance of Dual SRC Promoters and Differentially Spliced Exons 
 The presence of two SRC promoters does not appear to be conserved, and might 
represent an important difference in the regulation of SRC transcription between humans 
and other species.  Therefore, this implies that two SRC promoters could uniquely exist 
in humans to allow for increased diversity of c-Src expression in different tissues and/or 
developmental stages.  This is highlighted by the observation that while c-Src expression 
appears to be ubiquitous in nearly all normal human tissues, c-Src transcripts containing 
Exon 1α are more restricted to tissues such as stomach, kidney, pancreas, and fetal lung 
(Bonham et al., 2000).  Lower levels of SRC1α-derived transcripts are seen in colon, 
liver, prostate, fetal kidney, and fetal liver (Bonham et al., 2000).  These findings 
therefore suggest the fairly ubiquitous expression of c- Src in normal tissues is due to 
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transcription from the SRC1A promoter, since it is regulated by the ubiquitous Sp-
family of transcription factors (Philipsen and Suske, 1999), and has a typical make-up of 
the housekeeping class of promoters (Bonham and Fujita, 1993).  SRC transcriptional 
up-regulation in specific tissues during differentiation, development, or transformation, 
however, is likely due to increased usage of the SRC1α or even both the SRC1α and 
SRC1A promoters.  This could arise through activation of enhancer elements, or 
promoter cross-talk mediated by differential binding of factors to the SrcHNF site.  
These possibilities highlight the importance of future experiments designed to identify 
and characterize enhancer elements and SrcHNF binding factors in various cell types. 
 Differential SRC promoter use also results in two c-Src mRNA species that differ 
in their extreme 5' non-coding terminus.  These two different transcripts, however, are 
identical in their protein coding capacity.  Therefore, the possibility exists for further 
diversity in regulation of human c-Src expression by differential stability or translation 
potential of these two transcripts.  Studies detailed in section 4.1.4 examined c-Src 
mRNA half-life in HCCLs, and suggested differential c-Src mRNA stability in these 
cells was not the case.  However, there is a strong possibility that the two c-Src mRNA 
species differ in their translation efficiency.  For example, Exon 1α harbors an ATG 
codon, whereas Exon 1A does not (Bonham and Fujita, 1993; Bonham et al., 2000).  
Therefore, there is potential for premature engagement of ribosomes at this ATG codon 
during translation initiation.  This phenomenon is common for oncogenes and growth 
factors, which, like c-Src transcripts, contain relatively long 5' non-coding regions with 
potential open-reading frames (Willis, 1999).  Also, models have been developed that 
propose the affinity of ribosomal RNA for different mRNAs could also play a role in 
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regulating translational initiation (Mauro and Edelman, 2002).  Clearly, however, these 
theories must be addressed experimentally before any definitive conclusions can be 
made regarding differential translation efficiency between 1A or 1α containing c-Src 
mRNAs. 
 
4.2.6.6.  Scope and Significance 
 This line of investigation described a novel dual promoter reporter system to study 
the SRC1α and SRC1A promoters in their natural, physiologically linked context in 
human cancer cell lines.  Various experiments with this dual promoter reporter strongly 
suggested that SRC transcriptional activation in human cancer cell lines results from 
activation of an enhancer element(s).  In addition, these studies identified that the 
SRC1α and SRC1A promoters are able to communicate in HT29 cells, potentially 
through a novel factor that binds the SrcHNF site in the SRC1α promoter.  Identification 
of putative enhancer elements, in addition to purifying factors that interact with the 
SrcHNF site in HT29 nuclear extracts will form the basis for future detailed 
understanding of the mechanisms of SRC transcriptional activation in colon and other 
cancer cell lines.  This knowledge could lead to the development of therapeutic 
compounds targeting specific processes that regulate SRC transcription in human cancer.  
Such strategies would be an important addition to the large arsenal of compounds that 
have already been developed to target various functions of the c-Src protein (Sawyer et 
al., 2001). 
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4.3.  REPRESSION OF SRC TRANSCRIPTION BY HISTONE DEACETYLASE INHIBITORS 
4.3.1.  HDIs Directly Repress SRC Transcription 
 The previous section detailed findings that suggested an enhancer(s) mediates SRC 
transcriptional activation in colon and liver cancer cell lines.  However, the possibility 
that both SRC promoters were actively repressed in cell lines such as SW480 and 
SW620 cells was also examined concurrently.  The observation that these cell lines 
expressed very low levels of c-Src mRNA despite expressing levels of HNF-1α, Sp1, 
and Sp3 similar to HepG2 and HT29 cells strengthened this theory (see Section 4.2.2).  
The two most well studied mechanisms responsible for such repression are direct 
hypermethylation of CpG residues, or hypoacetylation of core histones at promoters.  
These modifications are generally believed to cooperate and elicit a silent, closed 
chromatin conformation (Richards and Elgin, 2002).  Promoters that are contained 
within CpG islands, such as SRC1A, are especially susceptible to these forms of 
epigenetic regulation (Antequera et al., 1990; Esteller, 2002).  To address the possibility 
of promoter hypermethylation, SW480 and SW620 cells were treated with the drug 5'-
azacytidine, a methylation inhibitor.  Following drug treatment, an increase in c-Src 
mRNA expression was not observed, suggesting promoter CpG hypermethylation was 
not responsible for the low levels of c-Src expression observed in SW480 or SW620 
cells (data not shown).  To address the possibility that histone hypoacetylation was 
responsible for closed, inactive chromatin at the SRC promoter, SW620 cells were 
treated with the drug Trichostatin A (TSA), a histone deacetylase (HDAC) inhibitor 
(HDI).  Surprisingly, a rapid decrease in c-Src mRNA expression was observed 
following treatment with TSA (Fig. 4.23).  Of particular relevance, HDIs have  
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Figure 4.23.  Effect of TSA on c-Src mRNA and protein expression in
human cancer cell lines.  (A) Total RNA was isolated from the indicated
cancer cell lines following varying periods of exposure to 1 µM TSA and
analyzed by Northern blot with a c-Src specific probe.  Equal RNA loading
is demonstrated by ethidium bromide stained gels.  Northern blots shown
are representative of several replicate experiments.  (B) Total cellular
proteins were isolated from SW480 or HT29 cells following various
periods of exposure to 1 µM TSA, and analyzed by Western blot for pp60c-
Src expression.  Much longer exposures to imaging screens were necessary
to obtain signals for c-Src expression in HCT-116, DLD-1, SW620, and
HCT-15 cells (2 days) compared with HepG2 and HT29 cells (5 hours). 
 
chemotherapeutic and chemopreventive action towards a wide range of human tumors 
and tumor derived cell lines (Suzuki et al., 2000; Vigushin et al., 2001).  Thus, the anti-
neoplastic properties of various HDIs are currently being investigated in clinical trials 
(Marks et al., 2001a).  Interestingly, a very similar degree of c-Src inhibition in SW620 
cells was observed following treatment with another HDI, the short chain fatty acid 
butyrate (Kostyniuk et al., 2002).  Butyrate is a natural component of the human large 
intestine, and is created by anaerobic bacterial fermentation of dietary fibre (Topping 
and Clifton, 2001).  This observation has prompted the theory that butyrate production 
could in part explain the preventative action of high-fibre diets towards colon tumors 
(Reddy, 1995; Trock et al., 1990).  Indeed, this idea has been supported by the 
demonstration that butyrate can protect from carcinogen-induced colon tumorigenesis in 
a rat model system (D'Argenio et al., 1996).  Significantly, and has been discussed in 
previous sections, c-Src has been strongly implicated in the development and 
progression of various human cancers, especially colon cancer.  These observations led 
to the hypothesis that the decrease in c-Src mRNA expression elicited by HDI treatment 
may explain in part these agents' anti-cancer activity.  A major interest therefore became 
elucidating the mechanism of c-Src repression by HDIs.    
 The effect of HDIs on c-Src expression was examined in various additional cancer 
cell lines (Fig. 4.23).  Regardless of whether cell lines displayed high levels of c-Src 
mRNA (HT29, HepG2), or low levels of c-Src mRNA (HCT-116, DLD-1, SW620, 
HCT-15), a rapid and effective decrease in c-Src expression was observed following 
treatment with 1 µM TSA (Fig. 4.23 A).  A concomitant decrease in c-Src protein 
expression was also observed following TSA treatment (Fig. 4.23 B).  The response to 
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TSA at the mRNA level was observed to be transient in most cell lines studied, and was 
attributed to a short cellular half-life of this agent.  Again, nearly identical results were 
observed when these same cell lines were treated with butyrate (Kostyniuk et al., 2002).  
By treating HT29 cells with a combination of cyclohexamide and butyrate, it was 
demonstrated that the decrease in c-Src mRNA expression was direct, and did not 
require new protein synthesis (Kostyniuk et al., 2002).  Therefore, HDIs directly 
inhibited c-Src mRNA and protein expression in various human cancer cell lines. 
 To determine if the repressive effect of HDIs on c-Src expression was at the level 
of transcription, the 0.38 SRC1A-CAT and -145 SRC1α-CAT reporter plasmids were 
assessed for their response to these agents in transient transfection experiments in 
HepG2 and SW480 cells (Fig. 4.24).  Following 24 hours of treatment with either 1 mM 
TSA or 5 mM butyrate, CAT levels from both promoter constructs were diminished 80 
to 90 % relative to untreated controls.  Therefore, TSA and butyrate were exerting a very 
similar level of repression on the transcriptional activity of either SRC promoter.  These 
results suggested that repression of the SRC promoters was primarily responsible for the 
decreased c-Src expression observed upon HDI treatment.  In large part, however, the 
mechanism of gene repression elicited by these agents has not been described. 
 
4.3.2.  Effect of HDIs on Factors bound to the SRC Promoters 
 One possibility that could explain SRC repression by HDIs could be that these 
agents inhibit binding of factors to the SRC promoters.  Therefore, to determine whether 
HDI treatment caused decreased binding of HNF-1α, Sp1, or Sp3 to their cognate cis-
acting DNA elements, EMSAs were performed using nuclear extracts from HepG2 cells  
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Figure 4.24.  Effect of HDIs on activities of the SRC promoters.
HepG2 (A) and SW480 (B) cells were transfected with SRC1α-CAT and
SRC1A-CAT reporter plasmids, and treated with 5 mM sodium butyrate
(NaB) or 1 µM TSA for 24 h.  CAT expression levels are shown relative to
untreated cells.  Bar graphs represent the mean +/- the standard deviation
from two separate experiments, each performed in duplicate. 
 
treated with TSA for various time points (Fig. 4.25).  Large promoter restriction 
fragments encompassing the SRC1α or SRC1A promoters were used as probes in these 
experiments (Fig. 4.25 A).  As shown in Fig. 4.25 B, when a Cla I/Hinc II fragment 
representing the SRC1α promoter was incubated with untreated or treated HepG2 
nuclear extracts, two major complexes were observed, which have been previously 
identified as containing HNF-1α (Bonham et al., 2000).  Treatment with TSA for up to 
12 hours did not result in an observable change in HNF-1α binding to the 
SRC1α promoter.  When SRC1A promoter fragments encompassing the GC1 and GA2 
Sp-family binding sites were utilized as EMSA probes, major species previously 
characterized as Sp1 or Sp3 complexes were observed (Fig. 4.25 B and C).  Similar to 
the results observed for the SRC1α promoter, there was no observable change in Sp1 or 
Sp3 binding to these SRC1A promoter fragments.  These results therefore demonstrated 
the repression of activities of the SRC promoters was not due to any obvious changes in 
binding of transcription factors to their respective cis-acting elements in vitro. 
 HDIs have been shown to effect changes in chromatin structure, which results 
from altered histone acetylation and deacetylation dynamics (Marks et al., 2000).  
Therefore, the effect of TSA treatment on the acetylation status of histone H3 at the SRC 
promoters was determined using a chromatin immunoprecipitation (ChIP) approach.  
Hyperacetylation of promoter bound histone H3 at lysines 9 and 14 is highly correlated 
with active transcription, due to a proposed role in aiding TFIID recruitment (Agalioti et 
al., 2002).  Therefore, any change or paradoxical decrease in the acetylation of histone 
H3 elicited by HDIs would be expected to influence SRC transcriptional activity.  An 
antibody specific for histone H3 acetylated at Lys 9 and Lys 14 was employed for  
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Figure 4.25.  Effect of HDIs on binding of factors to the SRC1α and
SRC1A promoters.  (A) Schematic of the origin of probes used for EMSA
analysis.  (B-D) Nuclear extractions were performed on HepG2 cells exposed
to 1 µM TSA for varying periods of time.  EMSA analysis was subsequently
performed by incubating these nuclear extracts with a probe spanning the
SRC1α promoter (B), or probes spanning the SRC1A promoter (C,D).
Complexes that have previously been identified as containing the
transcription factors Sp1, Sp3, and HNF-1α are labeled. 
 
immunoprecipitation of cross-linked protein-DNA complexes from treated and untreated 
HT29 (Fig. 4.26 A) and SW480 (Fig. 4.26 B) cells.  Following detection via PCR using 
primers specific for the SRC1α or SRC1A promoter, acetylated histone H3 was found to 
be associated with both promoters in untreated SW480 and HT29 cells.  In addition, 
there was no observable change in this pattern of acetylated H3 association in cells that 
had been treated with TSA for up to 6 hours.  Therefore, these results suggest HDIs were 
not affecting the acetylation pattern of histone H3 at either SRC promoter.  Combined 
with EMSA experiments, no change in the factors associated with either SRC promoter 
was observed following treatment with HDIs. 
 
4.3.3.  Search for Distinct 5' HDI Response Elements in the SRC Promoters  
 Previous studies with the WAF1 promoter have implicated Sp-family binding sites 
in transcriptional activation following HDI treatment (Huang et al., 2000; Nakano et al., 
1997).  Therefore, the role of the SRC1A GC1 and GA2 elements in HDI-mediated 
repression was assessed.  In most circumstances, assessing the roles of Sp1 and/or Sp3 
in mammalian transcription is difficult via co-transfection experiments due to the high 
endogenous levels of these transcription factors.  This potential pitfall prompted an 
alternative approach, using an engineered SRC1A promoter containing GAL4 
recognition sites, in co-transfection experiments with GAL4-Sp-family fusions.  An 
additional benefit of this approach is it allows for a separate analysis of the effect of Sp1 
or Sp3 on SRC1A transcription.  To this end, the GC1 and GA2 sites were replaced in a 
0.38 SRC1A promoter reporter construct with binding sites for the GAL4 yeast 
transcription factor (Fig. 4.27 A), and transfections in HepG2 cells performed (Fig. 4.27  
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Figure 4.26.  Effect of HDIs on acetylation of histone H3 at the
SRC promoters.  ChIP assays were performed on HT29 (A) and
SW480 (B) cells that had been treated with 1 µM TSA for various
periods of time.  Following cross-linking of proteins bound to DNA,
immunoprecipitations were performed on cell lysates with purified pre-
immune rabbit IgG, or a monoclonal antibody specific for histone H3
acetylated at lysines 9 and 14.  Following reversal of crosslinks,
immunoprecipitates were subjected to PCR with primers specific for
the SRC1α or SRC1A promoters. 
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Figure 4.27.  Functional necessity of the Sp- and HNF-binding sites for
HDI-mediated SRC transcriptional repression.  (A) Schematic of the SRC
locus.  The GC1 and GA2 sites in a SRC1A promoter construct, and the HNF
site in a SRC1α promoter construct were employed in this study.  (B) The
SRC1A∆GC1/GA2-GAL4 promoter was transactivated with various GAL4-
transcription factor fusions, and the response to 24 hr treatment with 1 µM
TSA assessed in HepG2 cells.  (C) The SRC1α∆HNF-GAL4 promoter was
transactivated with various GAL4-transcription factor fusions, and the
response to treatment with 1 µM TSA assessed in HepG2 cells. Bar graphs
represent the mean +/- the standard deviation from four separate experiments,
each performed in duplicate. 
B).  GAL4 replacement impaired SRC1A activity to a similar degree as mutation of 
these sites.  Following co-transfection with GAL4-Sp1 or GAL4-Sp3 fusions, but not the 
GAL4 DNA binding domain (DBD) alone, SRC1A activity was restored to levels of the 
wild-type promoter.  This represented the first evidence that Sp3, like Sp1, could 
activate the SRC1A promoter in mammalian cells.  When these transfected cells were 
exposed to TSA, SRC1A activity was consistently repressed regardless of whether the 
promoter construct was analyzed alone, or if an Sp1 or Sp3 GAL4 fusion was employed 
for co-transfection.  Strikingly, when the SRC1A GC1/GA2-GAL4 promoter was 
transactivated by GAL4 fused to the strong viral VP16 activator, repression was still 
observed following TSA treatment.  These findings suggested the repressive effects of 
TSA were not specific for Sp1 or Sp3 binding to GC1 or GA2.  Therefore, TSA was not 
inhibiting SRC1A activity through the Sp-family binding sites.  A similar approach was 
taken to analyze the HNF-1α binding site in the SRC1α promoter (Fig. 4.27 A and C).   
As shown in Figure 4.27 C, a GAL4-HNF-1α fusion, but not a GAL4-HNF-1β fusion or 
the GAL4 DBD alone, was able to moderately transactivate the SRC1α HNF-GAL4 
promoter.  However, regardless of whether the SRC1α HNF-GAL4 construct was 
transactivated by GAL4-HNF-1α or GAL4-VP16, it was still significantly repressed by 
TSA.  These findings suggested the SrcHNF site in the SRC1α promoter was not 
responsible for mediating the repressive effect of HDIs. 
 Next, it was determined if element(s) other than GC1 or GA2 were responsible for 
mediating the inhibitory effects of TSA on the SRC1A promoter.  Obvious candidate 
elements were the SPy/hnRNP K binding sites, TC1, TC2, and TC3.  A number of 5' and 
TC1, TC2, and TC3 SRC1A internal promoter deletions based on the 0.38 SRC1A-CAT 
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promoter construct have been previously analyzed in transfection experiments (Bonham 
and Fujita, 1993; Ritchie et al., 2000).  In this thesis study, deletion of TC1 had a 
pronounced effect on SRC1A promoter activity in HepG2 cells, diminishing CAT levels 
approximately 60% (Fig. 4.28).  However, regardless of the internal deletion generated, 
these constructs were still all further repressed following treatment with TSA.  A 0.2 
SRC1A-CAT reporter was subsequently created, which had the entire SRC1A promoter 
5' to the TC3 element deleted (Fig. 4.28).  Despite the very low activity of this truncated 
SRC1A reporter construct, repression was still observed following treatment with TSA.  
In summary, a distinct 5' TSA response element, which would block the repressive 
effects of TSA when deleted, was not observed in either SRC promoter.  These findings 
therefore implicate SRC core promoter elements in mediating the repressive effects of 
TSA. 
 
4.3.4.  Search for Distinct HDI Response Elements in the SRC Core Promoters 
4.3.4.1.  SRC Core Promoter Architecture 
 The major transcription initiation site in the SRC1α promoter maps to a 
CCA(+1)GGCT motif 39 bp downstream from the SrcHNF site in HepG2 and HT29 
cells (Fig. 4.29 A) (Bonham et al., 2000).  Alternatively, previous analysis of the 
SRC1A promoter determined that transcription was initiated from multiple weak start 
sites (Bonham and Fujita, 1993).  However, because these observations were generated 
in cells other than those used in this study, S1 nuclease protection analysis was 
employed to determine the major SRC1A transcription start sites in HepG2, HT29, and 
SW480 cells (Fig. 4.29 B).  Three major sites of transcription initiation were mapped to  
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Figure. 4.28.  Search for a 5' TSA response element.  Various
SRC1A constructs harboring deletions in upstream activation
sequences were evaluated for their response to 1 µM TSA in HepG2
cells.  Bar graphs represent the mean +/- the standard deviation from
two separate experiments, each performed in duplicate. 
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Figure 4.29.  Inr elements in the SRC core promoters.  (A) Sequence of the
SRC1α core promoter regions surrounding the SRC1α transcription start site.
The Inr element is underlined.  (B) S1 protection analysis was performed to
determine the initiation sites for transcription in the SRC1A promoter in
HepG2, HT29, and SW480 cells.  The residues mapped to the extreme 5'
termini of exon 1A-containing transcripts are denoted with bent black arrows
on the right.  (C) Sequence of the SRC1A core promoter regions surrounding
the SRC1A transcription start site.  The Inr element is underlined. 
 
a core CCA(+1)TTC in these cells, 27 bp downstream from the TC3 tract in the SRC1A 
promoter (Fig. 4.29 C).  This SRC1A transcription start site core perfectly matched the 
Inr consensus sequence of YYA(+1)NTYY (Smale et al., 1998).  Furthermore, the 
SRC1α transcription start site core loosely matched this consensus motif.  These 
findings suggested that both SRC promoters were TATA-less, but Inr driven.  It was 
therefore hypothesized that this commonality in SRC core promoter architecture might 
explain why both of these very different promoters were repressed by HDIs. 
 
4.3.4.2.  Effect of SRC1A and SRC1α 3' Deletions on TSA Mediated Repression 
 The role the SRC core promoter elements played in SRC1A and SRC1α 
transcription, as well as their response to HDIs were addressed by analyzing a series of 
SRC promoter-CAT constructs harboring deletions in the core promoter regions (Figs. 
4.30 A and C).  As shown in Fig. 4.30 B, 3' deletion of the SRC1A promoter to the SacII 
site and up to +13 had a much more pronounced effect in SW480 cells compared to 
HepG2 cells.  Deletions that eliminated the Inr element from the SRC1A promoter (∆-
26, ∆-60) nearly abolished all detectable transcriptional activity in both these cell lines, 
thus supporting the hypothesis that the SRC1A promoter was Inr driven.  However, 
despite these observations, core promoter deletions were unable to block transcriptional 
repression in response to TSA treatment.  Deletions in the SRC1α core promoter had a 
very similar effect to deletions in the SRC1A core promoter, and exclusion of the Inr 
element (∆-20) severely compromised promoter activity (Fig. 4.30 D).  Again, 
regardless of the effect the core promoter deletions had on transcriptional activity, 
further repression was still consistently observed following treatment with TSA.  These  
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Figure 4.30.  Effect of SRC core promoter deletions on TSA mediated
repression.  (A) SRC1A 3' deletion constructs.  (B) SRC1A 3' deletion
constructs were transfected in HepG2 and SW480 cells and analyzed for their
response to 1 µM TSA.  (C) SRC1α 3' deletion constructs.  (D) SRC1α 3'
deletion constructs were transfected in HepG2 and SW480 cells and analyzed
for their response to 1 µM TSA. Bar graphs represent the mean +/- the
standard deviation from two separate experiments, each performed in
duplicate. 
data suggested a distinct core promoter element in either SRC promoter was not 
responsible for mediating the effects of HDIs.  The SRC1A promoter was systematically 
deleted in its entirety in this study (Figs. 4.28 and 4.30 A,B), and no single deletion 
resulted in a significant change in its response to TSA.  These 5' and 3' deletion 
approaches, therefore, were unable to identify any distinct element that was responsible 
for HDI mediated SRC transcriptional repression.  This suggested some other common, 
inherent property of the SRC promoters was responsible for their repression by HDIs. 
 
4.3.5.  SRC1A and SRC1α Core Promoter Characterization 
4.3.5.1.  Binding of TAF1 to the SRC Core Promoters  
 Although discrete TSA response elements were not identified in either SRC 
promoter, the commonality in their core architecture still provided an attractive rationale 
for their inhibition by HDIs.  A major inherent property of many promoters with Inr 
elements is their dependence on the TFIID component, TAF1, for full activity.  
Significantly, TAF1 possesses AT activity, which could potentially play a role in HDI-
mediated SRC repression.  Therefore, to address whether the SRC core promoters could 
bind TAF1, EMSAs were performed with a recombinant TAF1-TAF2 heterodimer.  
These experiments were designed by the candidate, and subsequently performed by 
collaborators Dr. Edith Wang and Traci Hilton at the University of Washington.  The 
sequences of the double stranded oligonucleotides utilized as labeled EMSA probes and 
unlabeled competitors are shown in Fig. 4.31 A.  As shown in Fig. 4.31 B and C, both 
the wild-type SRC1α and SRC1A core promoters were able to bind recombinant TAF1-
TAF2.  This binding was effectively competed away with an excess of unlabeled probe  
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Figure 4.31.  TAF1 binding to the SRC core promoters.  (A)
Oligonucleotides used in EMSA experiments.  EMSAs were performed using a
recombinant TAF1-TAF2 heterodimer and [32P]-labeled probes representing
the SRC1α (B) or SRC1A (C) core promoters.  Competitions were performed
using excess unlabeled wild type probe (lanes 3-5), or unlabeled duplexes
harboring mutations in the Inr cores (lanes 6-8). 
 
(Figs 4.31 B and C, lanes 3-5).   However, unlabeled double stranded oligonucleotides 
representing Inr mutant forms of the SRC1α or SRC1A core promoters were less 
efficient competitors for TAF1-TAF2 binding (Figs. 4.31 B and C, compare lanes 6-8 to 
lanes 3-5).  These studies showed the SRC1α and SRC1A core promoters bind a TAF1-
TAF2 heterodimer in vitro, and that the Inr core plays a role in this binding. 
 
4.3.5.2.  TAF1 Dependence of the SRC Core Promoters  
 Given the SRC1α and SRC1A core promoters contain Inr elements and bind 
TAF1-TAF2, it was important to determine if SRC transcriptional activity was 
dependent on functional TAF1.  A useful tool for studying TAF1 function is the BHK-
21 (baby hamster kidney) derived tsBN462 cell line, which harbors a G690D mutation 
in the TAF1 protein (Hayashida et al., 1994).  These cells grow normally at 33oC, but 
undergo G1/S arrest when shifted to the restrictive temperature of 39oC.  At the 
permissive temperature, G690D TAF1 retains wild-type function; however, at 39oC, 
G690D TAF1 AT (Dunphy et al., 2000) as well as Inr binding (Hilton and Wang, 2003) 
activities are compromised.  A shift of these cells from 33oC to 39oC results in the 
activation of genes encoding p21 and p27, and reduction in the expression of cyclins D1 
and A (Rushton et al., 1997; Sekiguchi et al., 1996; Suzuki-Yagawa et al., 1997).  These 
transcriptional responses are generally believed to exert the halt in cell cycle 
progression.  Indeed, cell cycle arrest at 39oC in ts13 cells, which are similar to tsBN462 
cells, can be rescued by expression of wild-type TAF1, suggesting disruption of TAF1 
activity is directly responsible for this temperature sensitive phenotype (Wang and Tjian, 
1994). 
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 Transient transfections were therefore performed with SRC1α and SRC1A CAT 
reporters in tsBN462, as well as parental BHK-21 cells.  Following a shift in growth 
temperature from 33oC to 39oC, the activity of the SRC1A promoter was decreased in 
tsBN462 but not BHK-21 cells (Fig. 4.32 A).  This decrease in SRC1A activity at 39oC 
in tsBN462 cells was partially rescued by co-expression of wild-type TAF1 (Fig 4.32 B).  
Interestingly, however, the SRC1A promoter was no longer repressed by TSA or 
butyrate at the restrictive temperature in tsBN462 cells (Fig. 4.32 A).  Conversely, this 
promoter construct was still repressed by HDIs at 39oC in the parental BHK-21 cell line.  
This was the first time repression of either SRC promoter was not observed in response 
to HDIs.  These data therefore suggested the SRC1A promoter was TAF1 dependent, 
and compromised TAF1 activity blocked the repressive effects of HDIs on this 
promoter.  Similar experiments could not be performed with the SRC1α promoter 
because it was found to have lower activity at 39oC compared to 33oC in both tsBN462 
and BHK-21 cells (Fig. 4.32 C).  As a result, the decrease in SRC1α activity following a 
shift from 33oC to 39oC in tsBN462 cells was not rescued by wild-type TAF1 co-
expression (Fig. 4.32 D). 
 Previous studies have shown that the G690D TAF1 mutation compromises both 
AT activity and core promoter Inr binding at the restrictive temperature (Dunphy et al., 
2000; Hilton and Wang, 2003).  Therefore, to address if the decrease in SRC promoter 
activity following shift to the restrictive temperature in tsBN462 cells was due to 
reduced TAF1 core promoter binding, binding reactions were carried out using the 
SRC1A and SRC1α core promoters with wild-type or G690D mutant TAF1-TAF2 
heterodimers at 25oC or 37oC.  These temperatures have previously been shown to be  
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Figure 4.32.  TAF1 dependence of the SRC promoters.  (A) tsBN462 and BHK-21
cells were transfected with 0.38 SRC1A-CAT and grown at 33oC for 36 hours.
Following treatment with 1 µM TSA or 5 mM sodium butyrate, transfected cells were
grown at 33oC (permissive) or 39oC (restrictive) for 18 hours.  CAT levels were
subsequently determined.  (B) tsBN462 cells were transfected with 0.38 SRC1A-CAT
with or without CMV-hTAF(II)250.  Following 36 hours of growth at 33oC, cells were
shifted to 39oC, and grown for an additional 18 hours.  CAT levels were subsequently
determined.  (C) tsBN462 and BHK-21 cells were transfected with -145 SRC1α-CAT
and grown at 33oC for 36 hours.  Cells were then shifted to 39oC, or maintained at 33oC
for an additional 18 hours.  CAT levels were subsequently determined.  (D) tsBN462
cells were transfected with -145 SRC1α-CAT, as described in (B).  Bar graphs
represent the mean +/- the standard deviation from three separate experiments, each
performed in duplicate. (E) EMSAs were performed at 25oC or 37oC with a wild type
or G690D mutant TAF1 in a TAF1-TAF2 heterodimer and [32P]-labeled probes
representing the SRC1α or SRC1A core promoters. 
permissive and restrictive, respectively, for in vitro transcription reactions with ts13 
nuclear extracts (Wang and Tjian, 1994).  As with previous TAF1 EMSA analysis, these 
experiments were designed by the candidate, and performed by Dr. Edith Wang and 
Traci Hilton at the University of Washington.  Strong binding of TAF1-TAF2, 
containing either wild type or G690D forms of TAF1, to the SRC1α and SRC1A core 
promoters was observed at 25oC (Fig. 4.32 E).  However, binding of the TAF1-TAF2 
dimer containing G690D TAF1 to both SRC core promoters was compromised at 37oC.  
Conversely, the TAF1-TAF2 dimer containing wild type TAF1 did not display a 
decrease in binding to the SRC core promoters at this temperature.  These data suggest 
the decrease in SRC promoter activity at the restrictive temperature in tsBN462 cells is 
due to G690D TAF1 inability to bind the core promoter in addition to the well-
documented loss of AT activity.   
 In summary, these sets of experiments clearly showed the SRC1A promoter is 
TAF1 dependent.  Results for the SRC1α promoter were less definitive due to the 
observation of a decrease in activity following a shift from 33oC to 39oC in both 
tsBN462 and BHK-21 cells.  However, the ability of TAF1 to bind the SRC1α core 
promoter strongly suggested that this promoter was also TAF1 dependent.  This was 
supported by the observation that binding of the G690D TAF1 mutant to the SRC1α 
core promoter was compromised at the restrictive temperature of 37oC.  
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4.3.6.  Analysis of SRC:WAF1 Chimeric Promoters 
4.3.6.1.  Response of SRC:WAF1 Promoter Chimeras to TSA 
 The previous section detailed findings that suggested the SRC core promoters 
were both Inr driven and TAF1 dependent, and implicated a role for TAF1 in the 
repression of the SRC promoters by HDIs.  An important question therefore was 
whether the TAF1 dependence of the SRC promoters was responsible for their 
repression in response to HDIs.  Interestingly, previous studies with mammalian cells 
have shown that both core promoter elements and upstream activation sequences from a 
TAF1 dependent promoter can independently confer TAF1 dependence on a normally 
TAF1 independent promoter (Wang et al., 1997).  It was therefore asked whether 
upstream activation sequences and core promoter elements from the SRC promoters 
could independently confer HDI mediated repression on a TAF1 independent, 
heterologous promoter normally activated by HDIs.  To this end, a series of chimeric 
SRC:WAF1 promoter CAT reporters were generated, and analyzed for their response to 
HDIs following transfection in HT29 and SW480 colon cancer cells (Fig. 4.33).  
Previous studies have shown the WAF1 promoter contains a consensus TATA box (Fig. 
4.33 A), and a crucial Sp-family binding element, Sp1-3, which mediates its activation 
following HDI treatment (Huang et al., 2000; Nakano et al., 1997).  In agreement with 
these studies, two WAF1 promoter CAT constructs, -210 WAF1-CAT and -101 WAF1-
CAT, were significantly induced following TSA treatment in transfected HT29 cells 
(Fig. 4.33 B).  Conversely, in SW480 cells, constitutively strong WAF1 promoter 
activity was observed, which was not induced following TSA treatment (Fig. 4.33 B).  
However, when the WAF1 core promoter was replaced in the -210 WAF1 or -101 
WAF1 constructs with either the SRC1A (Fig. 4.33 B) or SRC1α (Fig. 4.33 C) core  
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Figure 4.33.  Response of SRC:WAF1 promoter chimeras to TSA.  (A) 
Schematic of the SRC1A, SRC1α, and WAF1 promoter constructs utilized to 
generate chimeras.  (B) Wild type SRC1A and WAF1 promoter constructs 
depicted in (A), as well as various promoter chimeras, were assessed for their 
response to 1 µM TSA following transfection in HT29 and SW480 cells.  (C) 
Wild type SRC1α and WAF1 promoter constructs depicted in (A), as well as 
various promoter chimeras, were assessed for their response to 1 µM TSA 
following transfection in HT29 and SW480 cells.  Bar graphs represent the mean 
+/- the standard deviation from three separate experiments, each performed in 
duplicate.   
promoters, repression was observed following TSA treatment in both HT29 and SW480 
cells.  With these chimeras, special care was taken to ensure the Inr elements from the 
SRC core promoters were positioned the same distance away from the Sp1-6 site as the 
major site of transcription initiation observed with the wild type WAF1 promoter   A 
similar repression was observed upon TSA treatment when the WAF1 upstream 
activation sequences were replaced in these constructs with SRC1A (Fig. 4.33 B) or 
SRC1α (Fig. 4.33 C) upstream activation sequences.  With these chimeras, spacing was 
selected such that the WAF1 TATA element was positioned the exact same distance 
from the TC3 or HNF sites as the Inr elements in the SRC1A and SRC1α core 
promoters, respectively.  In these sets of experiments, it was observed that the -145 
SRC1α, -101 WAF1:SRC1α, and -145 SRC1α:WAF1 reporters had extremely low 
activities in HT29 cells.  Taken together, these results demonstrated that core promoter 
elements and upstream activation sequences from both the SRC1A and SRC1α 
promoters could independently confer HDI-mediated repression on the heterologous 
WAF1 promoter. 
 
4.3.6.2.  TAF1 Dependence of SRC:WAF1 Promoter Chimeras 
 Upstream activation sequences and core promoter elements from the SRC 
promoters were independently able to confer HDI mediated repression on the WAF1 
promoter.  To examine whether the SRC upstream activation sequences and core 
promoter elements were also able to independently confer TAF1 dependence on the 
WAF1 promoter, the activities of the chimeric SRC:WAF1 and WAF1:SRC constructs 
were analyzed in tsBN462 cells (Fig. 4.34).  It was found that all WAF1 constructs had  
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Figure 4.34.  TAF1 dependence of SRC:WAF promoter chimeras.  (A) A
chimeric -210 WAF1:SRC1Acore construct was transfected alone or in
combination with increasing amounts of a wild type TAF1 expression vector into
tsBN462 cells.  Cells were grown at 33oC for 36 h, then maintained at 33oC or
shifted to 39oC for an additional 18 h.  CAT levels were subsequently
determined.  (B) A chimeric 0.38 SRC1A:WAF1core construct was analyzed as
described in (A).  (C) A chimeric -210 WAF1:SRC1αcore construct was
analyzed as described in (A).  (D) A chimeric -145 SRC1α:WAF1core construct
was analyzed as described in (A).  Bar graphs represent the mean +/- the
standard deviation from two separate experiments, each performed in duplicate. 
extremely high activity in tsBN462 and BHK-21 cells at both 33oC and 39oC (data not 
shown).  However, previous studies using ts13 cells stably expressing a WAF1-CAT 
construct showed that WAF1 transcription is normally induced approximately 2-fold 
following a shift from 33oC to 39oC in these cells (Rushton et al., 1997).  In contrast, a 
strong decrease in promoter activity was observed for both the -210 WAF1:SRC1A and 
0.38 SRC1A:WAF1 chimeras following a shift from 33oC to 39oC in tsBN462 cells 
(Figs. 4.34 A and B).  The decrease in activity of these chimeras at 39oC was rescued by 
co-expression of wild-type TAF1.  These findings confirmed the SRC1A core promoter 
elements and upstream activation sequences independently conferred TAF1 dependence 
on the WAF1 promoter.  Similarly, the -210 WAF1:SRC1α chimera showed diminished 
activity following a shift from 33oC to 39oC (Fig 4.34 C).  However, in contrast to 
previous results with the SRC1α promoter alone (Fig 4.32 D), the activity of the -210 
WAF1:SRC1α chimera was partially rescued by co-expression of wild type TAF1 at 
39oC.  Rescue of the transcriptional block at 39oC by TAF1 was not observed for the -
145 SRC1α:WAF1 chimera (Fig. 4.34 D).  These results therefore suggested the SRC1α 
core is indeed TAF1 dependent, and that the unusual temperature sensitive property 
described for this promoter in BHK-21 cells is mediated by upstream activation 
sequences.  Furthermore, similar to the results attained for the SRC1A promoter, the 
TAF1 dependence of the SRC1α core promoter was conferred on the heterologous 
WAF1 promoter. 
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4.3.7.  DISCUSSION 
4.3.7.1.  HDIs as Anti-Cancer Agents and Modulators of Gene Expression 
 HDIs have been described as exciting agents with impressive anti-cancer potential 
(Vigushin and Coombes, 2002).  Indeed, these agents effectively target the transformed 
phenotype of various tumor cell lines in vivo and in vitro by inhibiting proliferation and 
inducing differentiation and/or apoptosis (Marks et al., 2000).  The anti-cancer 
properties of HDIs have been hypothesized to result from the highly selective changes in 
gene expression that ensue following treatment.  For example, the most well-described 
cellular response to treatment with these agents is the p53 independent activation of the 
potent cell cycle inhibitor, p21/WAF1 (Huang et al., 2000; Nakano et al., 1997).  
Because of these previous findings, agents from different classes of HDIs are currently 
being analyzed for their anti-tumor effectiveness in various phases of human clinical 
trials (Vigushin and Coombes, 2002).  
 Given the potential clinical importance of these agents, it is surprising that very 
few studies have reported their mechanisms of gene expression modulation.  The X-ray 
crystal structures of TSA and suberoylanilide hydroxamic acid (SAHA) in complex with 
a Zn2+ dependent HDAC enzyme have been solved (Finnin et al., 1999).    These 
structures suggest the mechanism of HDAC inhibition by these agents is through active 
site binding, and sequestration of the Zn2+ cofactor.  Proposed rationales for subsequent 
activation of genes following this HDAC inhibition involve unbalanced activity of 
histone AT (HAT) enzymes, leading to hyperacetylation of histones at promoters.  
Indeed, treatment with HDIs in vivo has been shown to lead to accumulation of 
hyperacetylated nuclear histone proteins in both tumor and normal tissues (Warrell et al., 
1998).  Such an overall increase in the acetylation of histones at promoters is widely 
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believed to result in an open and relaxed chromatin conformation.  Therefore, these 
agents have been described as exerting their effects at the level of chromatin structure 
(Kouzarides, 2000).  This model is supported by the observation that many co-activator 
proteins, including GCN5, p300/CBP, P/CAF, SRC-1 and ACTR possess intrinsic HAT 
activity, while co-repressor complexes are associated with HDAC enzymes (Marks et 
al., 2001b; Vigushin and Coombes, 2002).  However, this theory offers very little 
explanation for the mechanism of gene repression by HDIs, and global gene expression 
studies have shown just as many genes are repressed as are activated by these agents 
(Mariadason et al., 2000).  In addition, such a global phenomenon as a general opening 
in chromatin structure could not account for the observation that the expression of a very 
select subset of genes is altered in response to HDIs (Mariadason et al., 2000; Van Lint 
et al., 1996).  Indeed, the most detailed studies into the mechanism of gene activation by 
these agents have involved the WAF1 promoter, and these concluded that specific Sp-
family binding sites were essential for transcriptional induction (Huang et al., 2000; 
Nakano et al., 1997).  Preliminary analysis of molecular pathways leading to activation 
or repression of genes in response to butyrate have suggested phosphorylation cascades 
co-operate with acetylation events to elicit these cellular effects.  For example, 
investigation into the activation of histone H1o expression or repression of c-myc gene 
expression by butyrate demonstrated an okadaic acid sensitive Ser/Thr phosphatase 
pathway plays a role in the transcriptional response to this HDI (Cuisset et al., 1997).  In 
addition, Ser/Thr kinase inhibition blocks the induction of choline acetyltransferase gene 
expression, and protein kinase C inhibition blocks the induction of WAF1 in response to 
butyrate (Espinos et al., 1999; Han et al., 2001).  Therefore, it is probably more accurate 
to describe HDIs as affecting acetylation-mediated signal transduction cascades, as well 
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as altering chromatin structure at promoters.  This is supported by the observation that 
transcriptional regulators such as p53 (Gu and Roeder, 1997), Sp3 (Braun et al., 2001), 
EKLF (Zhang and Bieker, 1998), GATA-1 (Boyes et al., 1998), TFIIE, and TFIIF 
(Imhof et al., 1997) are acetylated by AT enzymes.  
 
4.3.7.2.  HDIs and SRC Repression 
 This study has determined that HDIs were able to effectively inhibit c-Src mRNA 
and protein expression in a wide variety of human cancer cell lines.  This inhibition of 
expression was the result of direct SRC transcriptional repression.  Given the 
observation that SRC is transcriptionally activated in human colon cancer cell lines, and 
HDIs block this activation, it is hypothesized that SRC is an important cellular target of 
these agents.  One HDI used in these experiments, sodium butyrate, is particularly 
relevant to this theory because it is a breakdown product of dietary fibre, resulting from 
bacterial fermentation in the colonic lumen (Topping and Clifton, 2001).  Theories that 
suggest butyrate is in part responsible for the anti-cancer effect of a high fibre diet are 
strengthened, considering its ability to repress SRC transcription.  For example, 
inhibition of c-Src expression using antisense approaches in HT29 or a breast cancer cell 
culture model resulted in diminished parameters of transformation, including slower 
growth, reduced tumor-forming ability in nude mouse xenografts, and increased 
apoptosis (Karni et al., 1999; Staley et al., 1997).  Therefore, the reduction in c-Src 
expression elicited by HDI treatment would be expected to have a similar negative effect 
on cell proliferation and viability as these antisense approaches.  Experiments designed 
to address this hypothesis will be important to determine the significance of SRC 
repression by these agents. 
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4.3.7.3.  Core Promoter Architecture, TAF1 Dependence, and HDI Mediated SRC 
Repression 
 As a result of the potential clinical importance of HDIs, and the general lack of 
information regarding the mechanisms of gene repression by these agents, this study 
focused on addressing how SRC repression was elicited by HDIs.  GAL4 replacement 
strategies and promoter deletion analysis was employed, but a single element 
responsible for mediating repression of either the SRC1A or SRC1α promoters by HDIs 
was not implicated.  However, it was noted following deletion analysis of the SRC core 
promoters that elimination of very small fragments in the 3' end of SRC promoter 
constructs drastically impaired SRC transcriptional activity (Fig. 4.30).  These results 
therefore suggest the SRC core promoters are just as important for determining overall 
SRC expression in human cancer cell lines as upstream activation sequences.  Further 
investigation is therefore called for to understand how sequences in the SRC core 
promoter regions regulate SRC transcription, and potentially contribute to activation in 
human colon cancer cell lines.  Functional analysis of the SRC1A and SRC1α core 
promoters demonstrated that they were similar in that they were both Inr-driven and 
absolutely dependent on the TFIID component, TAF1, for full activity. However, a 
preliminary examination of the core sequences downstream from the Inr elements in the 
SRC promoters has not revealed any obvious homology or similarity that might 
implicate functional elements in these regions. 
 TAF1 has been characterized as a core promoter selectivity factor that binds the Inr 
element and responds to upstream activation sequences (Shen et al., 1998).  Initial TAF1 
studies in yeast, using chimeric promoters, demonstrated TAF1 dependence is dictated 
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solely by the core promoter (Shen and Green, 1997).  However, a similar approach 
involving a mammalian system determined that TAF1 dependence could be conferred on 
a heterologous, TAF1 independent promoter by both upstream activation sequences and 
core promoter elements (Wang et al., 1997).  These previous studies formed the basis for 
the experimental design of this study, which determined that TAF1 dependence could be 
conferred on the heterologous, TAF1 independent, WAF1 promoter by SRC promoter 
upstream activation sequences or core promoter elements.  Furthermore, this study also 
demonstrated that HDI mediated repression was conferred upon the WAF1 promoter by 
SRC upstream activation sequences or core promoter elements.  These observations 
implicated a potential functional link between TAF1 dependence and HDI mediated 
gene repression that was strengthened by the observation that the repressive effects of 
HDIs on the SRC1A promoter were completely blocked in tsBN462 cells grown at the 
restrictive temperature of 39oC.  Although the activity of the SRC1A promoter was 
already low at 39oC, this finding was very significant because this was the first time a 
complete absence of SRC1A repression was demonstrated following HDI treatment.  
Unexpectedly, a similar approach with the SRC1α promoter showed it to have lower 
activity at 39oC compared to 33oC in both tsBN462 and BHK-21 cells.  It was 
determined this temperature sensitive change in activity was actually due to an increase 
in SRC1α promoter activity at 33oC compared with 37oC.  This unusual "cold-induced" 
property of the SRC1α promoter was verified in HT29 colon cancer cells as well (data 
not shown).  The significance and mechanism of SRC1α induction at lower 
temperatures in these mammalian cell lines is currently not known. 
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 A single study has previously addressed the mechanism of gene repression by 
butyrate, using the cyclin D1 promoter as a model (Lallemand et al., 1996).  This report 
identified an 11 bp butyrate response element that could confer weak butyrate-mediated 
repression when placed upstream of a thymidine kinase (TK) promoter.  However, the 
repression mediated by the cyclin D1 butyrate response element was only 2-fold, and the 
basal activities of the promoter constructs in untreated cells were not included in the 
report (Lallemand et al., 1996).  In this thesis, it was observed that the basal activities of 
reporter constructs in untreated cells could significantly affect the fold induction or 
repression mediated by HDIs.  Therefore, it was deemed prudent to take a qualitative 
approach and catalogue responses to HDIs as activated, repressed, or unaffected.  Failure 
to do so could have inaccurately implicated discrete SRC promoter elements in 
mediating repression by HDIs.  A need for such caution is supported by the observation 
that elements in the WAF1 promoter that have been concluded as important for 
induction in response to HDIs are those that impair promoter activity most significantly 
when mutated and analyzed in transfection experiments (Huang et al., 2000; Nakano et 
al., 1997). 
 
4.3.7.4.  Models for HDI Mediated SRC Repression 
 Two models have been developed to explain the mechanism of SRC gene 
repression by HDIs (Fig. 4.35).  These models both propose that TAF1 serves a vital 
core promoter recognition and TFIID recruitment function at the SRC promoters.  In 
tsBN462 cells shifted to the restrictive temperature, these vital TAF1 functions are 
abrogated.  This study has shown this could be due to decreased TAF1 binding to the 
core promoters, compromised AT activity, or a combination of both of these effects.  In  
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Figure 4.35.  Models for HDI-mediated SRC repression.  (A) HDIs prevent 
TAF1 from acetylating a SRC transcriptional repressor.  (B) HDIs block TAF1 
from binding the SRC core promoters. 
 
the first model (Fig. 4.35 A), an unidentified factor is acetylated at the SRC promoters 
by TAF1, which can subsequently elicit direct transcriptional repression. Normally, 
acetylation of this putative factor is balanced by one or more of the Zn2+ dependent 
HDAC enzymes, thus preventing its negative influence on SRC transcription.  Treatment  
with HDIs, however, would shift the balance towards hyperacetylation of this factor, 
resulting in the SRC transcriptional repression observed in various cell lines.  In 
tsBN462 cells, the compromised G690D TAF1 AT activity and/or core promoter 
recognition prevents TAF1 from acetylating this factor, thus explaining the block of HDI 
mediated SRC repression in tsBN462 cells at 39oC.  In the second model (Fig. 4.35 B), 
HDIs prevent TAF1 binding to the SRC core promoters, thus accounting for SRC  
transcriptional repression.  This could be due to direct TAF1 acetylation, or acetylation 
of another component of the basal transcriptional apparatus essential for TAF1 core 
promoter binding.  This model suggests that the block in HDI mediated SRC repression 
in tsBN462 cells at 39oC is due to the fact that G690D TAF1 core promoter binding has 
already been abolished at the restrictive temperature. 
 These models also provide potential explanation for the response of SRC:WAF1 
and WAF1:SRC promoter chimeras to HDIs.  For chimeras containing SRC core 
promoter elements and WAF1 upstream activation sequences, the Inr elements in the 
SRC core promoters could dictate TAF1 dependence.  Repression following HDI 
treatment could then result from one of the two models proposed in Figure 4.35.  For 
chimeras containing WAF1 core promoter elements and SRC upstream activation 
sequences, TAF1 dependence could be dictated from undefined elements in the SRC 
upstream activation sequences.  In this situation, TAF1 probably is not responsible for 
TFIID recruitment, because the TATA element in the WAF1 core promoter would bind 
 187 
TBP.  Therefore, the model depicted in Figure 4.35 A would best explain the repression 
of these chimeras by HDIs.  Likely, however, these models represent two extremes, and 
the precise mechanism of repression of the SRC promoters, as well as SRC:WAF1 
chimeras, is through a combination of these two theories.            
 In light of these models, it is important to note the TAF1 AT substrates that 
mediate TAF1 dependence in tsBN462 cells have not yet been identified.  TAF1 has 
very weak activity towards histone proteins (Wassarman and Sauer, 2001), but has been 
shown to acetylate TFIIEβ and the RAP74 subunit of TFIIF in vitro (Imhof et al., 1997).  
The effect of these modifications on the function of these general transcription factors is 
not known.  In order to clarify the role of TAF1 AT activity in core promoter recognition 
and the repressive effects of HDIs, critical acetylated TAF1 substrates will have to be 
identified specifically in the context of the SRC promoters. 
 
4.3.7.5.  Other TAF1 Dependent Genes Repressed by HDIs 
 This study has described the first potential mechanistic link between promoter 
TAF1 dependence and repression by HDIs.  The importance of this relationship was 
provided by studies with SRC:WAF1 chimeras, which demonstrated that conferring 
TAF1 dependence on the WAF1 promoter also made it repressible in response to TSA 
treatment.  Interestingly, the cyclin D1 and cyclin A promoters, much like the SRC1α 
and SRC1A promoters, are also Inr driven, significantly inhibited in tsBN462 cells 
following a shift to the restrictive temperature, and repressed in response to HDI 
treatment (Iacomino et al., 2001; Suzuki et al., 2000; Suzuki-Yagawa et al., 1997; Wang 
et al., 1997).  Conversely, promoters of genes that are activated in response to HDI 
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treatment, such as WAF1, C-FOS, and CMV, contain TATA elements and are slightly 
induced or unaffected in tsBN462 cells following a shift to the restrictive temperature 
(Archer et al., 1998a; Rushton et al., 1997; Wang et al., 1997).  Interestingly, previous 
work that showed TAF1 dependence could be dictated independently by upstream 
activation sequences and core promoter elements utilized chimeras generated between 
the TAF1 dependent cyclin A promoter and the TAF1 independent FOS promoter 
(Wang et al., 1997).  Therefore, it would be of great interest to expand the findings 
reported here and determine if these cyclin A:FOS promoter chimeras would also be 
repressed by HDI treatment.  Taken together, these observations suggest there could be a 
more general, potentially functional, link between Inr driven, TAF1 dependent 
promoters and HDI mediated repression.  Indeed, treatment of various cells with HDIs 
elicits a similar response of G1/S arrest and/or apoptosis as does the shift of tsBN462 or 
ts13 cells from 33oC to 39oC.  To better understand this relationship, it will be important 
to dissect the complicated array of elements that dictate both TAF1 dependence and HDI 
mediated repression in the upstream activation sequences and core promoter elements of 
Inr driven genes. 
 
4.3.7.6.  Scope and Significance 
 HDIs are anti-neoplastic agents that inhibit proliferation and induce differentiation 
and/or apoptosis of cancer cells in culture and animal models.  The ability of these 
agents to re-program gene expression plays an important role in their chemotherapeutic 
action.  The transcriptional effects induced by these agents include the induction of 
growth inhibitory genes such as WAF1, and repression of growth promoting genes such 
as c-Src and cyclins D and A1.  Despite these well-defined cellular responses, the 
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knowledge surrounding the precise mechanisms of action of these agents on 
transcription is limited.  This study has provided evidence for a potential functional link 
between the SRC promoters' shared TAF1 dependence, and their repression following 
HDI treatment.  Interestingly, cyclins D and A1 are also TAF1 dependent genes, 
suggesting the conclusions derived for the SRC promoters could be more general, and 
provide fundamental information about the gene repression elicited by these important 
agents. 
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5.  CONCLUSIONS AND FUTURE STUDIES 
 Activation of the 60 kDa c-Src non-receptor tyrosine kinase is a frequent finding in 
cancers of the colon, breast, liver, lung, and pancreas.  Many previous reports have 
concluded this activation is accounted for by overexpression of c-Src protein (Biscardi et 
al., 1999).  This overexpression is deemed important for the cancerous phenotype of 
various tumor cells because antisense strategies preventing c-Src expression result in 
diminished proliferation, anchorage independent growth, tumor forming ability, and 
viability (Ellis et al., 1998; Karni et al., 1999; Staley et al., 1997; Wiener et al., 1999; 
Windham et al., 2002).  In this study, c-Src activation was determined to arise at the 
level of transcription in a subset of HCCLs.  These findings therefore suggest that SRC 
transcriptional activation could play an important role in the fully transformed 
phenotype of colon and other cancer cell lines.  Important future studies will 
complement these findings, and assess the contribution of SRC transcription to the 
expression and activity of c-Src in a wide variety of cancer cell lines where c-Src 
activation has been documented. 
  SRC transcription is controlled by two disparate promoters separated by 
approximately 1 kb.  The ubiquitously expressed SRC1A promoter is absolutely 
dependent on the Sp-family of transcription factors for full activity, but is also regulated 
in part by SPy/hnRNP-K (Ritchie et al., 2000; Ritchie et al., 2003).  The SRC1α 
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promoter, alternatively, is more tissue restricted in its pattern of expression and is 
absolutely dependent on a single HNF site, which has been shown to bind and respond 
to HNF-1α (Bonham et al., 2000).  In cancer cell lines, both promoters are utilized, 
albeit at very different ratios.  For example, HT29 and HepG2 cells both display very 
high c-Src expression levels; however, HepG2 cells display preferential SRC1α 
promoter usage while HT29 cells display nearly equal usage from both of these 
promoters.  The SW480 and HCT-116 cell lines, conversely, display very low levels of 
c-Src mRNA expression, which arises equally from both SRC promoters.  Despite these 
observations of differential SRC promoter use and transcriptional activity endogenously, 
transient transfection experiments with SRC promoter reporters consistently showed 
SRC1A to be a stronger promoter than SRC1α in isolation.  Because of these 
observations, it became of immediate interest to determine the mechanisms regulating 
differential SRC promoter usage and transcriptional activation.  This study detailed the 
development of a SRC DPCAT reporter system specifically designed to allow 
measurement of overall CAT activity, as well as relative SRC promoter usage following 
transient transfection in various human cancer cell lines. 
 When the SRC DPCAT reporters were assayed, consistently stronger SRC1A 
activity relative to SRC1α was still observed in all cell lines examined, regardless of 
their relative endogenous SRC promoter use.  A working hypothesis has therefore been 
developed that one or more enhancer element exist, and are likely important for the 
transcriptional activation observed in HepG2 and HT29 cells, respectively.  These 
elements are also proposed to play a general role in elevating SRC1α transcription in 
HepG2, HT29, SW480, and HCT-116 cells.  A strategy of searching for and testing the 
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function of DNaseI hypersensitive sites within the SRC locus was employed to identify 
potential functional elements that could represent this putative enhancer activity.  
Although this approach was unsuccessful, a discrete element was identified in HepG2 
cells that displayed a very weak ability to activate the SRC1α promoter.  Because this 
element did not account for the full relative SRC1α activity seen endogenously in 
HepG2 cells, it was deemed likely that a combination of elements might be required to 
constitute the enhancer activity that this study has suggested to exist.  Therefore, it will 
be important in the future to broaden the search for DNaseI hypersensitive sites in the 
SRC locus.  In addition, enhancer trap experiments could be employed in an effort to 
systematically test for potential enhancer activity of overlapping 1 to 2 kb DNA 
fragments derived from the SRC locus.  Such an approach, however, would require 
dozens, or even hundreds, of SRC1α reporter constructs to be developed and tested in 
transient or stable transfection experiments.  Nevertheless, identification and 
characterization of this potential enhancer will be essential in determining the 
mechanism of SRC transcriptional activation in colon and other cancer cell lines. 
  Transfection experiments with SRC DPCAT reporters in HT29 cells showed that 
the HNF site within the SRC1α promoter acted as a positive regulator of SRC1A 
promoter activity.  However, co-transfection experiments with HNF-1α and a SRC1α-
CAT reporter construct suggested that HNF-1α was unable to transactivate the SRC1α 
promoter in HT29 cells.  These observations have led to the proposal that an additional 
factor can bind to the HNF site in HT29 cells, and plays a role in the SRC1A activation 
observed in the SRC DPCAT reporter.  Results form the Bonham laboratory, showing 
the ability of an oligonucleotide probe to compete specifically for HNF-1 binding to the 
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SrcHNF site as well as to enrich for binding of a smaller, unknown factor in HepG2 
nuclear extracts, strengthened this theory.  Unfortunately, results described in this 
section were generated from the last sets of experiments performed in pursuit of this 
thesis study.  Therefore, it is very necessary for future experiments to gather more 
evidence that this factor exists, and then determine its identify and precise role in 
regulating SRC1α transcription, as well as SRC1A transactivation.  This could be 
accomplished first by using binding assays with various SrcHNF oligonucleotide probes 
to identify the critical sequences in this site that mediate binding of this unknown factor.  
This knowledge could then be employed in an affinity-based approach to preferentially 
purify this putative unknown factor from HT29 and other cellular extracts.  
  Because of the strong link between c-Src activation and transformation, a 
significant arsenal of anti-Src compounds has been developed.  These include natural 
products, synthetic peptides, peptidomimetics, and small molecules that target the SH2, 
SH3, or kinase domain (Sawyer et al., 2001).  All of these potential therapeutic agents 
are intended to block various cellular c-Src functions.  This study has demonstrated that 
HDIs are another groups of compounds that have anti-Src activity, and exert their effects 
in part by directly blocking SRC transcription in various cancer cell lines.  The 
significance of these findings are highlighted by many reports describing potent anti-
cancer activity of HDIs towards transformed cells in culture and animal models 
(Vigushin and Coombes, 2002).  Specifically, HDIs inhibit proliferation, and promote 
differentiation and/or apoptosis of a wide variety of cancer cells (Marks et al., 2000).  
Interestingly, these are a few of the many cellular processes for which c-Src function is 
necessary (Biscardi et al., 1999).  It will therefore be important for future experiments to 
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determine the precise contribution of decreased c-Src expression to the anti-cancer 
activities of HDIs.  This could be accomplished by a stable transfection approach in 
HT29 cells, where a promoter that is not repressed by HDIs controls overexpression of a 
c-Src transgene.  Such a model system would allow investigators to directly assess the 
effects of HDIs on these cancer cells when c-Src inhibition is prevented, and obtain 
clues to the essential c-Src signaling pathways that are shut down by HDIs. 
 Investigation into the mechanism of SRC transcriptional repression by HDIs has 
also revealed the importance of the SRC1A and SRC1α core promoters in regulating 
SRC transcription.  These studies defined both SRC core promoters as lacking TATA 
motifs, but containing functional Inr elements.  Therefore, despite the apparent 
differences between the SRC1A and SRC1α promoters, they shared a dependence on the 
TFIID component, TAF1, for full activity.  Of particular interest, it appears that this 
commonality is the primary reason why both of these disparate promoters are repressed 
following HDI treatment.  In addition, further important core promoter elements were 
hinted at by the observation that very small deletions from the 3' ends of either SRC 
promoter had significant negative effects on overall transcriptional activity.  Therefore, 
narrowing in on these elements will be important in the future, and could be initiated by 
introducing smaller deletions, followed by specific mutagenesis strategies to identify 
precise residues important for the function of these elements.  Identification and/or 
purification of factors binding to or interacting with these elements would be the goal of 
this line of investigation. 
 Ideally, the findings from these studies will all converge on a set of experiments 
involving a series of SRC DPCAT reporters designed to probe the interactions between 
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putative upstream (or downstream) enhancer element(s), previously defined transcription 
factor binding sites, and core promoter elements in the SRC locus.  Interactions between 
these DNA elements and the multitude of protein factors they recruit represent the 
"wiring" of the entire SRC promoter locus.  Understanding the interplay between factors 
in this complex is the ultimate, long-term goal for which this thesis has provided 
groundwork.  Introduction of mutations within the SRC DPCAT reporter, which would 
disrupt specific wiring circuits, or co-transfection with various factors deemed important 
for full activity, which will enhance specific wiring circuits, will likely prove crucial to a 
full understanding of the mechanisms of SRC transcriptional activation in human cancer 
cell lines.  Once the interactions between these DNA elements and protein factors are 
fully understood, the precise mechanism of disruption of this complex following HDI 
treatment could be elucidated.  Employment of other technologies, such as mass 
spectrometry, could be used to enhance this set of proposed experiments, and play a key 
role in identifying all the individual proteins that constitute a complete and active SRC 
transcription complex.    
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